

1974 AUTHOR INDEX

Asterisk indicates abstract

- Abdel-Dayem, H. H. and Alker, G. J.** Improving the 99m Tc-phosphate bone scan, 1229
- Abernathy, E. M.** see Habibian, M. R.
- Abreau, C.** see Serino, T. V.
- Aburano, T.** see Tonami, N.
- Ackerhalt, R. E., Blau, M., Bakshi, S. P. and Sondel, J. A.** Bone imaging with 99m Tc-phosphorous compounds and ^{18}F , 1153
- Adams, D. F.** see Kinoshita, M.
- Adams, R., Jansen, C., Grames, G. M. and Zimmerman, D.** Camera deadtime measurement, 722
- Adams, R., and Zimmerman, D.** Anger camera deadtime, 468
- Addlestone, R. and Workman, J. B.** Lipoma of the corpus callosum, 714
- Adelstein, S. J.**
see Kinoshita, M.
see McNeil, B. J.
- Adolph, R. J.** see Ashare, A. B.
- Agnew, J. E., Youngs, G. R., Lydford, R., Levin, G. E. and Bouquier, I. A. D.** False-positive pancreas scan, 90
- Ahluwalia, B., Kanarek, D., Jones, T., Hoop, B., Brownell, G. L. and Kazemi, H.** Extravascular lung water distribution, 474*
- Ahnberg, D.** see Treves, S.
- Aita, J. F. and Keyes, J. W.** Scanning in vascular infantile hemiplegia, 300
- Akcasu, Z.** see Knoll, G. F.
- Alagarsamy, V.**
see DePuey, G.
see Murphy, P. H.
- Alavi, A., Bond, J. P., Kuhl, D. E. and Creech, R. H.** Bone marrow infarcts in sickle cell disease, 1003
- Alavi, A.** see Kuhl, D. E.
- Alazraki, N. P., Hurwitz, S. R., Halpern, S. E. and Ashburn, W. L.** 109 Yb-DTPA cisternography radiation dose, 643
- Alazraki, N. P., Littenberg, R. L., Hurwitz, S. R., Quinto, R. R., Halpern, S. E. and Ashburn, W. L.** Choroid plexus concentration of pertechnetate, 884
- Alazraki, N. P., Schelbert, H. R., Verba, J. W., Brock, G. W. and Ashburn, W. L.** Cardiac output determinations, 474*
- Alazraki, N. P.**
see Breslow, W.
see Chauncey, D. M.
see Goergen, T. G.
see Halpern, S. E.
see Hurwitz, S. R.
see Verba, J. W.
- Alderson, P. O., Dew T. and Secker-Walker, R. H.** Regional ventilation and perfusion in alpha-1-antitrypsin deficiency, 474*
- Alderson, P. O.**
see Partain, C. L.
see Paull, B. R.
see Secker-Walker, R. H.
- Alker, G. J.** see Abdel-Dayem, H. M.
- Allen, D. R., Hartnett, D. E., Nelp, W. B. and Hamilton, G. W.** Labeling Sn-MAA with 113m InCl₃, 821
- Allen, D. R., Nelp, W. B., Cheney, F. and Hartnett, D. E.** Acute cardiopulmonary toxicity of Sn-MAA, 567
- Allen, D. R.** see Hamilton, G. W.
- Aloia, J. F.** see Cohn, S. F.
- Alpert, N. M., McKusick, K. A., Pohost, G. M., Dinsmore, R. E. and Potsaid, M. S.** Noninvasive nuclear kinecardiography, 1182
- Alter, A. J. and Farrer, P. A.** The perihepatic halo in liver studies, 398
- Alvarez, J., Maas, R. E. and Arriaga, C.** 99m Tc-Sn complex for kidney scanning, 474*
- Amrein, P. C., Larson, S. M. and Wagner, H. N.** Automated measurement of antibody titers, 1145
- Amrein, P. C., Larson, S. M. and Wagner, H. N.** Automated measurement of leukocyte metabolism, 352
- Anderson, D. W., Raeside, D. E., and Ficken, V. J.** Radionuclide impurities in 99m Tc eluate, 889
- Anderton, N. S.**
see Burdine, J. A.
see Monroe, L. A.
- Ando, A.** see Hisada, K.
- Anger, H. O.**
see Budinger, T. F.
see McRae, J.
see Yano, Y.
- Ansari, A. N.**
see Lebowitz, E.
see MacGregor, R. R.
- Anselmi, R. O.** see Touya, J. J.
- Antar, M. A.**
see Caride, V. J.
see Forman, B. H.
see Spencer, R. P.
- Antoni, F.** see Szabó, M. T.
- Aponte, L. J.** see Spencer, R. P.
- Aquilar, F.** see Webber, M. M.
- Archamboud, D.** see Planiol, T.
- Ariel, I. M.** Isotopic therapy for malignant lymphoma, 475*
- Ariwa, R.** see Kinoshita, F.
- Arkless, R.** Arthroscintigraphy of knee, 911
- Arnold, J.** see MacIntyre, W. J.
- Arnold, J. E., Johnston, A. S. and Pinsky, S. M.** Anger camera deadtime, 412
- Arnold, J. E., Johnston, A. S. and Pinsky, S. M.** Resolving time of scintillation cameras, 475*
- Arnold, R. W., Subramanian, G.,**
- McAfee, J. G., Rosenstreich, M. E. and Gebhardt, M. E.** 99m Tc complexes for kidney imaging, 475*
- Arriaga, C.** see Alvarez, J.
- Asard, P-E.** see Nordlander, S.
- Ashare, B., Romhilt, D. W., Sodd, V. J., Levenson, N. I., Adolph, R. J., Saenger, E. L. and August, L. S.** Quantification of myocardial infarction, 475*
- Ashburn, W. L.**
see Alazraki, N. P.
see Breslow, W.
see Goergen, T. G.
see Halpern, S. E.
see Higgins, C. B.
see Schelbert, H. R.
see Verba, J. W.
- Askenasi, J.** see Treves, S.
- Aspin, N.** see Coates, G.
- Assailly, J.** see Chanard, J.
- Atkins, H. L., Bradley-Moore, P. R., Lambrecht, R. M., Merrill, J. C., Packer, S. and Wolf, A. P.** Cyclotron production of 46 Ti and 203 Pb, 475*
- Atkins, H. L.**
see Cohn, S. F.
see Lambrecht, R. M.
see Lebowitz, E.
see MacGregor, R. R.
- Atkins, J. M.** see Parkey, R. W.
- Auersperg, M.** see Erjavek, M.
- August, L. S.** see Ashare, A. B.
- Austoni, M.** see Mantero, F.
- Azmudeh, K.** see Chen, I-W.
- Bachsmith, C.** see Lebowitz, E.
- Backhaus, J. W.** see Brown, D. W.
- Badellino, F.** see Calderola, L.
- Bader, C.** see Chanard, J.
- Bahr, G. K.** see Chen, I-W.
- Bailey, J. J.** see Green, M. V.
- Baker, G. A.** see Lamb, J. F.
- Baker, R. J., Bellen, J. C. and Ronai, P. M.** 99m Tc-pyridoxylidene-glutamate for gallbladder imaging, 476*
- Bakshi, S. P. and Parthasarathy, K. L.** Cleansing 67 Ga-citrate from bowels, 470
- Bakshi, S. P.** see Ackerhalt, R. E.
- Balachandran, S., Ryo, U. Y., Beierwaltes, W. H., Shaw, M. J. and Ice, R. D.** ^{14}C -diphenylhydantoin uptake in islet cells, 476*
- Balachandran, S.** see Seabold, J. E.
- Bandhauer, K.** see Bekier, A.
- Banerji, J. and Spencer, R. P.** Turnover of radioiodine in hyperthyroidism, 476*
- Barbier, J.** see Secker-Walker, R. H.
- Barnes, W. E.**
see Colombetti, L. G.
see Kaplan, E.
see Mayron, L. W.
- Barrett, H. H.** Fresnel zone plate imaging, 216

AUTHOR INDEX

- Barrett, I.** see Mishkin, F. S.
Barron, E. L. see Stevenson, J. S.
Barth, R. F., Singla, O. and Gillespie, G. Y. Migration of ^{99m}Tc -labeled cells in vivo, 658
Bartone, N. F. see Yang, C-S.
Basse-Cathalinat, B. see Blanquet, P.
Bates, B. B. see Harris, C. C.
Battaglia, D. J.
 see Poe, N. D.
 see Robinson, G. D.
Bauer, W. see Paull, B. R.
Bautovich, G. J., Genant, H. K., Hoffer, P. B., Harper, P. V. and Lathrop, K. A. Effect of tissue inflammation on ^{99m}Tc -EHDP bone uptake, 476*
Bautovich, G. J., Harper, P. V., Mock, B., Lembares, N., Krizek, H. and Rich, M. Left ventricular volume from ^{11}CO coincidence images, 477*
Bautovich, G. J. see Genant, H. K.
Beal, W., Soin, J. S. and Burdine, J. A. Hepatic cavernous hemangioma in a newborn, 902
Beal, W. see Soin, J. S.
Beauchamp, J. M., Belanger, M. A. and Neitzschman, H. R. Intrahepatic focal lesion in acute viral hepatitis, 356
Beaudoin, J. G. see Farrer, P. A.
Beck, R. N. see Metz, C. E.
Becker, L., Ferreira, R. and Thomas, M. Left ventricular blood flow with ^{82}Rb and microspheres, 969
Beckerman, C. see Gottschalk, A.
Beierwaltes, W. H., Harness, J. K., Thompson, N. W. and Sisson, J. C. Treatment of thyroid carcinoma metastases, 477*
Beierwaltes, W. H., Sturman, M. F., Ryo, U. Y. and Ice, R. D. Imaging functional nodules of adrenal glands, 246
Beierwaltes, W. H.
 see Balachandran, S.
 see Ice, R. D.
 see Koral, K. F.
 see Prakash, S.
 see Rogers, W. L.
 see Ryo, U. Y.
 see Seabold, J. E.
 see Sturman, M. F.
Beihn, R. M., Damron, J. R. and Hafner, T. Detection of subphrenic abscess, 371
Beihn, R. M., Reed, M. F., Zarocostas, G. and Jones, J. S. Sinus imaging with ^{133}Xe , 477*
Bekerman, C., Gottschalk, A. and Hoffer, P. B. ^{131}I total body imaging for thyroid carcinoma metastases, 477*
Bekerman, C. see Hoffer, P. B.
Bekier, A. and Bandhauer, K. Artifact in dynamic kidney imaging, 134
Belanger, M. A. see Beauchamp, J. M.
Bell, G. B.
 see Berman, D. S.
 see DeNardo, S. J.
Bellen, J. C. see Baker, R. J.
Belman, A. B. see Conway, J. J.
Benetello, G. P. see Ravasini, R. G.
Bennett, L. R.
 see Bosnjakovic, V.
 see MacDonald, N. S.
 see Stein, M. A.
 see Touya, J. J.
 see Uszler, J. M.
 see Verma, R. C.
Benua, R. S.
 see Johnston, G.
 see Leeper, R. D.
 see Yeh, S. D. J.
Berg, G., Castronovo, F. P., McKusick, K. A., Pendergrass, H. P., Callahan, R. J. and Potsaid, M. S. Bone dynamics of ^{99m}Tc -diphosphonate, 477*
Bergan, J. J. see Henkin, R. E.
Berger, H. G.
 see Krishnamurthy, G. T.
 see Pritchard, J. H.
Berke, R. A. see Nishiyama, H.
Berman, D. S., DeNardo, G. L., Salel, A. F., Zelis, R., Mason, D. T., Strauss, H. W. and Bogren, H. G. Imaging of cardiac systole and diastole, 478*
Berman, D. S., Salel, A. F., DeNardo, G. L., Mason, D. T., Zelis, R., Scheibe, P. O., Jackson, P. E. and Bell, G. B. Noninvasive cardiac output determination, 478*
Berman, J. A., Leh, F. K. V. and Wolf, W. Radiopharmokinetics of antineoplastic platinum compounds, 478*
Berman, M. see Singh, B.
Bernier, D. R. see Coleman, R. E.
Bernstein, J. and Hoffer, P. B. Delayed brain scans and calvarial lesions, 681
Bessent, R. G. see Citrin, D. L.
Bigler, R. E. see Russ, G. A.
Billinghurst, M. W., Groothedde, M. and Palser, R. F. Radiochemical purity of $^{99m}\text{TcO}_4^-$, 266
Billinghurst, M. W. and Palser, R. F. Gel chromatography of ^{99m}Tc radiopharmaceuticals, 722
Birdsall, R. L. see MacDonald, N. S.
Birken, S. and Canfield, R. E. Labeled asialo-human chorionic gonadotrophin for liver scanning, 1176
Black, M. B. GI tract visualization in pancreas imaging, 221
Blackburn, G. see McHardy-Young, S.
Blahd, B. H. see Graham, L. S.
Blahd, W. H.
 see Krishnamurthy, G. T.
 see Pritchard, J. H.
 see Winston, M. A.
Blanquet, P., Vérin, P., Basse-Cathalinat, B. and Safi, N. Ocular scintigraphy, 478*
Blatt, C. J., Hayt, D. B. and Freedman, L. M. Kidney imaging in tuberous sclerosis, 478*
Blatt, C. J., Hayt, D. B. and Freedman, L. M. Kidney imaging in tuberous sclerosis, 699
Blau, M.
 see Ackerhalt, R. E.
 see Owunwanne, A.
 see Ramanathan, P.
Blaufox, M.D. see Koenigsberg, M.
Bliss, R. D., Weber, P. M. and dos Remedios, L. V. Data recorder for the scintillation camera, 1130
Blizzard, J. see Thomas, F. D.
Bloch, P. and Sanders, T. Reduction of scattered radiation effect, 316
Block, M. H. see Brown, D. W.
Blockeel, R. see Tirkilikli, V.
Blottner, A. see Deckart, H.
Blum, A. S. see Carpenter, G. W.
Blumgart, L. H. see Karraan, S. J.
Blumin, L. J. see DeGrazia, J. A.
Bobinet, D. D., Sevrin, R., Zurbriggen, M. T., Spolter, L. and Cohen, M. B. Lung uptake of ^{99m}Tc -sulfur colloid, 1220
Bobinet, D. D.
 see Cohen, M. B.
 see Spolter, L.
Boddy, K., East, B. W., King, P. C., Milne, J. S., Price, W. H. and Tothill, P. Total-body K and lean body mass in abnormal chromosome complement, 448
Bogren, H. G. see Berman, D. S.
Bolles, T. F. see Krejcarek, G. F.
Bond, J. P. see Alavi, A.
Bonte, F. J. and Parkey, R. W. Imaging myocardial infarcts, 479*
Bonte, F. J.
 see Murry, R. C.
 see Parkey, R. W.
 see Stokely, E. M.
Bonwit, S. E. see Knowles, L. G.
Borkat, F. R. see Wiener, S. N.
Bosch, A. see Lanaro, A. E.
Bosnjakovic, V. and Bennett, L. R. Evaluation of nonfocused collimator, 679
Bostrom, S. E., Brown, D. W. and Nelson, G. L. Nuclear medicine in human liver transplantation, 479*
Bouchier, I. A. D. see Agnew, J. E.
Bowen, B. M. and Garnett, E. S. ^{99m}Tc -polyphosphate and -pyrophosphate, 652
Boyd, C. see DeLand, F. H.
Boyett, J. D., Mahler, D. J. and Jansen, A. Thyroid uptake of ^{131}I , 213
Bradford, K. L. see Krejcarek, G. F.
Bradley-Moore, P. R. see Atkins, H. L.
Brady, L. W. see Wallner, R. J.
Braunstein, P., Kricheff, I. I., Ko-rein, J. and Chandra, R. Diagnostic techniques for cerebral death, 912
Braunstein, P. see McCauley, D.
Braverman, L. E. see Serino, T. V.
Brenner, R. see Strauss, M. G.
Breslow, W., Halpern, S. E., Schwartz, F. C., Alazraki, N. P. and Ashburn, W. L. ^{99m}Tc -tetraacycline complex stability and tumor uptake, 987
Brill, A. B.
 see Erickson, J. J.
 see Greenlaw, R. H.

- see Ivancevic, D.
 see McKee, L. C.
 see Patton, J. A.
 see Rhea, T. C.
- Briner, W. H. and Harris, C. C.** Contamination of ^{99m}Tc eluates, 466
- Brocchi, A.** see Cappelli, G.
- Brochier, M.** see Planiol, T.
- Brock, G. W.**
 see Alazraki, N. P.
 see Verba, J. W.
- Brookeman, V. A., Morin, R. L. and Fitzgerald, L. T.** Dosimetry of DTPA radiopharmaceuticals in cisternography, 479*
- Brookeman, V. A.** see Morin, R. L.
- Brooks, W. H., Mortara, R. H. and Preston, D. F.** Limitations of brain scanning in metastatic disease, 620
- Brower, A. C. and Teates, C. D.** ^{99m}Tc-polyphosphate scan in metastatic osteogenic sarcoma and pulmonary osteoarthropathy, 53
- Brown, C.** see McHardy-Young, S.
- Brown, D. H.** see Hayes, R. L.
- Brown, D. W., Block, M. H., Wallner, S. F., Backhaus, J. W. and Ryerson, T. W.** Comparison of bone marrow scans and biopsies, 479*
- Brown, D. W.**
 see Bostrom, S. E.
 see Kirch, D. L.
- Brown, M. L., Hannah, T. and Stephens, G.** Cross-reaction of digoxin antibody with a normal control serum, 465
- Browne, A. D. and Wellman, H. N.** Preparation and distribution of a ^{99m}Tc-hematoporphyrin derivative, 480*
- Brownell, G. L.**
 see Ahluwahlia, B.
 see Jones, T.
- Brust, J. C. M.** see Johnson, P. M.
- Bruun, P.** ^{99m}Tc-sulfur colloid lung retention, 727
- Buchignani, J. S.** see Rockett, J. F.
- Budinger, T. F., Gullberg, G. T., McRae, J. and Anger, H. O.** Isotope distribution reconstruction from multiple camera views, 480*
- Budinger, T. F., McRae, J., Yano, Y. and Myers, W. G.** Myocardial imaging with ⁸²Rb, 480*
- Budinger, T. F.** see Gullberg, G. T.
- Burdine, J. A., Anderton, N. S., Soin, J. S. and Calderon, M.** Evaluation of a lyophilized ^{99m}Tc-pyrophosphate kit, 480*
- Burdine, J. A.**
 see Beal, W.
 see Calderon, M.
 see DePuey, G.
 see Monroe, L. A.
 see Murphy, P. H.
 see Soin, J. S.
- Burleson, R. L., Johnson, M. C. and Head, H.** Labeling rabbit leukocytes with ⁶⁷Ga-citrate, 98
- Burrows, B.** see Genna, S.
- Burrows, B. A.** Editorials, 1, 831, 1073
- Burrows, B. A.** see McNeil, B. J.
- Burt, R. W.** EEG procedure effect on brain scan, 369
- Busse, W. W.** Radioactivity retention in abnormal lung scans, 1230
- Buswink, A. A.** see Counsell, R. E.
- Button, L. N.** see McNeil, B. J.
- Byfield, J.** see Touya, J. J.
- Byrd, B. L.** see Hayes, R. L.
- Cabal, E. C.** see George, E. A.
- Caldarola, L. and Badellino, F.** Intra-arterial injection of radioactive microspheres in tongue cancer, 481*
- Caldarola, L., DeFilippi, P. G., Polloni, R. and Badellino, F.** ⁶⁷Ga-citrate in cancer diagnosis, 480*
- Calderon, M. and Burdine, J. A.** Left upper abdomen evaluation in children, 481*
- Calderon, M. and Burdine, J. A.** Pulmonary veno-occlusive disease, 455
- Calderon, M.**
 see Burdine, J. A.
 see DePuey, G.
 see Murphy, P. H.
- Callahan, R. J.**
 see Berg, G.
 see Lamson, M.
- Camargo, E. E., Larson, S. M., Tepper, B. S., Charache, P. and Wagner, H. N.** Detection of M. tuberculosis and M. lepraeumurium, 481*
- Camin, L. L.** see Zweiman, F. G.
- Canfield, R. E.** see Birken, S.
- Cannon, P. J.** see Johnson, P. M.
- Capelli, G., Grandonicco, F. and Brocchi, A.** High solid phase radioimmunoassay, 481*
- Carey, J. E., Purdy, J. M. and Moses, D. C.** ¹³³Xe liver uptake during lung studies, 1179
- Caride, V. J., Antar, M. A. and Spencer, R. P.** Computer and visual interpretation of liver flow studies, 481*
- Carlton, J. E.** see Hayes, R. L.
- Carmel, A.** see Dewanjee, M. K.
- Carpenter, G. W. and Blum, A. S.** Radioimmunoassay for T₃, 482*
- Carr, E. A.** see Counsell, R. E.
- Carretta, R. F., DeNardo, S. J., Janesholt, A. L. and DeNardo, G. L.** ¹²⁵I-fibrinogen for diagnosis of deep vein thrombosis, 482*
- Carretta, R. F.** see DeNardo, S. J.
- Carroll, M.** see Counsell, R. E.
- Carter, A. P.** see Teplick, S. K.
- Castronovo, F. P.** Synthesis of ^{99m}Tc-HEDSPA for bone scanning, 127
- Castronovo, F. P.**
 see Berg, G.
 see Lamson, M.
- Cattano, G. A.** see Ravasini, R. G.
- Cavalieri, R. R., Moser, C., Martin, P. and Perez-Mendez, V.** Renal uptake kinetics of T₃, 482*
- Celis, C.** see Skromme-Kadlubik, G.
- Chanard, J., Assailly, J., Bader, C. and Funck-Brentano, J-L.** Meas-
- urement of calcium absorption, 588
- Chandler, H. L.** see Kaplan, W. D.
- Chandra, R.** see Braunstein, P.
- Chandra, S. and Prezio, J. A.** Pancreas imaging modification, 935
- Chaney, E. L.** see Hare, D. L.
- Chang, C. C.**
 see Cohen, M. B.
 see Spolter, L.
- Chang, L-T., Kaplan, S. N., Macdonald, B., Perez-Mendez, V. and Shirashi, L.** Tomographic imaging with a multiple pinhole-coded aperture, 1063
- Chang, S. C.** see Nodine, J. H.
- Charache, P.**
 see Camargo, E. E.
 see Larson, S. M.
- Charkes, N. D., Dugan, M. A., Maier, W. P., Soulen, R., Escozovitz, E., Learner, N., Dubin, R. and Kozar, J.** ¹³¹I-fibrinogen deep vein thrombosis scanning, 1163
- Charkes, N. D.** see Perlmuter, G. S.
- Chaudhuri, Tapan K.** ^{87m}Sr imaging of colorectal cancer, 825
- Chaudhuri, Tapan K.** ^{99m}Tc-DTPA for measuring gastric emptying time, 391
- Chaudhuri, Tapan K., Chaudhuri, Tuhi K. and Christie, J. H.** Tumor uptake of ^{99m}Tc-polyphosphate, 458
- Chaudhuri, Tapan K., Chaudhuri, Tuhi K., Gulesserian, H. P., Christie, J. H. and Tonami, N.** Extraskeletal tissue uptake of ^{99m}Tc-polyphosphate, 1054
- Chaudhuri, Tapan K., Heading, R. C., Greenwald, A. J. and Chaudhuri, Tuhi K.** Gastric emptying time measured with ^{99m}Tc-DTPA, 483*
- Chaudhuri, Tapan K., Saparoff, G. R., Dolan, K. D. and Chaudhuri, Tuhi K.** Comparison of contrast and nuclear dacryocystogram, 482*
- Chaudhuri Tapan K.** see Greenwald, A. J.
- Chaudhuri Tuhi K., Ehrhardt, J. C., DeGowin, R. L. and Christie, J. H.** ⁵⁷Fe whole body scanning, 667
- Chaudhuri, Tuhi K.**
 see Chaudhuri, Tapan K.
 see Christie, J. H.
 see Greenwald, A. J.
- Chauncey, D. M., Halpern, S. E. and Alazraki, N. P.** Preparation and distribution of ¹³¹I-tetracyclines, 483*
- Chauncey, D. M.** see Schelbert, H. R.
- Chayes, Z., Koenigsberg, M. and Freeman, L. M.** The "hot" hepatic abscess, 305
- Chen, I-W., Azmudeh, K., Connell, A. M. and Saenger, E. L.** Breath test for pancreatic insufficiency, 1125
- Chen, I-W., Park, H-M., King, L. R., Bahr, G. K. and Goldsmith,**

AUTHOR INDEX

- R. E. Plasma PTH response to EDTA, 763
- Chen, M., Rhodes, B. A., Larson, S. M. and Wagner, H. N. Sterility testing of radiopharmaceuticals, 1142
- Chen, M. see Larson, S. M.
- Chen, W-L. see Yeh, S-H.
- Cheney, F. see Allen, D. R.
- Cheng, H-F. see Go, R. T.
- Cheng, K. see Mayer, K.
- Chervu, L. R. and Sternlieb, I. Dosimetry of Cu radionuclides, 1011
- Chesnut, C. H., Nelp, W. B. and Denney, J. D. Efficiency of dianabol in osteoporosis, 483*
- Chesnut, C. H. see Lewellen, T. K.
- Chien, M-T. see Yeh, S-H.
- Chisholm, G. D., Short, M. D., Gadianian, R., McRae, C. U. and Glass, H. I. ^{65}Zn prostate imaging, 739
- Chiu, C. L. see Go, R. T.
- Cho, K. J. and Doust, B. D. ^{75}Se -selenomethionine liver uptake suppression, 1171
- Christie, J. H., Chaudhuri, Tuhin K., DeGowin, R. L. and Ehrhardt, J. C. ^{59}Fe whole body scanning, 483*
- Christie, J. H.
see Chaudhuri, Tapan K.
see Chaudhuri, Tuhin K.
see Go, R. T.
- Christie, T. R., Monahan, W. G., Gelbard, A. S., Clarke L. P. and Laughlin, J. S. ^{15}N -ammonium and -glutamine for tumor localization, 483*
- Christie, T. R. see McDonald, J. M.
- Christman, D. R. see MacGregor, R. R.
- Christy, B., King, G. and Smoak, W. M. Preparation and distribution of ^{123}I -rose bengal, 484*
- Chu, P. see Yano, Y.
- Church, L. B. see Owunwanne, A.
- Citrin, D. L., Bessent, R. G. and Greig, W. R. Comparison of ^{99m}Tc -monofluorophosphate and EHDP, 1110
- Clarke, R. E. see Teplick, S. K.
- Clarke, L. P.
see Christie, T. R.
see Gelbard, A. S.
see Mayer, K.
see McDonald, J. M.
see Monahan, W. G.
- Cloonan, E. see Serino, T. V.
- Coates, G., Aspin, N., Wong, P. Y. and Wood, D. E. Preparation and distribution of ^{67}Cu -bleomycin, 484*
- Coates, G., Stadnik, R. C., Palmer, J. M. and DeNardo, G. L. Hepatic scintangiography in parasitic tumors, 137
- Codd, J. E. see George, E. A.
- Coffey, W. C. see Hodges, H. D.
- Cohen, G. A., Smoak, W. M. and Goldberg, L. D. Acromegalic cholelithiasis, 720
- Cohen, E. L. see Seabold, J. E.
- Cohen, M. B., Spolter, L., Chang, C. C., MacDonald, N. S., Takahashi, J. and Bobinet, D. D. Enzymes in ^{15}N -amino acid production, 1192
- Cohen, M. B.
see Bobinet, D. D.
see Poe, N. D.
see Spolter, L.
- Cohn, S. H., Ellis, K. J., Wallach, S., Zanzi, I., Atkins, H. L. and Aloia, J. F. Total body Ca and radial bone mineral in osteoporosis, 429
- Coleman, R. E. Renal colloid localization, 367
- Coleman, R. E., Bernier, D. R., Pasternak, S. and Siegel, B. A. Skull imaging in routine bone scanning, 1185
- Coleman, R. E. see Harwig, J. F.
- Coles, J. L. see Heck, L. L.
- Collins, P. J. see O'Reilly, R. J.
- Colman, M. see McIntyre, P. A.
- Colombetti, L. G. and Barnes, W. E. Radiation dose from ^{99m}Tc impurities, 484*
- Colombetti, L. G., Mayron, L. W., Kaplan, E., Barnes, W. E., Friedman, A. M. and Gindler, J. E. Continuous ^{85}Rb - ^{85m}Kr generator, 868
- Colombetti, L. G.
see Kaplan, E.
see Mayron, L. W.
- Conn, J. W. see Seabold, J. E.
- Connell, A. M. see Chen, I-W.
- Constable, W. C. see Teates, C. D.
- Conway, J. J. Artifact of brain imaging, 485*
- Conway, J. J., Luck, S., Filmer, R. B. and Belman, A. B. Differentiation of a flank mass in the newborn, 485*
- Conway, J. J. and Muster, A. J. Pulmonary perfusion in transposition of the great arteries, 484*
- Cooper, M. D. see Hagan, P.
- Cooper, P. H. Scanner deadtime losses, 729
- Cooper, P. H. see Pircher, F. J.
- Corriveau, O. J. see Thomson, R. A. E.
- Counsell, R. E., Yu, T., Ranade, V. V., Buswink, A. A., Carr, E. A. and Carroll, M. ^{125}I -bretyleum analogs for myocardial scanning, 991
- Cradduck, T. D. see Wong, P. Y.
- Cragin, M. D. see Webber, M. M.
- Creech, R. H. see Alavi, A.
- Croll, M. N. see Wallner, R. J.
- Cruz, P. see Hall, J. N.
- Cuatrecasas, P. see Thorell, J. I.
- Curry, G. C. see Parkey, R. W.
- Czarnomska, A. see Szymendera, J.
- Czerniak, P. and Nathan, H. Radioisotope anatomy, 485*
- Czerniak, P. and Zwaz, T. S. Multitorgan studies with multiple radiopharmaceuticals, 485*
- D'Ambrosia, R. see Riggins, R. S.
- Damron, J. R. see Beihn, R. M.
- Danigelis, J. A., Fisher, R. L. and
- Osonoff, M. B. ^{99m}Tc -polyphosphate imaging in Legg-Perthes disease, 485*
- Darter, E. L. ^{133}Xe transmission source, 453
- Davidson, T. see Wieland, H. C.
- Davis, M. A. Radioactivity retention in abnormal lung scans, 1230
- Davis, M. A., Jones, A. G. and Trindale, H. Sizing of radiocolloids, 923
- Davis, M. A. and King, M. F. Capillary blockade with ^{99m}Tc -Fe hydroxide, 436
- Davis, M. A.
see Dewanjee, M. K.
see Jones, A. G.
see Kaplan, W. D.
- Deckart, H., Herzmann, H., Blottnar, A., Flentje, H. and Schwartz, K-D. Pharmacokinetics of radioiodine labeled organomercurials, 486*
- DeFillippi, P. G. see Calderola, L.
- DeGowin, R. L.
see Chaudhuri, Tuhin K.
see Christie, J. H.
- DeGrazia, J. A., Scheibe, P. O., Jackson, P. E., Lucas, Z. J., Fair, W. R., Vogel, J. M. and Blumin, L. J. Applications of hippurate kinetic models, 102
- DeGrazia, J. A., Scheibe, P. O., Jackson, P. E., Lucas, Z. J., Fair, W. R., Vogel, J. M. and Blumin, L. J. Hippurate kinetic models, 1066
- DeLand, F. H. Diagnostic criteria in cisternography, 486*
- DeLand, F. H. Radiometric xylose tolerance test, 486*
- DeLand, F. H. and Garcia, F. Perfusion studies in cerebral aneurysm diagnosis, 358
- DeLand, F. H., Sauerbrunn, B. J. L., Boyd, C., Wilkinson, R. H., Friedman, B. I., Moinuddin, M., Preston, D. F. and Knisely, R. M. ^{67}Ga -citrate in lung cancer, 408
- DeLand, F. H. and Tilden, R. Enzymatic analysis of oxalic acid in urine and plasma, 486*
- DeLand, F. H.
see Morin, R. L.
see Tonkin, A. K.
- DeNardo, G. L. Editorial, 385
- DeNardo, G. L.
see Berman, D. S.
see Carretta, R. F.
see Coates, G.
see DeNardo, S. J.
see Hines, H. H.
see Peek, N. F.
see Riggins, R. S.
see Stadnik, R. C.
- DeNardo, S. J., Bell, G. B., DeNardo, G. L., Scheibe, P. O., Jackson, P. E. and Carretta, R. F. Dual isotope assessment of liver disease, 487*
- DeNardo, S. J., DeNardo, G. L., O'Brien, T., Peek, N. F., Zielski, F. W. and Jungerman, J. A.

- ¹²³I-fibrinogen imaging of thrombi, 487*
- DeNardo, S. J.
see Carretta, R. F.
see Staldalnik, R. C.
- Denney, J. D. see Chesnut, C. H.
- DePuey, G., Alagarsamy, V., Thompson, W. L., Calderon, M., Kutka, N. and Burdine, J. A. Functional imaging for bone mineral content, 487
- DeRao, M. J. K. False-positive ⁷⁵Se-selenite scans, 622
- Desaulniers, M., Fuks, A., Hawkins, D., Lacourciere, Y. and Rosenblatt, L. ^{99m}Tc-polyporphosphate joint imaging, 417
- Devenny, J. see Rothenberg, H.
- Dew, T. see Alderson, P. O.
- Dewanjee, M. K. Binding of ^{99m}Tc ion to hemoglobin, 703
- Dewanjee, M. K., Fliegel, C., Treves, S. and Davis, M. A. ^{99m}Tc-tetracyclines, 177
- Dewanjee, M. K. and Kahn, P. C. ^{99m}Tc binding to hemoglobin, 487*
- Dewanjee, M. K., Kahn, P. C., Carmel, A. and Dewanjee, U. Lymph node scintigraphy, 487*
- Dewanjee, M. K. and Prince, E. W. ^{99m}Tc-tetracycline in cellular necrosis model, 577
- Dewanjee, M. K. see Holman, B. L.
- Dewanjee, U. see Dewanjee, M. K.
- Diamanti, C. I. and Goodwin, D. A. Lung retention of ^{113m}In- and ⁵⁷Fe-ferric hydroxide, 488*
- Diamanti, C. I. see Goodwin, D. A.
- Diaz, F. see Skromme-Kadlubik, G.
- DiChiro, G., Timins, E. L., Jones A. E., Johnston, G. S., Hammock, M. K. and Swann, S. J. Brain scans and microangiography in stroke, 488*
- Dickinson, P. see Polga, J. P.
- Dietrich, R. see Lanaro, A. E.
- Diez, L. see Ortiz-Berrocot, J.
- Dinsmore, R. E. see Alpert, N. M.
- DiSaia, P. J. see Woolfenden, J. M.
- Dizmang, D. see Rudd, T. G.
- Dodd, T. see Rutner, H.
- Dolan, K. D. see Chaudhuri, Tapan K.
- Dollfuss, R. E. see Farrer, P. A.
- Domek, N. S. and Loken, M. K. Quality control testing of ^{99m}Tc-radiopharmaceuticals, 488*
- Donati, R. M.
see George, E. A.
see Henry, R. E.
- Dore, E. K.
see Gates, G. F.
see Poe, N. D.
- Dorta, T. see Pasquier, J.
- Doscherholmen, A. see Shafer, R. B.
- dos Remedios, L. V.
see Bliss, R. D.
see Enlander, D.
see Weber, P. M.
- Doty, D. B. see Go, R. T.
- Douglas, M. A. see Green, M. V.
- Doust, B. D. see Cho, K. J.
- Dowdley, J. E.
- see Murry, R. C.
see Tipton, M. D.
- Dowsett, D. J. and Roberts, K. Long distance transmission of camera signals, 896
- Dubin, R. see Charkes, N. D.
- Dugan, M. A. see Charkes, N. D.
- Dupuy, M. S. and Mitchell, T. G. Ocular blood flow, 488*
- Durie, B. G. see Lilien, D. L.
- Duxbury, C.
see Scharoff, J. R.
see Thomas, F. D.
- Dworkin, H. J. see Gutkowski, R. F.
- Dwyer A. see Freedman, G. S.
- East, B. W. see Boddy, K.
- Eber, L. M. see Poe, N. D.
- Eckelman, W. C., Reba, R. C., Kubota, H. and Stevenson, J. S. ^{99m}Tc-pyrophosphate for bone imaging, 279
- Eckelman, W. C., Reba, R. C., Kubota, H. and Stevenson, J. S. Radiolabeled bleomycin uptake in mammary carcinoma, 489*
- Eckelman, W. C.
see Grove, R. B.
see Steigman, J.
see Stevenson, J. S.
- Eckerman, K. F. see Friedman, A. M.
- Edwards, C. L. see Johnston, G.
- Edwards, R. Q. see Kuhl, D. E.
- Ehrhardt, J. C., Oberley, L. W. and Lensink, S. C. Scattering medium and gamma-ray imaging, 943
- Ehrhardt, J. C.
see Chaudhuri, Tuhin K.
see Christie, J. H.
- Eichling, J. O. see Phelps, M. E.
- Eikman, E. A. see McIntyre, P. A.
- Elam, D. A.
see Poe, N. D.
see Robinson, G. D.
see Taplin, G. V.
- El-Arini, A. F. see Nofal, M. M.
- El-Beheiry, A. see Nofal, M. M.
- Elias, H. see Lambrecht, R. M.
- Elings, V. B., Martin, C. B., Pollock, I. and McClinton, J. T. Motion artifact correction, 36
- Ellis, K. J. see Cohn, S. F.
- Elsborg, L. Gas proportional counting in biologic materials, 115
- El-Shaboury, G. see Hallaba, E.
- Emerson, D. A., Pitt, M. J., O'Mara, R. E., Van Antwerp, J. D. and Gall, E. P. Intra-articular ^{99m}TcO₄⁻, 489*
- Endow, J. S.
see Krishnamurthy, G. T.
see Pritchard, J. H.
see Winston, M. A.
- Enlander, D., Weber, P. M. and dos Remedios, L. V. Renal cortical imaging with ^{99m}Tc-DMSA, 743
- Entine, G. see Garcia, D. A.
- Erickson, J. J., Brill, A. B., Patton, D. D., Williams, H. and Price, R. R. Automated brain bolus analysis, 489*
- Erjavec, M., Auersperg, M., Golouh, R., Snajder, J. and Turnšek, T. Computer-assisted ⁶⁷Ga-citrate scanning, 810
- Escovitz, E. see Charkes, N. D.
- Evens, R. G. see Paull, B. R.
- Everhart, H. see Witcofski, R. L.
- Fair, W. R. see DeGrazia, J. A.
- Fang, V. S. see Hoffer, P. B.
- Farmer, R. E. L.
see Rollo, F. D.
see Shames, D. M.
- Farrer, P. A., Guttman, R. D., Beauvoir, J. G., Morehouse, D. D. and Knaack, J. Radionuclide procedures in renal transplant patients, 489*
- Farrer, P. A. and Saha, G. B. Comparison of ¹¹¹InCl₃, ⁶⁷Ga-citrate and ^{199m}HgCl₂ in tumor bearing mice, 489*
- Farrer, P. A., Saha, G. B., Munro, D. D., Dollfuss, R. E., Meakins, J. F. and MacLean, L. D. ^{199m}HgCl₂ and ^{99m}Tc-MAA imaging of intrathoracic lesions, 490*
- Farrer, P. A. see Alter, A. J.
- Fawwaz, R. A., Frye, F., Loughman, W. D. and Hemphill, W. Skin homografting using ¹⁰⁹Pb-protoporphyrin, 997
- Feehan, P. see Ryo, U. Y.
- Feigin, D. S., Strauss, H. W. and James, A. E. Bone marrow scanning for osteomyelitis, 490*
- Feltrini, G. see Ravasini, R. G.
- Fenton, S. see Harrison, J. E.
- Ferreira, R. see Becker, L.
- Ficken, V. J. see Anderson, D. W.
- Figueroa, W. G. see Touya, J. J.
- Filmer, R. B. see Conway, J. J.
- Filo, R. see Kirchner, P.
- Fischer, K. C., Pendergrass, H. P., McKusick, K. A. and Potsaid, M. S. ^{99m}Tc-diphosphonate brain scan, 490*
- Fisher, R. L. see Danigelis, J. A.
- Fitzer P. M. ^{99m}Tc-polyporphosphate uptake in neuroblastoma, 904
- Fitzgerald, L. T. see Brookeman, V. A.
- Flamm, M. D. see Martin, N. D.
- Fleming, J. S. and Goddard, B. A. Absolute measurement of regional lung volume, 605
- Flentje, H. see Deckart, H.
- Fletcher, J. W. see Henry, R. E.
- Fletcher M. see Nodine, J. H.
- Fliegel, C. see Dewanjee, M. K.
- Floyd, R. M. see Wiener, S. N.
- Floyrac, R., Itti, R. and Planiol, T. Cardiac output and coronary blood flow with ¹³¹Cs, 491*
- Fontana, R. S. see Nolan, N. G.
- Fordham, E. W. see Rayudu, G. V. S.
- Forman, B. H., Antar, M. A., Touloudian, R. J., Mulrow, P. J. and Genel, M. ¹³¹I-cholesterol scan of metastatic adrenal carcinoma, 332
- Fortman, D. L. see Robbins, P. J.
- Foulkes, A. see Merrick, M. V.
- Fowler, J. S.
see Lambrecht, R. M.
see MacGregor, R. R.
- Franchi, R. see Tori, G.
- Francis, M. D. see Tofe, A. J.

AUTHOR INDEX

- Franco, J.**
see Kovaleski, B.
see Schreyer, M.
- Frankel, R. S., Richman, S. D., Gelrud, L. G. and Johnston, G. S.** Renal localization of ^{67}Ga -citrate, 491*
- Frankel, R. S., Richman, S. D., Levenson, S. M., Nelson, R. L., Ingle, J. N., Tormey, D. C., Jones, A. E. and Johnston, G. S.** Bone scintigraphy in breast carcinoma, 491*
- Frankel, R. S.** see Richman, S.D.
- Fratkin, M. J., Hirsch, J. I. and Sharpe, A. R.** ^{67}Ga scanning of postoperative abscesses, 491*
- Freedman, G. S. and Dwyer, A.** Cardiac ejection fraction, 491*
- Freedman, G. S.** see Handmaker, H.
- Freeman, L. M.** ^{131}I -rose bengal visualization of splenic blood pool, 823
- Freeman, L. M.**
see Blatt, C. J.
see Chayes, Z.
see Koenigsberg, M.
- Friedman, A. W., Oltman, B. G., Kastner, J., Eckerman, K. F. and Goodman, L. S.** ^{24}Cm and ^{149}Pm sources for bone mineralization studies, 335
- Friedman, A. M.**
see Colombetti, L. G.
see Kaplan, E.
see Mayron, L. W.
see Rayudu, G. V. S.
- Friedman, B. H., Lovegrove, F. T. A. and Wagner, H. N.** Variant in cerebral circulation studies, 363
- Friedman, B. H., Siegel, M. E. and Wagner, H. N.** Breast uptake of ^{99m}Tc -diphosphonate, 491*
- Friedman, B. H.**
see Rossman, D. J.
see Siegel, M. E.
- Friedman, B. I.**
see DeLand, F. H.
see McAfee, J. G.
- Front, D. and Penning, L.** Subcutaneous extravasation of CSF, 200
- Front, D.** see Penning, L.
- Fröhling, J. and Henry, J.** GI tract visualization in pancreas imaging, 220
- Frye, F.** see Fawwaz, R. A.
- Fuks, A.** see Desaulniers, M.
- Fukushima, K.** see Sasaki, Y.
- Fulmer, L. A. and Sfakianakis, G. N.** Cerebral ventricle visualization in brain scan, 202
- Funck-Brentano, J-L.** see Chanard, J.
- Furumatsu, C.** see Itoh, H.
- Fuzita, T.** see Itoh, H.
- Gall, E. P.** see Emerson, D. A.
- Ganatra, R. D.**
see Raikar, U. R.
See Ramanathan, P.
- Gander, M. P.** see Grames, C. M.
- Garafola, J. H.** see Park, C. H.
- Garcia, D. A., Entine, G. and Tow, D. E.** Bone scanning with a CdTe probe, 492*
- Garcia, D. A., Entine, G. and Tow, D. E.** Detection of small bone abscesses, 892
- Garcia, F.** see DeLand, F. H.
- Gardner, C.** see Rockett, J. F.
- Garnett, E. S.** see Bowen, B. M.
- Gates, G. F., Dore, E. K., Markarian, M. and Takenaka, J.** Infantile obstructive airway disease, 492*
- Gates, G. F., Orme, H. W. and Dore, E. K.** The hyperfused lung in congenital heart disease, 492*
- Gebhardt, M. E.** see Arnold, R. W.
- Geddes, E. W.**
see Kew, M. C.
see Levin, J.
- Gehring, D.** see Hoffman, G.
- Gelbard, A. S., Clarke, L. P. and Laughlin, J. S.** ^{15}N -asparagine for myocardial imaging, 1223
- Gelbard, A. S., Clarke, L. P., McDonald, J. M. and Laughlin, J. S.** ^{15}N -amino acids for myocardial scanning, 492*
- Gelbard, A. S.**
see Christie, T. R.
see McDonald, J. M.
- Gelrud, L. G.** see Frankel, R. S.
- Genant, H. K., Bautovich, G. J., Lathrop, K. A. and Harper, P. V.** Factors affecting uptake of bone agents, 493*
- Genant, H. K.** see Bautovich, G. J.
- Genel, M.** see Forman, B. H.
- Genna, S.** Book Review; *Tomographic Imaging in Nuclear Medicine*, 144
- Genna, S., Pang, S., Zimmerman, S. and Burrows, B.** Dual window spatial filtering, 493*
- Genna, S.** see Pang, S.
- George, E. A., Codd, J. E., Newton, W. T., Henry, R. E., Herbig, F. K. and Donati, R. M.** ^{99m}Tc -sulfur colloid imaging in kidney transplant rejection, 493*
- George, E. A., Shields, J. B., Cabal, E. C., Herbig, F. K. and Donati, R. M.** First transit deposit of ^{99m}Tc -sulfur colloid, 493*
- Gerber, M. S. and Miller, D. W.** Parallel-hole collimator design, 724
- Gerber, M. S.** see Miller, D. W.
- Geslien, G. E., Pinsky, S. M., Poth, R. K. and Johnson, M. C.** ^{99m}Tc -S colloid scanning in diffuse hepatocellular disease, 493*
- Geslien, G. E., Thrall, J. H. and Johnson, M. C.** ^{67}Ga scanning in hepatic amebic abscess, 561
- Geslien, G. E.** see Thrall, J. H.
- Chaud, N.** see Thrall, J. H.
- Chanadian, R.** see Chisholm, G. D.
- Giargiana, F. A.** see Siegel, M. E.
- Cibbs, W. D.** see Hodges, H. D.
- Gilday, D. L.** Bone scan in osteoid osteoma, 494*
- Gilday, D. L.** Pediatric cystic brain tumors, 494*
- Gilday, D. L. and Paul, D. J.** Osteomyelitis and cellulitis differentiation, 494*
- Gillespie, G. Y.** see Barth, R. F.
- Gillespie, P. J.** ^{99m}Tc -sulfur colloid lung retention, 728
- Gindler, J. E.**
see Colombetti, L. G.
see Kaplan, E.
see Mayron, L. W.
- Giorgetti, P. G.** see Tori, G.
- Gitomer, W.** see Sturman, M. F.
- Glass, H. I.**
see Chisholm, G. D.
see Szur, L.
- Glaubitt, D. M. H. and Haberland, K. U. R.** Kinetics of ^{111}In -citrate, 494*
- Glenn, H. J.** see Konowski, T.
- Gnau, T. R.** see Witcofski, R. L.
- Go, R. T., Chiu, C. L., Doty, D. B., Cheng, H-F. and Christie, J. H.** Myocardial contusion imaging with ^{99m}Tc -polyphosphate, 494*
- Go, R. T., Chiu, C. L., Doty, D. B., Cheng, H-F. and Christie, J. H.** Myocardial contusion imaging with ^{99m}Tc -polyphosphate, 1174
- Gobuty, A.** see Kennedy, T.
- Goddard, B. A.** see Fleming, J. S.
- Goergen, T. G., Alazraki, N. P., Halpern, S. E., Heath, V. and Ashburn, W. L.** "Cold" bone lesions, 1120
- Goergen, T. G., Halpern, S. E., Alazraki, N. P., Heath, V., Taketa, R. M. and Ashburn, W. L.** Photon deficient areas in bone scanning, 495*
- Gold, R. H.** see Samuels, B. I.
- Goldberg, B. B.** see Perlmutter, G. S.
- Goldberg, L. D.** see Cohen, G. A.
- Goldberg, M. E.** see Tully, T. E.
- Goldman, M.** see Riggins, R. S.
- Goldsmith, R. E.** see Chen, I-W.
- Golouh, R.** see Erjavek, M.
- Good, A. E.** see Pozderac, R. V.
- Goodman, L. S.** see Friedman, A. M.
- Goodman, S. J. and Hayes, M.** Isotope flow studies and aneurysm surgery, 1113
- Goodrich, J. K.**
see Harris, C. C.
see Jones, R. H.
see Tyson, J. W.
see Witherspoon, L. R.
- Goodwin, D. A., Diamanti, C. I., Meares, C. F. and Sundberg, M. W.** Angular correction measurement with positron camera, 495*
- Goodwin, D. A., Meares, C. F., Diamanti, C. I. and Sundberg, M. W.** Bifunctional chelates, 495*
- Goodwin, D. A.**
see Diamanti, C. I.
see Lin, M. S.
see Matin, P.
- Goodwin, P. M.** see Rao, D. V.
- Goodyear, M.** see Grove, R. B.
- Gordon, M. E.** see Puri, S.
- GORLIN, R.** see Holman, B. L.
- Gorten, R. J., Nishimura, A. and Williams, J. F.** K myocardial scan accuracy, 495*
- Goswitz, F.** Spleen scanning in lymphoma and lymphocytic leukemia, 496*

- Goswitz, F., Morris, C., Kim, K. and Hansard, M.** RE function in hematologic disease, 495*
- Gottlieb, S.** see Kallos, N.
- Gottschalk, A., Oppenheim, B. E., Beckerman, C. and Hoffer, P. B.** Advanced liver imaging, 496*
- Gottschalk, A.** see Bekerman, C.
- Gould, K. L.** see Hamilton, G. W.
- Graham, L. S., Krishnamurthy, G. T. and Blahd, B. H.** Dosimetry of bone agents, 496*
- Graham, T. A., Hall, J. N. and O'Mara, R. E.** Radiation dose versus cost and quality control, 496*
- Graham T. P.** see Ivancevic, D.
see Rhea, T. C.
- Grames, G. M., Jansen, C., Gander, M. P., Wieland, H. C. and Judkins, M. P.** Safety of direct coronary injection, 3
- Grames, G. M., Reiswig, R., Jansen, C. and Herber, R.** Consecutive day Schilling tests, 949
- Grames, G. M.** see Adams, R.
see Wieland, H. C.
- Grando R. E.** see Yeh, S. D. J.
- Grandonicco, F.** see Capelli, G.
see Masi, R.
- Gray, F.** see Kirchner, P.
- Grebe, S. F., Siemsen, J. K., Wentz, D. and Sargent, E. N.** ^{67}Ga studies in chest disease, 497*
- Green, J.** see Halpern, S. E.
- Green, M. V., Ostrow, H. G., Douglas, M. A., Scott, R. N., Myers, R. W., Bailey, J. J. and Johnston, G. S.** ECG gated imaging of ventricular function, 497*
- Greenberg, A.** see Poe, N. D.
- Greenlaw, R. H.** A cooperative group to study radiopharmaceutical localization, 497*
- Greenlaw, R. H., Weinstein, M. B., Brill, A. B., McBain, J. K., Murphy, L. and Kniseley, R. M.** ^{67}Ga -citrate in malignant lymphoma, 404
- Greenwald, A. J., Chaudhuri, Tapan K., Heading, R. C. and Chaudhuri, Tuhin K.** Gastric emptying time, 497*
- Greenwald, A. J.** see Chaudhuri, Tapan K.
- Greig, W. R.** see Citrin, D. L.
- Greyson, N. D. and LeBlanc, J.** Scattered radiation in cerebral flow studies, 1035
- Grieco, R. V.** see Yang, C-S.
- Groothedde, M.** see Billinghurst, M. W.
- Grove, R. B., Reba R. C., Eckelman, W. C. and Goodyear, M.** Radiolabeled bleomycin, 387
- Gulesserian, H. P.** see Chaudhuri, Tapan K.
- Gullberg, G. T. and Budinger, T. F.** Attenuation correction for 3-D imaging, 497*
- Gullberg, G. T.** see Budinger, T. F.
- Gutcho, S.** see Rutner, H.
- Guth, P.** see Winston, M. A.
- Gutkowski, R. F. and Dworkin, H. J.** Kit for ^{99m}Tc -Sn-glucoheptanate for RBC labeling, 498*
- Gutkowski, R. F. and Dworkin, H. J.** Kit-produced ^{99m}Tc -RBC for spleen imaging, 1187
- Guttman R. D.** see Farrer, P. A.
- Haberland, K. V. R.** see Glaubitt, D. M. H.
- Habibian, M. R. and Abernathy, E. M.** Splenomegaly in sarcoidosis, 45
- Hafner, T.** see Beihn, R. M.
- Hagan, P., Loberg, M. D., Rhodes, B. A., Harrison, K. and Cooper, M. D.** Kit preparation of ^{131}I -fibrinogen, 974
- Hall, J. N., Jeffrys, D. P. and O'Mara, R. E.** ^{203}Pb for erythrocyte labeling, 499*
- Hall, J. N., O'Mara, R. E. and Cruz, P.** ^{67}Cu -bleomycin for tumor imaging, 498*
- Hall, J. N.** see Graham, T. A.
- Hallaba, E. and El-Shaboury, G.** ^{131}I -labeled thyroid hormone preparation, 270
- Halpern, S. E., Alazraki, N. P., Littenberg, R. L., Hurwitz, S. R., Green, J., Kunsa, J. and Ashburn, W. L.** Thyroid uptake of ^{131}I , 213
- Halpern, S. E., Ashburn, W. L. and Alazraki, N. P.** Radionuclide cisternography and surgical shunts, 465
- Halpern, S. E.** see Alazraki, N. P.
see Breslow, W.
see Chauncey, D. M.
see Goergen, T. G.
see Higgins, C. B.
see Schelbert, H. R.
- Halse, T.** see Peabody, R. A.
- Hamamoto, K., Yamamoto, I., Morita, R., Mori, T. and Torizuka, K.** Bone scintigraphy and metabolism with ^{99m}Tc -pyrophosphate, 498*
- Hamamoto, K.** see Itoh, H.
see Mori, T.
- Hamburger, J. I.** Subacute thyroiditis, 81
- Hamilton, G. W., Gould, K. L., Allen, D. and Ritchie, J. L.** Stress-induced myocardial ischemia, 499*
- Hamilton, G. W., Ritchie, J. L., Gould, K. L. and Allen, D. R.** Stress-induced myocardial ischemia, 499*
- Hamilton, G. W.** see Allen, D. R.
- Hammock, M. K.** see DiChiro, G.
- Hanc, R. P.** see Turner, J. W.
- Handmaker, H. and Freedman, G. S.** Diagnosis of splenic abscess, 499*
- Handmaker, H., Young, B. W. and Stutzman, R. E.** ^{99m}Tc -DMSA for kidney imaging, 499*
- Hannah, T.** see Brown, M. L.
- Hansard, M.** see Goswitz, F.
- Hara, K.** see Kasahara, A.
- Harbert, J. C.** ^{131}I -HSA and ^{100}Yb -DTPA for cisternography, 917
- Harbert, J. C. and Wells, N.** Radiation exposure to patient's family, 499*
- Harbert, J. C. and Wells, N.** Radiation exposure to patient's family, 887
- Harbert, J. C.** see Ledley, R. S.
- Hare, D. L., Hendee, W. R., Whitney, W. P. and Chaney, E. L.** Well ionization chamber calibrators, 1138
- Harness, J. K.** see Beierwaltes, W. H.
- Harper, P. V., Rich, B., Lembares, N. and Lathrop, K. A.** Imaging with ^{81}Rb - ^{81}Kr , 500*
- Harper, P. V.** see Bautovich, G. J.
see Genant, H. K.
see Oppenheim, B. E.
- Harris, C. C., Jones, R. H., Goodrich, J. K., Witherspoon, L. R. and Bates, B. B.** Maximum count rates for dynamic studies, 500*
- Harris, C. C.** see Briner, W. H.
see Witherspoon, L. R.
- Harrison, J. E., McNeill, K. G., Meema, H. E., Fenton, S., Oreopoulos, D. G. and Sturbridge, W. C.** Partial body Ca by neutron activation analysis and x-ray photodensitometry, 929
- Harrison, K.** see Hagan, P.
- Hartman, R. C.** see Staab, E. V.
- Hartnett, D. E.** see Allen, D. R.
- Harvey, W. C. and Silva, J.** ^{55}Cr -leukocyte abscess detection, 375
- Harwig, J. F., Coleman, R. E., Harwig, S. L., Welch, M. J., Sherman, L. A. and Siegel, B. A.** Iodinated fibrinogen for pre-formed thrombi, 500*
- Harwig, S. S. L.** see Harwig, J. F.
- Hattner, R. S., Maltz, H. and Holliday, M.** ^{131}I -hippurate scan in nephrosis, 500*
- Hattner, R. S., Miller, S. W. and Schimmel, D.** Renal asymmetry in bone scans, 500*
- Hattner, R. S. and Shames, D. M.** Liver hot spot, 1041
- Hattner, R. S.** see Huberty, J. P.
- Hauser, W.** Accuracy of radioactivity assay procedures, 501*
- Hawkins, D.** see Desaulniers, M.
- Hayden, P.** see Rudd, T. G.
- Hayes, M.** see Goodman, S. J.
- Hayes, R. L., Brown, D. H., Byrd, B. L. and Carlton, J. E.** Distribution of ^{67}Ga and rare earth radionuclides, 501*
- Hayes, R. L., Brown, D. H. and Carlton, J. E.** Subcellular distribution of ^{67}Ga , ^{111}In , ^{203}Bi and ^{167}Tm , 501*
- Haynie, T. P.** see Konikowski, T.
- Hays, M. T.** Intestinal absorption of pertechnetate, 316
- Hayt, D. B.** see Blatt, C. J.
- Head, H.** see Burleson, R. L.
- Heading, R. C.**

AUTHOR INDEX

- see Chaudhuri, Tapan K.
see Greenwald, A. J.
- Heasty, R. G.** see Wenzel, W. W.
- Heath, V.** see Goergen, T. G.
- Heck, L. L., Coles, J. L., VanHove, E. D. and Riley, T. W.** 99m TcO₄-imaging in testicular torsion evaluation, 501*
- Heck, L. L.** see VanHove, E. D.
- Hegedus, F.** see Peek, N. F.
- Heminger, L.**
see Scharoff, J. R.
see Thomas, F. D.
- Hemphill, W.** see Fawwaz, R. A.
- Hendee, W. R.** see Hare, D. L.
- Henkin, R. E., Yao, J. S. T. and Bergan, J. J.** 99m Tc-albumin aortography, 502*
- Henkin, R. E., Yao, J. S. T., Quinn, J. L. and Bergan, J. J.** Radionuclide venography, 171
- Henkin, R. E., Yao, J. S. T., Quinn, J. L. and Bergan, J. J.** Radionuclide venography, 915
- Henning, H.** see Schelbert, H. R.
- Henry, J.** see Frühling, J.
- Henry, R. E., Fletcher, J. W., Solaric-George, E. and Donati, R. M.** Marrow RE patterns, 343
- Henry, R. E.** see George, E. A.
- Herber, R.** see Grames, G. M.
- Herbig, F. K.** see George, E. A.
- Herzmann, H.** see Deckart, H.
- Heyssel, R. M.** see McKee, L. C.
- Higashi, T., Kanno, M. and Tomura, K.** Tumor uptake of 67 Ga-citrate and 67 Co-bleomycin, 1167
- Higgins, C. B., Taketa, R. M., Taylor, A., Halpern, S. E. and Ashburn, W. L.** Renal uptake of 99m Tc-sulfur colloid, 564
- Higgins, H. P.** see McQuade, S.
- Hilal, S. K.** see Johnson, P. M.
- Hill, J. H. and Wagner, H. N.** 67 Ga uptake in regenerating rat liver, 818
- Hines, H. H., Peek, N. F. and DeNardo, G. L.** Cyclotron production and properties of 136 Xe, 502*
- Hinn, G. M.** see Lewellen, T. K.
- Hiraki, T.** see Hisada, K.
- Hirsch, J. I.** see Fratkin, M. J.
- Hisada, K., Ando, A., Hiraki, T. and Sanada, S.** Mechanism of tumor uptake of 103 Yb, 67 Ga and 113 In, 502*
- Hisada, K., Tonami, N., Hiraki, T. and Ando, A.** Tumor scanning with 103 Yb-citrate, 210
- Hisada, K.** see Tonami, N.
- Hodges, H. D., Gibbs, W. D., Morris, A. C. and Coffey, W. C.** High-level whole-body counter, 610
- Hodkinson, B. A.** see McIntyre, P. A.
- Hoffer, P. B., Lathrop, K. A., Bekerman, C., Fang, V. S. and Refeoff, S.** 131 CEA-antibody as a tumor imaging agent, 323
- Hoffer, P. B.**
see Bautovich, G. J.
see Bekerman, C.
see Bernstein, J.
- see McCartney, W. H.
see Gottschalk, A.
- Hoffman, G. and Gehring, D. T.** and thyroid hormone metabolism, 502*
- Holan, T. S., Miclutia, M., Rodan, G. and Toma, N.** Radiation dose in gynecologic 137 Cs therapy, 502*
- Hollenberg, N. K.** see Kinoshita, M.
- Holliday, M.** see Hattner, R. S.
- Hollifield, J.** see Patton, J. A.
- Holman, B. L., Lesch, M., Zwieman, F. G., Temte, J., Dewanjee, M. K., Lown, B. and Gorlin, R.** Myocardial infarct studies with 99m Tc-tetracycline, 503*
- Holman, B. L.**
see Kaplan, W. D.
see Kinoshita, M.
see McNeil, B. J.
see Zweiman, F. G.
- Holmes, R.** see Nodine, J. H.
- Holmes, R. A., Isitman, A. T., Manoli, R. and Zimmer, A. M.** Alveolar retention of 99m Tc-Sn phytate, 503*
- Holmes, R. A.**
see Kaplan, W. D.
see McAfee, J. G.
see Zimmer, A. M.
- Hook, G. R.** see McRae, J.
- Hoop, B.** see Ahluwahlia, B.
- Horiuchi, K.** see Mena, I.
- Horn, W. C.** see Meade, R. C.
- Hossain, F.** Quality control of 99m Tc-DTPA, 442
- Hotte, C. E. and Ice, R. D.** 131 I-19-iod cholesterol stability, 38
- Howell, T. R.** see Tinglestad, J. B.
- Hrabák, A.** see Szabó, M. T.
- Hsu, J. D.** see Sakimura, I. T.
- Huberty, J. P.** Shelf-life of 99m Tc-MAA kits, 464
- Huberty, J. P., Hattner, R. S. and Powell, M. R.** 99m Tc-pyrophosphate kit, 124
- Hueboller, R. J.** see Krishnamurthy, G. T.
- Hulley, S.** see Vogel, J. M.
- Hung, S. T.-C.** see Price, D. C.
- Hunter, W. W.** see Miller, D. W.
- Hurwitz, S. R., Alazraki, N. P. and Kessler, W. O.** Pyelonephritis diagnosis with 67 Ga-citrate, 503*
- Hurwitz, S. R.**
see Alazraki, N.
see Halpern, S. E.
- Huth, G.** see Spolter, L.
- Huttig, M.** Anger camera deadtime, 468
- Ice, R. D., Wieland, D. M., Beierwaltes, W. H. and Lawton, R. G.** Preparation and distribution of dopamine analogs, 503*
- Ice, R. D.**
see Balachandran, S.
see Beierwaltes, W. H.
see Hotte, C. E.
see Ryo, U. Y.
see Sturman, M. F.
- Idoine, J.** see Zweiman, F. G.
- Iio, M.** Diagnosis in geriatrics, 503*
- Inada, S.** see Kaneko, M.
- Ingle, J. N.** see Frankel, R. S.
- Inia, P.** Reduction of scattered radiation effects, 316
- Inukai, A.** see Kaneko, M.
- Isaacs, H. S.** see Steigman, J.
- Ishii, Y., Kawamura, J., Mukai, T., Takahashi, M., Onoyama, Y. and Torizuka, K.** Imaging intrarenal blood flow, 504*
- Ishii, Y.** see Itoh, H.
- Ishikawa, S.** see Serino, T. V.
- Isitman, A. T.**
see Holes, R. A.
see Kaplan, W. D.
see Zimmer, A. M.
- Itoh, H., Ishii, Y., Mori, T., Hamamoto, K., Fuzita, T., Furumatsu, C., Torizuka, K. and Takahashi, K.** Aerosol deposition in the respiratory tract, 504*
- Itti, R.**
see Floyrac, R.
see Planiol, T.
- Ivancevic, D., Price, R. R., Rhea, T. C., Graham, T. P. and Brill, A. B.** Pulsatile flow model for cardiac shunt estimates, 504*
- Ivancevic, D.** see Rhea, T. C.
- Iwasaki, J.** see Kasahara, A.
- Jackson, P. E.**
see Berman, D. S.
see DeGrazia, J. A.
see DeNardo, S. J.
- Jacobstein, J. G.** 133 Xe ventilation following 99m Tc perfusion scan, 964
- Jahns, M. F.** see Konikowski, T.
- James, A. E.** see Feigin, D. S.
- Jansen, A.** see Boyett, J. D.
- Jansen, C.**
see Adams, R.
see Grames, C. M.
see Wieland, H. C.
- Jansholt, A. L.** see Carretta, R. F.
- Jeffreys, D. P.** See O'Mara, R. E.
- Johnson, A.** see Schelbert, H. R.
- Johnson, J.** see Rutner, H.
- Johnson, L. E.** see McKee, L. C.
- Johnson, M. C.**
see Burleson, R. L.
see Geslien, G. E.
see Thrall, J. H.
- Johnson, P. M., Hilal, S. K., Sciaccia, P. R., Brust, J. C. M. and Cannon, P. J.** Regional cerebral blood flow, 504*
- Johnston, A. S.** see Arnold, J. E.
- Johnston, G. S., Benua, R. S., Teates, C. D., Edwards, C. L. and Kniseley, M.** 67 Ga-citrate in Hodgkin's disease, 399
- Johnston, G. S.**
see DiChirop, G.
see Frankel, R. S.
see Green, M. V.
see Richman, S. D.
- Johnston, R.** see Serino, T. V.
- Johnston, R. E.** see McKee, L. C.
- Jones, A. E.**
see DiChirop, G.
see Frankel, R. S.
- Jones, A. G. and Davis, M. A.** Thiocyanate complexes of technetium, 505*
- Jones, A. G.** see Davis, M. A.
- Jones, J. J.** Plasma renin assay, 220

- Jones, J. S.** see Beihn, R. M.
Jones, L. W. see Rogers, W. L.
Jones, R. H., Goodrich, J. K. and Sabiston, D. C. ^{133}Xe techniques and regional ventilation, 599
Jones, R. H. see Harris, C. C.
Jones, S. E. see Lilien, D. L.
Jones, T., Brownell, G. L. and Ter-Pogossian, M. M. Equilibrium images of ^{15}O labeled CO, CO_2 and O₂, 505*
- Jones, T.** see Ahluwahlia, B.
Judkins, M. P. see Grames, C. M.
Jungerman, J. A. see DeNardo, S. J.
Kahn, P. C. see Dewanjee, M. K.
Kallos, N., Gottlieb, S. and Miale, A. Echocardiography and radionuclide angiography in pericardial perfusion, 505*
- Kameda, H.** see Sasaki, Y.
Kanarek, D. see Ahluwalia, B.
Kaneko, M., Inada, S. and Inukai, A. Axial view in liver imaging, 505*
- Kanno, M.** see Higashi, T.
Kanoor, R. see Rayudu, G. V. S.
Kaplan, E., Mayron, L. W., Barnes, W. E., Colombetti, L. G., Friedman, A. M. and Gindler, J. E. Capillary exchange studies with ^{85}Kr , 874
- Kaplan, E.**
 see Colombetti, L. G.
 see Mayron, L. W.
 see Sparagana, M.
Kaplan, S. N. see Chang, L-T.
Kaplan, W. D. and Holman, B. L. Delayed bone scanning, 1228
Kaplan, W. D., Holman, B. L., Liebow, P. A. and Davis, M. A. Delayed ^{99m}Tc -polyphosphate bone imaging, 47
Kaplan, W. D., Holman, B. L., Selenkov, H. A., Davis, M. A., Holmes, R. A., Isitman, A. T. and Chandler, H. L. ^{67}Ga -citrate in the thyroid nodule, 424
Karelitz, J. R. and Richards, J. B. Evaluating thyroid nodules with oblique views, 782
Kariyone, S. see Uchida, T.
Karran, S. J., Leach, K. G. and Blumgart, L. H. Rat liver regeneration, 10
Kasahara, A., Ochi, H., Tamaki, M., Iwasaki, J. and Hara, K. ECG-gated dilution curves of the right heart, 505*
- Kastner, J.** see Friedman, A. M.
Katz, J. H. see Lusins, J.
Kaufman, L. see Price, D. C.
Kawamura, J. see Ishii, Y.
Kay, C. J. and Rosenberg, M. A. ^{99m}Tc -polyphosphate uptake in secondary hypertrophic osteoarthropathy, 312
Kay, D. B., Keyes, J. W. and Simon, W. Fourier transform techniques for tomographic image reconstruction, 981
Kazemi, H. see Ahluwahlia, B.
Kehr, M. D. see Krishnamurthy, G. T.
Kennedy, T., Robinson, R. G. and
- Gobuty, A.** ^{99m}Tc -penicillamine for kidney scanning, 506*
- Kessler, W. O.** see Hurwitz, S. R.
Kew, M. C., Geddes, E. W. and Levin, J. False negative ^{75}Se -selenomethionine liver scans, 234
Kew, M. C. see Levin, J.
Keyes, J. W. Limitations of orthogonal tangent correction, 378
Keyes, J. W.
 see Aita, J. F.
 see Kay, D. B.
 see Snow, R. M.
 see Walters, T. E.
 see Wilson, G. A.
Khalil, F. L. see Rao, D. V.
Khentigan, A. S.
 see Lamb, J. F.
 see Lin, T. H.
Kim, K. see Goswitz, F.
King, G. see Christy, B.
King, L. R. see Chen, I-W.
King, M. F. see Davis, M. A.
King, P. C. see Boddy, K.
Kinoshita, F., Ushio, T., Malkawa, A., Ariwa, R. and Kubo, A. ^{67}Ga -citrate scanning of lung disease, 227
Kinoshita, M., Holman, B. L., Zimmerman, R. E., Adams, D. F., Adelstein, S. J. and Hollenberg, N. K. Regional intrarenal perfusion in man, 775
Kinsley, M. see Lebowitz, E.
Kirch, D. L., Metz, C. E., Steele, P. P. and Brown, D. W. Pulsatile regurgitant heart model, 506*
- Kirch, D. L., Steele, P. P., Trow, R. S., LeFree, M. T. and Brown, D. W.** Silicon diode array for an image intensifier camera, 506*
- Kirchner, F. R.** see Robinson, R. G.
Kirchner, P., Gray, F., Short, D. and Filo, R. Gamma camera and flow meter measurement of renal blood flow, 506*
- Kiser, S. R.** see Lawson, M. A.
Kitani, K. and Taplan, G. V. Rapid hepatic turnover of radioactive HSA, 938
Klein, H. A. see Silver, L.
Klingensmith, W. C. Spleen uptake of ^{99m}Tc -sulfur colloid in melanoma, 1203
Klingensmith, W. C. ^{99m}Tc -sulfur colloid retention by lung, 727
Klingensmith, W. C. and Lovett, V. J. Lung uptake of ^{99m}Tc -sulfur colloid, 1028
Klinger, L. ^{32}P therapy for thyroid adenocarcinoma metastases, 1037
Klotz, P. see Lebowitz, E.
Knaack, J. see Farrer, P. A.
Kniseley, R. M.
 see DeLand, F. H.
 see Greenlaw, R. H.
 see Johnston, G.
Knoll, G. F., May, R. S. and Akcasu, Z. Pseudorandom filters and correlation analysis of gamma imaging, 507*
- Knoll, G. F., Strange, D. R. and O'Neill, W. J.** Deadtime by decaying source method, 507*
- Knowles, L. G., Bonwit, K. S., Bonwit, S. E., Kohlenstein, L. C. and Schulz, A. G.** Observer count estimation of paired kidneys, 507*
- Koenigsberg, M. and Freeman, L. M.** The total body scintillation effect, 507*
- Koenigsberg, M., Novich, I., Lory, M., Freeman, L. M. and Blaufox, M. D.** Asymmetrical renal perfusion, 507*
- Koenigsberg, M.** see Chayes, Z.
Kohlenstein, L. C. see Knowles, L. G.
Konikowski, T., Haynie, T. P. and Glenn, H. J. Kinetics of ^{111}In -bleomycin and ^{111}In -chloride in mice, 508*
- Konikowski, T., Jahns, M. F., Haynie, T. P., and Glenn, H. J.** Brain tumor agents in an animal model, 508*
- Kopp, J.** see Preston, D. F.
Koral, K. F., Rogers, W. L. and Beierwaltes, W. H. Time modulated pseudorandom aperture, 508*
- Korein, J.** see Braunstein, P.
Kovalski, B., Vanags, K., Schreyer, M. and Franco, J. Diagnosis of hepatic amebiasis, 508*
- Kovaleski, B.** see Schreyer, M.
Kozar J. see Charkes, N. D.
Krejcarek, G. E., Bradford, K. L. and Bolles, T. F. ^{99m}Tc -HSA microsphere kit, 509*
- Kricheff, I. I.** see Braunstein, P.
Krishnamurthy, G. T., Endow, J. S., Walsh, C. F., Singhi, V., Tubis, M. and Blahd, W. H. Kinetics of ^{99m}Tc -polyphosphate and -diphosphonate, 509*
- Krishnamurthy, G. T., Huebotter, R. J., Walsh, C. F., Kehr, M. D., Taylor, J. R., Tubis, M. and Blahd, W. H.** Kinetics of ^{99m}Tc -polyphosphate and -pyrophosphate, 509*
- Krishnamurthy, G. T., Thomas, P. B., Tubis, M., Endow, J. S., Pritchard, J. H. and Blahd, W. H.** ^{99m}Tc -polyphosphate and ^{18}F kinetics, 832
- Krishnamurthy, G. T., Tubis, M., Endow, J. S., Singhi, V., Walsh, C. F. and Blahd, W. H.** ^{99m}Tc -polyphosphate and -diphosphonate kinetics, 848
- Krishnamurthy, G. T., Walsh, C. F., Shoop, L. E., Berger, H. G. and Blahd, W. H.** ^{99m}Tc -polyphosphate and ^{18}F imaging, 837
- Krishnamurthy, G. T.** see Graham, L. S.
Kriss, J. P. see Lin, M. S.
Krizek, H. see Bautovich, G. J.
Kruse, S. L. see Lin, M. S.
Kubo, A. see Kinoshita, F.
Kubota, H. see Eckelman, W. C.
Kuhl, D. E. and Edwards, R. Q. Orthogonal tangent correction, 379
Kuhl, D. E., Reivich, M., Alavi, A., Nyary, L. and Staum, M. Local cerebral blood volume using transverse section scanning, 509*

AUTHOR INDEX

- Kuhl, D. E.**
see Alavi, A.
see Rothenberg, H.
- Kuisk, H.** see Shafer, R. B.
- Kunsa, J.** see Halpern, S. E.
- Kusubov, N.** see Pierson, R. N.
- Kutka, N.** see DePuey, G.
- Lacourciere, Y.** see Desaulniers, M.
- Laguarda, R.** see Treves, S.
- Lamb, J. F., Khentigan, A. S., Baker, G. A. and Winchell, H. S.** Regional myocardial perfusion imaging with ^{81}Rb , 509*
- Lambrecht, R. M., Atkins, H. L., Elias, H., Fowler, J. S., Lin, S. S. and Wolf, A. P.** A novel ^{123}I labeling reagent, 863
- Lambrecht, R. M.** see Atkins, H. L.
- Lamson, M., Callahan, R. J., Castrovovo, F. P., McKusick, K. A. and Potsaid, M. S.** Free activity in ^{99m}Tc -albumin preparations, 1061
- Lanaro, A. E., Dietrich, R. and Bosch, A.** Diagnostic potential of the radiosophagogram, 510*
- Landaw, S.** see Pierson, R. N.
- Laor, Y.** see Mattar, A.
- Larson, S. M., Charache, P., Chen, M. and Wagner, H. N.** Antisera inhibition of streptococci and salmonella, 510*
- Larson, S. M., Merz, T. and Wagner, H. N.** Radiometric screening test of cell-mediated immunity, 510*
- Larson, S. M.**
see Amrein, P. C.
see Camargo, E. E.
see Chen, M.
see McIntyre, P. A.
see Thrall, J. I.
- Lasa-Perez, D., Martos, A. and Perez-Modrego, S.** Preparation of ^{99m}Tc -MAA, 510*
- Lathrop, K. A.**
see Bautovich, G. J.
see Genant, H. K.
see Harper, P. V.
see Hoffer, P. B.
- Laughlin, J. S.**
see Mayer, K.
see Christie, T. R.
see Gelbard, A. S.
see McDonald, J. M.
see Monahan, W. G.
see Pentlow, K. S.
see Russ, G. A.
- Lawrence, D.** see Mishkin, F. S.
- Lawrence, E.** see McCartney, W. H.
- Lawson, M. A. and Kiser, S. R.** Programable desk top calculator, 511*
- Lawton, R. G.** see Ice, R. D.
- Leach, K. G.** see Karran, S. J.
- Learner, N.** see Charkes, N. D.
- LeBel, E.** see Tran, N.
- LeBlanc, J.** see Greysen, N. D.
- Lebowitz, E., Kinsley, M., Klotz, P., Bachsmith, C., Ansari, A. N., Richards, P. and Atkins, H. L.** Development of ^{75}Ru and ^{67}Cu , 511*
- Lebowitz, E.** see Steigman, J.
- Lecky, J. W.** see Samuels, B. I.
- Ledley, R. S., Ommaya, A. K.** and Harbert, J. C. Transverse axial tomography, 511*
- Lee, A. W.** see Poe, N. D.
- Lee, A. Y.** see Robinson, G. D.
- Lee, G. C., Wilson, R. L., Waxman, A. D. and Siemsen, J. K.** Correlation of scans and ultrasound in focal liver disease, 511*
- Lee, G. C.** see Waxman, A. D.
- Lee, J. I.** see Ryo, U. Y.
- Lee, M. S.** see Patton, J. A.
- Lee, W. Y.** see Tashima, C. K.
- Leeper, R. D., Powell, M. and Benua, R. S.** Measurement of $^{99m}\text{TcO}_4^-$ thyroid uptake, 1117
- Le Farge, G.** see Treves, S.
- LeFree, M. T.** see Kirch, D. L.
- Leh, F. K. V.** see Berman, J. A.
- Lembares, N.**
see Bautovich, G. J.
see Harper, P. V.
- Lemmon, R.** see Pierson, R. N.
- Lenkszus, F. R.** see Strauss, M. G.
- Lensink, S. C.** see Ehrhardt, J. C.
- Leonard, J. R.** see Witherspoon, L. R.
- Leong, A.** see Tashima, C. K.
- Lerner, S. R.** see Pircher, F. J.
- Lesch, M.** see Holman, B. L.
- Levenson, N. I.** see Ashare, A. B.
- Levenson, S. M.** see Frankel, R. S.
- Levin, G. E.** see Agnew, J. E.
- Levin, J., Geddes, E. W. and Kew, M. C.** Scanning in primary hepatic cancer, 297
- Levin, J.** see Kew, M. C.
- Levin, S. C.** see Stevenson, J. S.
- Levy, G.** Fresnel zone plate imaging, 214
- Lewellen, T. K., Nelp, W. B., Palmer, H. E., Murano, R., Hinn, C. M. and Chesnut, C. H.** ^{113}In excretion after total body neutron activation, 511*
- Lewis, G.** see Nodine, J. H.
- Lewis, J. T.** see Nishiyama, H.
- Lewis, S. E.** see Stokely, E. M.
- Liang, J.-C.** see Yeh, S.-H.
- Liao, S.-Q.** see Yeh, S.-H.
- Licinska, I.** see Szymendera, J.
- Liebow, P. A.** see Kaplan, W. D.
- Lilien, D. L., Jones, S. E. and O'Mara, R. E.** ^{113}In -bleomycin in lymphoma, 512*
- Lilien, D. L., Jones, S. E., O'Mara, R. E., Salmon, S. E. and Durie, B. G.** Clinical evaluation of ^{113}In -bleomycin, 512*
- Lin, M. S., Goodwin, D. A. and Kruse, S. L.** ^{99m}Tc -bleomycin for tumor imaging, 338
- Lin, M. S., Kruse, S. L., Goodwin, D. A. and Kriss, J. P.** Saline paper analysis of ^{99m}Tc -albumin, 1018
- Lin, S. S.** see Lambrecht, R. M.
- Lin, T. H., Khentigan, A. S. and Winchell, H. S.** ^{99m}Tc -DMSA for kidney studies, 34
- Lin, T. H., Khentigan, A. S. and Winchell, H. S.** ^{99m}Tc -DMSA for renal imaging, 512*
- Lin, T. H., Khentigan, A. S. and Winchell, H. S.** ^{99m}Tc -Sn-mercapto-iso-butyric acid for biliary studies, 613
- Littenberg, R. L.**
see Alazraki, N. P.
see Halpern, S. E.
- Loberg, M. D.** see Hagan, P.
- Lockwood, D.** see Vogel, J. M.
- Loken, M. K.**
see Domek, N. S.
see Payne, J. T.
see Preimesberger, K. F.
see Tully, T. E.
- Lopez, G.** see Mena, I.
- Lory, M.** see Koenigsberg, M.
- Loughman, W. D.** see Fawwaz, R. A.
- Lovegrove, F. T. A.** see Friedman, B. H.
- Lovett, V. J.** see Klingensmith, W. C.
- Lown, B.** see Holman, B. L.
- Lucas, Z. J.** see DeGrazia, J. A.
- Luck, S.** see Conway, J. J.
- Lusins, J. and Katz, J. H.** Imaging in unoperated subdural hematoma, 1084
- Lyster, D. M., Scott, J. R., Mineey, E. K. and Morrison, R. T.** Preparation of a ^{99m}Tc -Sn-MAA kit, 198
- Maass, R. E., Pérez, R. E. and Montesinos, R. M. C.** Kinetics of ^{131}I -Hippuran, 512*
- Maass, R. E.** see Alvarez, J.
- Macdonald, B.** see Chang, L-T.
- MacDonald, N. S., Bennett, L. R., Uszler, J. M., Robinson, G. D. and Takahashi, J.** Distribution of ^{13}C -ethanol, 512*
- MacDonald, N. S., Neely, H. H., Wood, R. A., Takahashi, J. M., Wakakuwa, S. T. and Birdsall, R. L.** Cyclotron production of ^{113}In , 513*
- MacDonald, N. S.**
see Cohen, M. B.
see Poe, N. D.
see Pritchard, J. H.
see Spolter, L.
see Uszler, J. M.
- MacDonnell, K. F.** see Serino, T. V.
- MacGregor, R. R., Ansari, A. N., Atkins, H. L., Christman, D. R., Fowler, J. S. and Wolf, A. P.** ^{18}F -6-fluorodopamine for adrenal scanning, 513*
- Machida, T.** see Miki, M.
- MacIntyre, W. J., Rubinson, B., Sufka, B. and Arnold, J.** Display systems for computerized transaxial tomographs, 513*
- MacLean, L. D.** see Farrer, P. A.
- Macri, C.** see Mantero, F.
- Maekawa, A.** see Kinoshita, F.
- Mahaley, M. S.** see Witherspoon, L. R.
- Maher, F. T.** see Nolan, N. G.
- Mahler, D. J.** see Boyett, J. D.
- Maier, W. P.** see Charkes, N. D.
- Maisey, M. N.** see McHardy-Young, S.
- Malmud, L. S.** see Perlmutter, G. S.
- Maltz, D. L.** see Treves, S.
- Maltz, H.** see Hattner, R. S.
- Manoli, R.** see Holmes, R. A.
- Mantero, F., Macri, C. and Austoni,**

- M.** Unilateral vs. bilateral adrenal disease, 513*
- Marabini, A.** see Tori, G.
- Marin, M.** see Ortiz-Berrocral, J.
- Markarian, M.** see Gates, G. F.
- Martin, C. B.** see Elings, V. B.
- Martin, N. D., Zaret, B. L., McGowan, R. L., Wells, H. P. and Flamm, M. D.** ^{82}Rb vs. ^{45}K for myocardial perfusion scans, 514*
- Martin, P.** see Cavalieri, R. R.
- Martin, R. B.** see Siemson, J. K.
- Martinez, J. R.** see Ortiz-Berrocral, J.
- Martos, A.** see Lasa-Perez, D.
- Masi, R., Voegelin, M. R., Grandinico, F., Pesciullesi, E., Morfini, M. and Rossi-Ferrini, P. L.** Compartmental analysis in hemophilic joint imaging, 514*
- Mason, D. T.** see Berman, D. S.
- Massoud, M. G.** see Nofal, M. M.
- Matin, P., Goodwin, D. A. and Nayyer, S. N.** ^{99m}Tc cerebral angiography in carotid-cavernous fistula, 1105.
- Matsumoto, N.** see Sasaki, Y.
- Mattar, A. G. and Laor, Y.** Pancreas imaging improvement, 707
- Maugham, E.** see Mayer, K.
- Maxwell, T. M.** see Miyamoto, A. T.
- May, R. S.** see Knoll, G. F.
- Mayer, K., Cheng, K., Clarke, L. P., Maugham, E. and Laughlin, J. S.** Splenic sequestration, 514*
- Maynard, W. P.** see Mishkin, F. S.
- Mayron, L. W., Kaplan, E., Barnes, W. E., Colombetti, L. G., Friedman, A. M. and Gindler, J. E.** Continuously generated ^{81m}Kr angiography, 514*
- Mayron, L. W.** see Colombetti, L. G.
- see Kaplan, E.
- McAfee, J. G., Powell, M. R., O'Mara, R. E., Friedman, B. I., Holmes, R. A. and Nelp, W. B.** Academic nuclear medicine divisions in U.S. medical schools, 22
- McAfee, J. G.** see Arnold, R. W.
- see Scharoff, J. R.
- McBain, J. K.** see Greenlaw, R. H.
- McCartney, W. H., Hoffer, P. B. and Lawrence, E.** CEA titer adjunct to liver scan, 514*
- McCauley, D. and Braunstein, P.** Lateral liver scan artifact, 1201
- McClintock, J. T.** see Elings, V. B.
- McDonald, J. M., Clarke, L. P., Christie, T. R., Gelbard, A. S. and Laughlin, J. S.** Uptake of ^{15}N -glutamic acid in bone and joint tumors, 515*
- McDonald, J. M.** see Gelbard, A. S.
- see Russ, G. A.
- McDougall, I. R. and Pistenma, D. A.** Rib abnormality hidden by breast prosthesis, 379
- McGowan, R. L.** see Martin, N. D.
- McHardy-Young, S., Blackburn, G., Brown, C. and Maisey, M. N.** Serum TSH and thyroid hormone interrelations, 514*
- McIntee, B. B.** see Shreeve, W. W.
- McIntosh, S.** see Spencer, R. P.
- McIntyre, P. A., Larson, S. M., Eikman, E. A., Colman, M., Scheffel, U. and Hodkinson, B. A.** Erythropoietic marrow metabolism of Fe- and In-transferrin, 856
- McKee, D.** see Telfer, N.
- McKee, L. C., Price, R. R., Johnstom, R. E., Heyssel, R. M., Johnson, L. E. and Brill, A. B.** Iron metabolism in normal males, 156
- McKeighen, R. E.** Gamma camera collimation, 1226
- McKeighen, R. E., Muehllehner, G. and Moyer, R. A.** ^{123}I collimator considerations, 328
- McKusick, K. A., New, P. F. J., Pendergrass, H. P. and Potsaid, M. S.** Computerized and axial tomography brain scans, 515*
- McKusick, K. A.** see Alpert, N. M.
- see Berg, G.
- see Fischer, K. C.
- see Lamson, M.
- see New, P. F. G.
- McMahon, J.** see Shafer, R. B.
- McNeil, B. J., Holman, B. L., Button, L. N. and Rosenthal, D. S.** ^{111}In scanning in myelofibrosis, 647
- McNeil, B. J., Varady, P. D., Burrows, B. A. and Adelstein, S. J.** Cost/benefit analysis in renovascular disease, 516*
- McNeill, K. G.** see Harrison, J. E.
- McQuade, S. and Higgins, H. P.** ^{99m}Tc -polyphosphate in sphenoid wing melanoma, 1205
- McRae, C. U.** see Chisholm, G. D.
- McRae, J. and Anger, H. O.** Bone imaging with the multiplane tomographic scanner, 516*
- McRae, J., Sugar, R. M., Shipley, B. and Hook, G. R.** Tissue distribution of $^{99m}\text{TcO}_4^-$ in rats, 151
- McRae, J.** see Budinger, T. F.
- see Valk, P. E.
- Meade, R. C. and Horn, W. C.** Radioimmunoassay for hepatitis antigen, 516*
- Meakins, J. F.** see Farrer, P. A.
- Meares, C. F.** see Goodwin, D. A.
- Meema, H. E.** see Harrison, J. E.
- Meinken, G.** see Steigman, J.
- Mena, I., Horiuchi, K. and Lopez, G.** Manganese transport into brain, 516*
- Mena, I.** see Touya, J. J.
- see Uszler, J. M.
- Merrick, M. V. and Foulkes, A.** High intensity areas in bone scans, 1228
- Merrill, J. C.** see Atkins, H. L.
- Merz, T.** see Larson, S.
- Metz, C. E. and Beck, R. N.** Quantitative effects of image processing, 164
- Metz, C. E., Beck, R. N. and Tsui, B.** Geometrical component of multi-hole focused collimator MTF, 516*
- Metz, C. E., Tsui, M. W. and Beck, R. N.** Geometric transfer function for focused collimators, 1078
- Metz, C. E.** see Kirch, D. L.
- Meves, M.** see Winkel, K. Z.
- Meyer, S. L.** see Parkey, R. W.
- Meyers, S.** see Spolter, L.
- Miale, A.** see Kallos, N.
- see Weinstein, M. B.
- Mielutia, M.** see Holan, T. S.
- Miki, M., Machida, T. and Minami, T.** ^{99m}Tc -pyrophosphate imaging of bone metastases, 517*
- Mikulicich, A. G.** see Trackler, R. T.
- Miller, D. W., Schlosser, P. A., Gerber, M. S., Redmond, R. F. and Hunter, W. W.** Camera system based on a strip electrode Ge detector, 517*
- Miller, D. W.** see Gerber, M. S.
- Miller, R. E.** see Spencer, R. P.
- Miller, S. W. and Potsaid, M. E.** Focal brain scan abnormalities in multiple sclerosis, 131
- Miller, S. W.** see Hattner, R. S.
- Milne, J. S.** see Boddy, K.
- Milstein, D. M., Nusynowitz, M. L., Stein, S. and Urban, R.** Lung imaging in the fat embolism syndrome, 517*
- Minami, T.** see Miki, M.
- Mincey, E. K., Wilcox, M. E. and Morrison, R. T.** Effective thyroxine ratio test without alcohol extraction, 1032
- Mincey, E. K.** see Lyster, D. M.
- Minehan, T. F.** see Slavin, J. D.
- Mioduszewska, O.** see Szymendera, J.
- Mishkin, F. S.** Determination of cerebral death, 517*
- Mishkin, F. S. and Barrett, I.** Brain scan in infantile cerebral paralysis, 517*
- Mishkin, F. S. and Lawrence, D.** Imaging of scrotal abnormalities, 518*
- Mishkin, F. S. and Maynard, W. P.** Lacrimal gland uptake of ^{67}Ga , 630
- Mishkin, F. S. and Prosin, M. A.** Diagnosis of tricuspid deficiency, 518*
- Mishkin, F. S. and Prosin, M. A.** Tricuspid insufficiency confirmation, 205
- Mishkin, F. S.** see Miyamoto, A. T.
- see Prosin, M. A.
- see Wong, D. W.
- Mitchell, T. G.** see Dupuy, M. S.
- Mittal, A. K.** see Sy, W. M.
- Miyamoto, A. T., Mishkin, F. S. and Maxwell, T. M.** ^{45}K scanning of extremity perfusion, 518*
- Mock, B.** see Bautovich, G. J.
- Moinuddin, M.** see DeLand, F. H.
- see Rockett, J. F.
- Monahan, W. G., Clarke, L. P. and**

- Laughlin, J. S.** Organ blood flow by fractional distribution of $^{15}\text{NH}_4^+$, 518*
- Monahan, W. G.** see Christie, T. R.
- Monroe, L. A., Thompson, W. L., Anderton, N. S. and Burdine, J. A.** Evaluation of an improved ^{99m}Tc -Sn aggregated albumin, 192
- Montesinos, R. M. C.** see Maass, R. E.
- Morales, J. O.** see Perlmuter, G. S.
- Morehouse, D. D.** see Farrer, P. A.
- Morfini, M.** see Masi, R.
- Mori, T., Hamamoto, K., Morita, R. and Torizuka, K.** ^{99m}Tc -bleomycin imaging of thyroid cancer, 518*
- Mori, T.** see Hamamoto, K.
see Itoh, H.
- Morin, R. L. and Brookeman, V. A.** ^{109}Yb -DTPA cisternography, 786
- Morin, R. L. and DeLand, F. H.** Safety of ^{109}Yb -DTPA in cisternography, 375
- Morin, R. L.** see Brookeman, V. A.
- Morita, R.** see Hamamoto, K.
see Mori, T.
- Morris, A. C.** see Hodges, H. D.
- Morris, C.** see Goswitz, F.
- Morrison, R. T.** see Lyster, D. M.
see Mincey, E. K.
- Mortara, R. H.** see Brooks, W. H.
- Moser, C.** see Cavalieri, R. R.
- Moses, D. C.** see Carey, J. E.
- Moyer, R. A.** Converging and pinhole collimators, 59
- Moyer, R. A.** see McKeighen, R. E.
- Muehllehner, G.** see McKeighen, R. E.
- Muienberg, M. I.** Perchlorate in brain imaging, 221
- Mukai, T.** see Ishii, Y.
- Mulrow, P. J.** see Forman, B. H.
- Munro, D. D.** see Farrer, P. A.
- Murano, R.** see Lewellen, T. K.
- Murphy, L.** see Greenlaw, R. H.
- Murphy, P. H., Alagarsamy, V. and Burdine, J. A.** Frequency of the ventilation-to-perfusion ratio, 519*
- Murphy, P. H., Burdine, J. A. and Calderon, M.** Clinical appraisal of experimental converging collimator, 291
- Murray, M.** see Rigo, P.
- Murray, S.** see Rosenberg, A.
- Murry, R. C., Dowd, J. E. and Bonte, F. J.** Image formation in scintillating crystals, 519*
- Muster, A. J.** See Conway, J. J.
- Myers, R. W.** see Green, M. V.
- Myers, W. G.** Nuclear Medicine Pioneer Citation; Hal Oscar Anger, 471
- Myers, W. G.** see Budinger, T. F.
- Nathan, H.** see Czerniak, P.
- Nayyar, S. N.** see Matin, P.
- Neely, H. H.** see MacDonald, N. S.
see Spolter, L.
- Neill, G. D. S.** Section scanning using orthogonal tangent correction, 377
- Neitzschman, H. R.** see Beauchamp, J. M.
- Nelp, W. B.** see Allen, D. R.
see Chesnut, C. H.
see Lewellen, T. K.
see McAfee, J. G.
- Nelson, G. L.** see Bostrom, S. E.
- Nelson, J. P.** see Serafini, A. N.
- Nelson, R. L.** see Frankel, R. S.
- New, P. F. J., McKusick, K. A., Pendergrass, H. P. and Potsaid, M. S.** Computerized axial tomography for brain studies, 519*
- New, P. F. J.** see McKusick, K. A.
- Newiger, T.** see Winkel, K. Z.
- Newton, W. T.** see George, E. A.
- Ngo, N.** see Sy, W. M.
- Nicoloff, J. T.** see Siemsen, J. K.
- Nishimura, A.** see Gorten, R. J.
- Nishiyama, H., Lewis, J. T. and Saenger, E. L.** Interpretation of liver images, 519*
- Nishiyama, H., Sodd, V. J., Berke, R. A. and Saenger, E. L.** Clinical value of ^{123}I and ^{131}I in thyroid disease, 261
- Nodine, J. H., Chang, S. C., Holmes, R., Lewis, G. and Fletcher, M.** Radioactive cancer detection, 733
- Nofal, M. M., El-Beheiry, A., El-Arini, A. F., Salama, M. N. and Massoud, M. G.** ^{67}Zn evaluation of spermatogenic function, 520*
- Nohara, N., Tomitami, T. and Tanaka, E.** 2D analog image processing by omnidirectional scanning, 844
- Nolan, N. G.** ^{99m}Tc -diphosphonate uptake by extraosseous neurofibroma, 1207
- Nolan, N. G., Fontana, R. S. and Sanderson, D. R.** ^{133}Xe lung studies, 520*
- Nolan, N. G. and Maher, F. T.** ^{197}Hg -chlormerodrin brain scanning, 520*
- Nordlander, S., Wiklund, P-E. and Åsard, P-E.** Diagnostic techniques for cerebral death, 914
- Norman, A. S.** see Poe, N. D.
- Novich, I.** see Koenigsberg, M.
- Ntundulu, T.** see Tran, N.
- Nusynowitz, M. L.** see Milstein, D. M.
- Nuttall, F. Q.** see Shafer, R. B.
- Nyary, I.** see Kuhl, D. E.
- Oberley, L. W.** see Ehrhardt, J. C.
- O'Brien, T.** see DeNardo, S. J.
- Ochi, H.** see Kasahara, A.
- O'Hara, A. E.** see Park, C. H.
- O'Keefe, A.** see Zweiman, F. G.
- Okubo, R.** see Stein, M. A.
- Oldendorf, W. H.** Expression of tissue isotope distribution, 725
- Oltman, B. G.** see Friedman, A. M.
- O'Mara, R. E.** see Emerson, D. A.
see Graham, T. A.
see Hall, J. N.
see Lilien, D. L.
see McAfee, J. G.
- Ommaya, A. K.** see Ledley, R. S.
- O'Neill, W. J.** see Knoll, G. F.
- Onoyama, Y.** see Ishii, Y.
- Oppenheim, B. E. and Harper, P. V.** Iterative 3D reconstruction, 520*
- Oppenheim, B. E.** see Gottschalk, A.
- O'Reilly, R. J., Collins, P. J. and Ronai, P. M.** The digital cerebral angiogram, 520*
- Oreopoulos, D. G.** see Harrison, J. E.
- Orme, H. W.** see Gates, G. F.
- O'Rourke, R.** see Schelbert, H. R.
- Ortiz-Berrocal, J., Martinez, J. R., Marin, M. and Diez, L.** Computerized diagnosis of thyroid disease, 521*
- Ostrow, H. G.** see Green, M. V.
- Ott, D. G.** see Shreve, W. W.
- Owunwanne, A., Church, L. B. and Blau, M.** Effect of O_2 on Sn(II) reduction of pertechnetate, 521*
- Ozonoff, M. B.** see Danigelis, J. A.
- Packer, S.** see Atkins, H. L.
- Palmer, H. E.** see Lewellen, T. K.
- Palmer, J. M.** see Coates, G.
- Paloyan, E.** see Sparagana, M.
- Palser, R. F.** see Billinghurst, M. W.
- Pang, S. and Genna, S.** Optimization and limitation of spatial filtering, 521*
- Pang, S.** see Genna, S.
- Papavasiliou, C.** ^{87m}Sr imaging of colorectal cancer, 824
- Park, C. H., Garafola, J. H. and O'Hara, A. E.** Diagnosis of choledochal cyst by rose bengal scan, 310
- Park, H-M.** see Chen I-W.
- Parkey, R. W., Bonte, F. J., Meyer, S. L., Willerson, J. T., Atkins, J. M. and Curry, G. C.** Acute myocardial infarction detection with ^{99m}Tc -pyrophosphate, 521*
- Parkey, R. W.** see Bonte, F. J.
see Stokely, E. M.
- Partain, C. L., Alderson, P. O. and Siegel, B. A.** Mathematical model for cisternography, 521*
- Parthasarathy, K. L.** see Bakshi, S. P.
- Pasquier, J. and Dorta, T.** Focal liver uptake, 725
- Pasternak, S.** see Coleman, R. E.
- Patel, M. C.** see Singh, B.
- Patton, D. D.** see Erickson, J. J.
- Patton, J. A., Hollifield, J., Lee, G. S. and Brill, A. B.** Quantitative scanning of thyroidal iodine pools, 522*
- Paul, D. J.** see Gilday, D. L.
- Paull, B. R., Alderson, P. O., Siegel, B. A., Bauer, W. and Evans, R. G.** Thyroid scan in lymphocytic thyroiditis, 522*
- Payne, J. T., Loken, M. K. and Ponto, R. A.** Comparison of dose calibrators, 522*
- Payne, J. T., Reinke, D. B. and Loken, M. K.** Tomography using an unmodified Anger camera, 439
- Peabody, R. A., Halse, T. and Tsapogas, M. J.** Preparation of ^{125}I -fibrinogen, 195

- Pearson, H. A. see Spencer, R. P.
- Peek, N. F., Hegedus, F., DeNardo, G. L. and Solar, M. L. ^{85}Rb for myocardial studies, 522*
- Peek, N. F.
see DeNardo, S. J.
see Hines, H. H.
- Pellois, A. see Planiol, T.
- Peña, H. G. see Watts, R. S.
- Pendergrass, H. P.
see Berg, G.
see Fischer, K. C.
see McKusick, K. A.
see New, P. F. G.
- Peng, C. T. "Radiopharmaceutical scientist," 723
- Penning, L. and Front, D. Image of bullet track in brain, 141
- Penning, L. see Front, D.
- Pentlow, K. S. and Laughlin, J. S. Depth independent response to positron emissions, 523*
- Perelli, R. C. see Ravasini, R. G.
- Pérez, R. E. see Maass, R. E.
- Perez-Mendez, V.
see Cavalieri, R. R.
see Chang, L-T.
- Perez-Modrego, S. see Lasa-Perez, D.
- Perlmutter, G. S., Goldberg, B. B., Charkes, N. D., Morales, J. O. and Malmud, L. S. Ultrasound evaluation of thyroid nodules, 523*
- Pesciullesi, E. see Masi, R.
- Phelps, M. E. and Eichling, J. O. Calculation of vascular mean transit time, 814
- Pierson, R. N., Kusubov, N., Lemmon, R., Landaw, S. and Winchell, H. S. Quantitation of in vivo fat synthesis using ^{14}C -substrates, 119
- Pinsky, S. M.
see Arnold, J. E.
see Geslien, G. E.
see Ryo, U. Y.
see Thrall, J. H.
- Pircher, F. J., Cooper, P. H., Lerner, S. R. and Pittman, J. P. Unit record equipment coding system, 218
- Pistenma, D. A. see McDougall, I. R.
- Pitt, B.
see Rigo, P.
see Rossman, D. J.
- Pitt, M. J. see Emerson, D. A.
- Pittman, J. P. see Pircher, F. J.
- Pizzarello, D. J. see Witcofski, R. L.
- Planiol, T., Brochier, M., Pellois, A. and Archambaud, D. Dual isotope cardiac scanning, 523*
- Planiol, T. and Itti, R. Specific diagnosis of brain lesions, 523*
- Planiol, T. see Floyrac, R.
- Platthy, A. and Shah, U. False-positive liver scan, 717
- Pliego, M. P. see Tully, T. E.
- Poe, N. D., Dore, E. K., Greenberg, A. and Cohen, M. B. Delayed radioaerosol inhalation imaging, 524*
- Poe, N. D., Eber, L. M., MacDonald, N. S., Norman, A. S. and Terao, E. N. Noncoronary patterns in myocardial imaging, 524*
- Poe, N. D., Robinson, G. D., Elam, D. A. and Battaglia, D. J. Dual tracer evaluation of myocardial infarction, 524*
- Poe, N. D., Robinson, G. D., Mac Donald, N. S., Lee, A. W. and Selin, C. E. 16-iodo-hexadecanoic acid for regional myocardial perfusion, 524*
- Poe, N. D. see Robinson, G. D.
- Pohost, G. M. see Alpert, N. M.
- Polga, J. P. Nasogastric suction in GI scanning, 374
- Polga, J. P., Sargent, J. and Dickinson, P. Positive intestinal scan of carcinoid tumor, 365
- Pollak, E., Webber, M. M. and Victory, W. Autologous ^{131}I -fibrinogen test, 524*
- Pollak, K. see Shafer, R. B.
- Pollock, I. see Elings, V. B.
- Polloni, R. see Caldarola, L.
- Ponto, R. A. see Payne, J. T.
- Poth, R. K. see Geslien, G. E.
- Potsaid, M. S.
see Alpert, N. M.
see Berg, G.
see Fischer, K. C.
see Lamson, M.
see McKusick, K. A.
see Miller, S. W.
see New, P. F. G.
- Powell, M. see Leeper, R. D.
- Powell, M. R.
see Huberty, J. P.
see McAfee, J. G.
- Pozderac, R. V. and Good, A. E. Acute synovial rupture, 7
- Pozderac, R. V. and Good, A. E. Diagnosing synovial cyst dissection, 912
- Prakash, S. and Beierwaltes, W. H. Brain screening for acoustic neuromas, 525*
- Prakash, S. see Sturman, M. F.
- Preimesberger, K. F., Loken, M. K. and Shafer, R. B. Abnormal brain scan in Paget's disease of bone, 880
- Preston, D. F., Winternitz, W. W. and Kopp, J. $^{99m}\text{TcO}_4^-$ uptake in hyperthyroidism, 525*
- Preston, D. F.
see Brooks, W. H.
see DeLand, F. H.
- Prezio, J. A. see Chandra, S.
- Price, D. C., Hung, S. T-C., Kaufman, L. and Shohet, S. B. Red cell volume by fluorescent excitation analysis, 525*
- Price, R. R.
see Erickson, J. J.
see Ivancevic, D.
see McKee, L. C.
see Rhea, T. C.
- Price, W. H. see Boddy, K.
- Prince, E. W. see Dewanjee, M. K.
- Pritchard, J. H., Tubis, M., Blahd, W. H., Endow, J. S. and MacDonald, N. S. ^{113}In -gamma globulin, 526*
- Pritchard, J. H., Winston, M. A., Berger, H. G. and Blahd, W. H. Radioisotope and ultrasound diagnosis of focal hepatic lesions, 525*
- Pritchard, J. H.
see Krishnamurthy, G. T.
see Winston, M. A.
- Prosin, M. A. and Mishkin, F. S. Diagnosis of pulmonary sequestration, 636
- Prosin, M. A. see Mishkin, F. S.
- Purdy, J. M. see Carey, J. E.
- Puri, S., Spence, R. P. and Gordon, M. E. Positive brain scan in toxoplasmosis, 641
- Quinn, J. L. see Henkin, R. E.
- Quinto, R. R. see Alazraki, N. P.
- Radwan, M. see Szymendra, J.
- Raeaside, D. E. see Anderson, D. W.
- Raghavendran, K. V. see Singh, B.
- Raikar, U. R. and Ganatra, R. D. Anatomic landmarks on scintiphotos, 1226
- Ramachandran, P. C. see Rayudu, G. V. S.
- Ramanathan, M. and Wilson, J. E. Resolution capability of a multi-probe system, 959
- Ramanathan, P., Ganatra, R. D. and Blau, M. Liver blood flow studies, 1021
- Ramanna, L. see Taplin, G. V.
- Ranade, V. V. see Counsell, R. E.
- Ranalli, R. see Surprenant, E.
- Rao, D. V. and Goodwin, P. N. ^{166}Er for tumor imaging, 526*
- Rao, D. V. and Goodwin, P. N. ^{203}Pb for bone scanning, 210
- Rao, D. V., Goodwin, P. N. and Khalil, F. L. ^{166}Er for pressurized multiwire proportional camera imaging, 1008
- Raskin, M. M. see Serafini, A. N.
- Ravasini, R. G., Cattaneo, G. A., Benetello, G. P., Feltrin, G. and Perelli, R. C. Adrenal scanning with ^{131}I -iodocholesterol, 526*
- Raventos, A. see Stadalnik, R. C.
- Ray, M. see Rockett, J. F.
- Rayudu, G. V. S., Fordham, E. W., Ramachandran, P. C., Friedman, A. M. and Sullivan, J. Citrate and bleomycin complexes of lanthanides and actinides for tumor, 526*
- Rayudu, G. V. S., Kanoor, R., Turner, D. A., Fordham, E. W. and Friedman, A. M. ^{134m}Cs and ^{134}Cs distribution, 526*
- Reba, R. C.
see Eckelman, W. C.
see Grove, R. B.
see Stevenson, J. S.
- Redmond, R. F. see Miller, D. W.
- Reed, M. F. see Beihn, R. M.
- Reese, L. Hippurate kinetic models, 1066
- Refetoff, S. see Hoffer, P. B.
- Reinke, D. B.
see Payne, J. T.
see Tully, T. E.
- Reiswig, R. see Grames, G. M.
- Reivich, A. see Kuhl, D. E.
- Rhea, T. C., Ivancevic, D., Price, R. R., Graham, T. P., Smith, C.

AUTHOR INDEX

- V. and Brill, A. B.** Pulsatile heart model computer code, 527*
- Rhea, T. C.** see Ivancevic, D.
- Rhodes, B. A. and Wagner, H. N.** Adverse reactions to radiopharmaceuticals, 213
- Rhodes, B. A.** see Chen, M.
see Hagan, P.
see Siegel, M. E.
see Som, P.
- Rich, B.** see Harper, P. V.
- Rich, M.** see Bautovich, G. J.
- Richards, A. G.** 99m Tc-polyphosphate uptake in metastatic calcification, 1057
- Richards, J. B.** see Karelitz, J. R.
- Richards, P.** see Lebowitz, E.
see Smith, T. D.
see Steigman, J.
- Richman, S. D., Frankel, R. S., Tormey, D. C. and Johnston, G. S.** Breast imaging with 99m TcO₄⁻ and 67 Ga, 527*
- Richman, S. D.** see Frankel, R. S.
- Riggins, R. S., DeNardo, G. L., D'Ambrosia, R. and Goldman, M.** Femoral head scintigraphy, 183
- Rigo, P., Murray, M., Strauss, H. W. and Pitt, B.** Imaging left ventricular aneurysm, 527*
- Riley, R. R.** see Touya, J. J.
- Riley, T. W.** see Heck, L. L.
- Ripley, D.** see Shafer, R. B.
- Ritchie, J. L.** see Hamilton, G. W.
- Rivera, J. V.** 131 I-rose bengal visualization of splenic blood pool, 823
- Robbins, P. J., Silberstein, E. B. and Fortman, D. L.** 113 In-bleomycin kinetics, 273
- Roberts, K.** see Dowsett, D. J.
- Robertson, J. S., Verhasselt, M. and Wahner, H. W.** Capsule effect in thyroid iodine uptake, 770
- Robinson, G. D. and Battaglia, D. J.** A model for evaluating myocardial imaging agents, 527*
- Robinson, G. D., Battaglia, D. J., Poe, N. D. and Elam, D. A.** 99m Tc-tetracycline distribution, 528*
- Robinson, G. D., Poe, N. D., Lee, A. Y. and Selin, C. S.** 123 I-hexadecanoic acid preparation and myocardial specificity, 528*
- Robinson, G. D. and Siegel, R. K.** Learned "puffing response" of monkeys, 528*
- Robinson, G. D.** see MacDonald, N. S.
see Poe, N. D.
see Taplin, G. V.
- Robinson, R. G., Kirchner, F. R. and Wegst, A. V.** 133 Xe studies of sinus cavities and middle ear, 528*
- Robinson, R. G.** see Kennedy, T.
- Rockett, J. F. and Buchignani, J. S.** Radionuclide perfusion of hepatic metastases, 314
- Rockett, J. F., Ray, M., Moinuddin, M. and Gardner, C.** 99m Tc cerebral angiogram tumor detection, 1050
- Rodan, G.** see Holan, T. S.
- Rogers, W. L., Jones, L. W. and Beierwaltes, W. H.** Fresnel zone plate imaging, 216
- Rogers, W. L.** see Koral, K. F.
- Rollo, F. D.** Imaging system performance index, 757
- Rollo, F. D., Shames, D. M. and Farmer, R. E. L.** Renal function in renal transplant, 528*
- Rollo, F. D.** see Shames, D. M.
- Romhilt, D. W.** see Ashare, A. B.
- Ronai, P. M.** 131 I-HSA vs. 100 Tb-DTPA for cisternography, 916
- Ronai, P. M.** see Baker, R. J.
see O'Reilly, R. J.
- Rose, F.** see Schelbert, H. R.
- Rosenberg, A., Murray, S. and Teare, F. W.** Preparation methods for radioiodinated TSH, 529*
- Rosenberg, M. A.** see Kay, C. J.
- Rosenfield, A. T. and Schneider, P. B.** Liver size on radioisotope scan, 237
- Rosenthal, D. S.** see MacNeil, B. J.
- Rosenthal, L.** see Desaulniers, M.
- Rosenstreich, M. E.** see Arnold, R. W.
- Rossi-Ferrini, P. L.** see Masi, R.
- Roszman, D. J., Siegel, M. E., Friedman, B. H., Strauss, H. W. and Pitt, B.** 99m Tc-glucoheptonate in acute myocardial infarction, 539*
- Rothenberg, H., Kuhl, D. E. and Devenney, J.** Transverse section 113 In-DTPA cisternography, 529*
- Rubin, P.** see Thomson, R. A. E.
- Rubinson, B.** see MacIntyre, W. J.
- Rudd, T. G., Dizmang, D. and Hayden, P.** Arrested hydrocephalus diagnosis, 529*
- Russ, G. A., Bigler, R. E., McDonald, J. M., Tilbury, R. S. and Laughlin, J. S.** 15 O steady state scanning and imaging, 529*
- Rutner, H., Gutcho, S., Johnson, J. and Dodd, T.** Peptidase activity of proteins in radioimmunoassay, 557
- Ryerson, T. W.** see Brown, D. W.
- Ryo, U. Y.** Radionuclide venography, 915
- Ryo, U. Y., Beierwaltes, W. H., Feahan, P. and Ice, R. D.** 14 C- and 3 H-streptozotocin distribution, 572
- Ryo, U. Y., Beierwaltes, W. H. and Ice, R. D.** Enhanced uptake of 14 C-isoxazole by estrogen treatment, 187
- Ryo, U. Y., Lee, J. I., Zarnow, H., Schwartz, M. P. and Pinsky, S. M.** 99m Tc-RBC angiography in aortic aneurysm, 1014
- Ryo, U. Y., Shaw, M. J., Beierwaltes, W. H. and Ice, R. D.** Distribution of 14 C-diphenylhydantoin in toadfish, 685
- Ryo, U. Y.** see Balanchandran, S.
see Beierwaltes, W. H.
see Sturman, M. F.
- Sabiston, D. C.** see Jones, R. H.
- Sackler, J. P.** see Sy, W. M.
- Saenger, E. L.** see Ashare, A. B.
see Chen, I-W.
see Nishiyama, H.
see Sodd, V. J.
- Safi, N.** see Blanquet, P.
- Saha, G. B.** see Farrer, P. A.
- Sakimura, I. T., Hsu, J. D., Stauffer, E. S. and Siemsen, J. K.** 99m Tc-diphosphonate scans of heterotrophic bone formation, 530*
- Sakimura, I. T.** see Wolfstein, R. S.
- Salama, M. N.** see Nofal, M. M.
- Salel, A. F.** see Berman, D. S.
- Salmon, S. E.** see Lilien, D. L.
- Samuels, B. I., Gold, R. H. and Lecky, J. W.** Parathyroid thermography, 530*
- Sanada, S.** see Hisada, K.
- Sanders, T.** see Bloch, P.
- Sanderson, D. R.** see Nolan, N. G.
- Saparoff, G. R.** see Chaudhuri, Tapas K.
- Sargent, E. N.** see Grebe, S. F.
- Sargent, J.** see Polga, J. P.
- Sasaki, Y., Someya, K., Matsumoto, N., Kameda, H., Shindo, K., Yamazaki, R. and Fukushima, K.** Deconjugation of bile salts by intestinal bacteria, 530*
- Sauerbrunn, B. J. L.** see DeLand, F. H.
- Scharoff, J. R., Thomas, F. D., McAfee, J. G., Subramanian, G., Duxbury, C., Heminger, L. and Vescio, P.** Imaging of microsphere induced kidney disease, 530*
- Scheffel, U.** see McIntyre, P. A.
- Scheibe, P. O. and Yoshikawa, B. M.** Dose calculations from compartmental models, 1025
- Scheibe, P. O.** see Berman, D. S.
see DeGrazia, J. A.
see DeNardo, S. J.
- Schelbert, H. R., Ashburn, W. L., Chauncey, D. M. and Halpern, S. E.** Comparative myocardial uptake of radionuclides, 1092
- Schelbert, H. R., Henning, H., O'Rourke, R., Johnson, A., Rose, F. and Ashburn, W. L.** Left ventricular ejection fraction, 531*
- Schelbert, H. R.** see Alazraki, N. P.
see Verba, J. W.
- Schimmel, D.** see Hattner, R. S.
- Schmidt, L.** see Winkel, K. Z.
- Schmitt, G. H.** see Zimmer, A. M.
- Schneider, P. B.** see Rosenfield, A. T.
- Schneider, V.** see Vogel, J. M.
- Schosser, P. A.** see Miller, D. W.
- Schreiner, D. P.** Reticuloendothelial scans in bone marrow disorders, 1158
- Schreyer, M., Vanags, K., Franco, J. and Kovaleski, B.** Comparison of 99m TcO₄⁻ carotid blood flow studies with thermography, 531*
- Schreyer, M.** see Kovaleski, B.
- Schulz, A. G.** see Knowles, L. G.
- Schwartz, F. C.** see Breslow, W.
- Schwartz, K.-D.** see Deckart, H.
- Schwartz, M. P.** see Ryo, U. Y.

- Sciaccia, R. R.** see Johnson, P. M.
- Scott, J. R.** see Lyster, D. M.
- Scott, R. N.** see Green, M. V.
- Seabold, J. E.**, Beierwaltes, W. H., Conn, J. W., Balachandran, S. and Cohen, E. L. ^{131}I -iodocholesterol adrenal imaging in aldosteronism, 531*
- Sear, R.** Minification of photoscans, 219
- Secker-Walker, R. H.**, Barbier, J., Wiener, S. N. and Alderson, P. O. ^{133}Xe delivery system for regional ventilation studies, 288
- Secker-Walker, R. H.** see Alderson, P. O.
- Selenkow, H. A.** see Kaplan, W. D.
- Selin, C. E.** see Poe, N. D.
- Selin, C. S.** see Robinson, G. D.
- Serafini, A. N.**, Raskin, M. M., Zand, L. C. and Watson, D. D. Breast scanning in carcinoma, 1149
- Serafini, A. N.**, Watson, D. D., Nelson, J. P. and Smoak, W. M. Bone imaging with ^{99m}Tc -polyphosphate and -diphosphonate, 1101
- Serino, T. V.**, MacDonnell, K. F., Ishikawa, S., Braverman, L. E., Abreau, C., Johnston, R. and Cloonan, E. Differential vital capacity determinations, 625
- Sevrin, R.** see Bobinet, D. D.
- Sfakianakis, G. N.** see Fulmer, L. R.
- Shafer, R. B.**, Nuttall, F. Q., Polak, K. and Kuisk, H. Thyroid function after treatment of head and neck cancer, 531*
- Shafer, R. B.**, Ripley, D., McMahon, J. and Doscherholmen, A. Vitamin B₁₂ radioassay, 688
- Shafer, R. B.** and Tully, T. E. Thyroid carcinoma presenting as bone cyst, 50
- Shafer, R. B.**
see Preimesberger, K. F.
see Tully, T. E.
- Shah, U.** see Platthy, A.
- Sham, R.** see Silver, L.
- Shames, D. M.**, Farmer, R. E. L. and Rollo, R. D. Relative renal blood flow in hypertension, 532*
- Shames, D. M.**
see Hattner, R. S.
see Rollo, F. D.
- Sharma, S. M.** see Singh, B.
- Sharpe, A. R.**
see Fratkin, M. J.
see Tinglestad, J. B.
- Shaw, M. J.**
see Balachandran, S.
see Ryo, U. Y.
- Sherman, I-S.** see Strauss, M. G.
- Sherman, L. A.** see Harwig, J. F.
- Shields, J. B.** see George, E. A.
- Shih, W-J.** see Yeh, S-H.
- Shindo, K.** see Sasaki, Y.
- Shipley, B.** see McRae, J.
- Shiraishi, L.** see Chang, L-T.
- Shohet, S. B.** see Price, D. C.
- Shoop, J. D.** see Shreeve, W. W.
- Shoop, L. E.** see Krishnamurthy, G. T.
- Short, D.** see Kirchner, P.
- Short, M. D.** see Chisholm, G. D.
- Shreeve, W. W.**, Shoop, J. D., Ott, D. G. and McInteer, B. B. ^{13}C - and ^{13}C -galactose oxidation test of liver function, 532*
- Shreiner, D. P.** Reticuloendothelial scans in hematologic diseases, 532*
- Siegel, B. A.**
see Coleman, R. E.
see Harwig, J. F.
see Partain, C. L.
see Paull, B. R.
- Siegel, E.** and **Siegel, E. P.** Effects of serum on T_3 stimulation of kidney cells, 532*
- Siegel, E.** and **Siegel, E. P.** T_3 stimulation of DNA in kidney cells, 532*
- Siegel, E. P.** see Siegel, E.
- Siegel, M. E.**, Giargiana, F. A., Rhodes, B. A. and Wagner, H. N. Peripheral vascular perfusion scanning, 533*
- Siegel, M. E.**, Giargiana, F. A., White, R., Friedman, B. H. and Wagner, H. N. Arteriography and perfusion scanning in peripheral vascular disease, 533*
- Siegel, M. E.**
see Friedman, B. H.
see Rossman, D. J.
- Siegel, R. K.** see Robinson, G. D.
- Siemsen, J. K.**, Wallack, M. S., Martin, R. B. and Nicoloff, J. T. ^{131}I therapy of Graves' disease, 257
- Siemsen, J. K.** and Waxman, A. D. Early diagnosis of osteomyelitis, 533*
- Siemsen, J. K.**
see Grebe, S. F.
see Lee, G. C.
see Sakimura, I. T.
see Telfer, N.
see Waxman, A. D.
see Wolfstein, R. S.
see Woolfenden, J. M.
- Silberstein, E. B.** Ca, P and ^{99m}Tc uptake, 918
- Silberstein, E. B.** Decreased $^{99m}\text{TcO}_4^-$ uptake in epidural hematoma, 712
- Silberstein, E. B.** Diagnostic efficiency of ^{99m}Tc -sulfur colloid angiography and liver function tests, 533*
- Silberstein, E. B.** see Robbins, P. J.
- Silva, J.** see Harvey, W. C.
- Silver, L.**, Sham, R. and Klein, H. A. Cerebral hematoma with intraventricular bleeding, 639
- Simon, W.**
see Kay, D. B.
see Walters, T. E.
- Singh, B.**, Sharma, S. M., Patel, M. C., Raghavendran, K. V. and Berman, M. Large doses of ^{131}I in thyroid cancer therapy, 674
- Singhi, V.** see Krishnamurthy, G. T.
- Singla, O.** see Barht, R. F.
- Sisson, J. C.** see Beierwaltes, W. H.
- Skromme-Kadlubik, G.**, Diaz, F. and Celis, C. Basal ganglia scan, 534*
- Slavin, J. D.**, Minehan, T. F. and
- Spencer, R. P.** Image of delayed splenic rupture, 632
- Small, M. J.** Scan of tuberculosis of the liver, 135
- Smith, C. V.** see Rhea, T. C.
- Smith, E. M.** see Witcofski, R. L.
- Smith, P. H. S.** and **Taylor, D. M.** Distribution and retention of ^{106}Pt -DDP in man, 349
- Smith, T. D.** and **Richards, P.** ^{99m}Tc -RBC kit, 534*
- Smoak, W. M.**
see Christy, B.
see Cohen, G. A.
see Serafini, A. N.
- Snajder, J.** see Erjavek, M.
- Snow, R. M.** and **Keyes, J. W.** "Luxury perfusion syndrome" following CVA, 907
- Sobociński, P. Z.** see Stevenson, J. S.
- Sodd, V. J.**, Velten, R. J. and Saenger, E. L. Radiopharmaceuticals in the Ohio River, 534*
- Sodd, V. J.**
see Ashare, A. B.
see Nishiyama, H.
- Soin, J. S.**, Beal, W. and Burdine, J. A. Autonomous thyroid nodule disappearance, 1209
- Soin, J. S.**
see Beal, W.
see Burdine, J. A.
- Solar, M. L.** see Peek, N. F.
- Solarie-George, E.** see Henry, R. E.
- Som, P.** and **Rhodes, B. A.** ^{99m}Tc - and ^{123}I -urokinase distribution, 534*
- Someya, K.** see Sasaki, Y.
- Sondel, J. A.** see Ackerhalt, R. E.
- Sopher, R. L.** see Watts, R. S.
- Sorenson, J. A.** Deadtime of Anger camera systems, 534*
- Soulen, R.** see Charles, N. D.
- Sparagana, M.**, Veatch, R., Supan, W., Kaplan, E. and Paloyan, E. ^{131}I -toluidine blue insulinoma scan, 1212
- Spellberg, R.** see Surprenant, E.
- Spencer, R. P.** Healing of a splenic infarct, 303
- Spencer, R. P.** Hepatic flow studies, 317
- Spencer, R. P.** and Aponte, L. J. Coupling of static and dynamic brain studies, 32
- Spencer, R. P.**, McIntosh, S., Pearson, H. A. and Touloudian, R. J. ^{99m}Tc -sulfur colloid fraction in spleen, 446
- Spencer, R. P.**, Miller, R. E. and Antar, M. A. ^{99m}Tc -protamine complex, 535*
- Spencer, R. P.** and Pearson, H. A. Splenic uptake in the presence of circulating Howell-Jolly bodies, 294
- Spencer, R. P.**
see Banerji, J.
see Caride, V. J.
see Puri, S.
see Slavin, J. D.
- Spolter, L.**, Cohen, M. B., MacDonald, N. S., Chang, C. C., Taka-

AUTHOR INDEX

- hashi, J., Neely, H. H., Huth, G., Meyers, S. and Bobinet, D. D.** ¹¹³N-alanine for pancreas imaging, 535*
- Spolter, L.** see Bobinet, D. D.
see Cohen, M. B.
- Staab, E. V. and Hartman, R. C.** Serial liver scans in paroxysmal nocturnal hemoglobinuria, 535*
- Stadnik, R. C., DeNardo, S. J., Raventos, A. and DeNardo, G. L.** Liver scintangiography in neoplastic tumors, 535*
- Stadnik, R. C.** see Coates, G.
- Stauffer, E. S.** see Sakimura, I. T.
- Staum, M.** see Kuhl, D. E.
- Steele, P. P.** see Kirch, D. L.
- Steffens, J.** see Surprenant, E.
- Steigman, J., Eckelman, W. C., Meinken, G., Isaacs, H. S. and Richards, P.** Technetium labeling by electrolysis, 75
- Stiegman, J., Williams, H. P., Richards, P., Lebowitz, E. and Meinken, G.** Gel chromatography analysis of ^{99m}Tc-radiopharmaceuticals, 318
- Stein, M. A., Okubo, R., Winter, J. and Bennett, L. R.** Storage and retrieval system, 535*
- Stein, M. A. and Winter, J.** Cerebral blood flow in anterior communicating artery aneurysm, 1217
- Stein, S.** see Milstein, D. M.
- Stephens, G.** see Brown, M. L.
- Sternlieb, I.** see Chervu, L. R.
- Stevenson, J. S., Eckelman, W. C., Sobocinski, P. Z., Reba, R. C., Barron, E. L. and Levin, S. G.** Toxicity of Sn-polyphosphate, 252
- Stevenson, J. S.** see Eckelman, W. C.
- Stokeley, E. M., Parkey, R. W., Lewis, S. E. and Bonte, F. J.** Computer processing of ^{99m}Tc-pyrophosphate myocardial images, 536*
- Strange, D. R.** see Knoll, G. F.
- Strauss, M. G., Sherman, I. S., Brenner, R. and Lenkszus, F. R.** Coaxial germanium gamma-ray camera, 1196
- Strauss, H. W.** see Berman, D. S.
- see Feigin, D. S.**
- see Rigo, P.**
- see Rossman, D. J.**
- Strieder, D. J.** see Treves, S.
- Strong, J. D.** see Weiss, P. H.
- Sturbridge, W. C.** see Harrison, J. E.
- Sturman, M. F., Beierwaltes, W. H., Prakash, S., Ryo, U. Y., Ice, R. D. and Gitomer, W.** Steroid uptake by canine prostate, 94
- Sturman, M. F.** see Beierwaltes, W. H.
- Stutzman, R. E.** see Handmaker, H.
- Subramanian, G.** see Arnold, R. W.
see Scharoff, J. R.
- Sufka, B.** see MacIntyre, W. J.
- Sugar, R. M.** see McRae, J.
- Sullivan, J.** see Rayudu, G. V. S.
- Sundberg, M. W.** see Goodwin, D. A.
- Supan, W.** see Sparagana, M.
- Surprenant, E. and Spellberg, R.** Regional perfusion and ventilation in mitral valve disease, 536*
- Surprenant, E. and Steffens, J.** Space occupying lesions of the abdomen, 536*
- Surprenant, E., Steffens, J. and Ranalli, R.** The M-B cardiac scan, 536*
- Swann, S. J.** see DiChiro, G.
- Sy, W. M.** Bone scan in primary hyperparathyroidism, 1089
- Sy, W. M. and Mittal, A. K.** Bone scan in renal failure with hyperparathyroidism, 536*
- Sy, W. M., Weinberger, G., Ngo, N. and Sackler, J. P.** Subdural hematoma brain scan classification, 693
- Syed, I. B.** ²⁰³Pb for bone scanning, 910
- Syed, I. B.** see Turner, J. W.
- Szabó, M. T., Hrabák, A. and Antoni, F.** Radiochromate binding of tonsillar lymphocytes, 750
- Szur, L. and Glass, H. I.** Standard techniques for RBC and plasma volume measurements, 376
- Szymendera, J., Mioduszewska, O., Licinska, I., Czarnomska, A. and Radwan, M.** Fate of ferric hydroxide macroaggregates, 17
- Szymendera, J. and Radwan, M.** Intestinal absorption of pertechnetate, 314
- Takahashi, J.** see Cohen, M. B.
see MacDonald, N. S.
see Spolter, L.
- Takahashi, K.** see Itoh, H.
- Takahashi, M.** see Ishii, Y.
- Takenaka, J.** see Gates, G. F.
- Taketa, R. M.** see Goergen, T.
see Higgins, C. B.
- Tamaki, M.** see Kasahara, A.
- Tanaka, E.** see Nohara, N.
- Tanasescu, D.** see Wolfstein, R. S.
- Taplin, G. V. and Elam, D. A.** Visualization of 1-2 mm bronchogenic tumor phantoms, 537*
- Taplin, G. V., Ramanna, L., Taskin, D. and Elam, D. A.** Radioaerosol imaging in early chronic lung disease, 537*
- Taplin, G. V., Robinson, G. D. and Elam, D. A.** Dry aerosols for lung imaging, 537*
- Taplin, G. V.** see Kitani, K.
- Tashima, C. K., Lee, W. Y. and Leong, A.** Tumor blood flow study, 463
- Taskin, D.** see Taplin, G. V.
- Tatarczuk, J. R.** Scanner deadtime losses, 728
- Taylor, A.** see Higgins, C. B.
- Taylor, D. M.** see Smith, P. H. S.
- Taylor, J. R.** see Krishnamurthy, G. T.
- Teare, F. W.** see Rosenberg, A.
- Teates, C. D. and Constable, W. C.** Intraperitoneal ^{99m}Tc-sulfur colloid distribution, 1067
- Teates, C. D.**
- see Brower, A. C.**
see Johnston, G.
- Telfer, N., Siemsen, J. K., and McKee, D.** Brain imaging with a multicrystal camera, 537*
- Temte, J.** see Holman, B. L.
- Teplick, S. K., VanHeertum, R. L., Clark, R. E. and Carter, A. P.** Displacement of falx and superior sagittal sinus, 1047
- Tepper, B. S.** see Camargo, E. E.
- Terao, E. N.** see Poe, N. D.
- Ter Pogossian, M. M.** see Jones, T.
- Thomas F. D., Duxbury, C., Vescio, P., Heminger, L. and Blizzard, J.** Quantitative renal function studies, 538*
- Thomas, F. D.** see Scharoff, J. R.
- Thomas, M.** see Becker, L.
- Thomas, P. B.** see Krishnamurthy, G. T.
- Thompson, N. W.** see Beierwaltes, W. H.
- Thompson, W. L.** see DePuey, G.
see Monroe, L. A.
- Thomson, R. A. E., Corriveau, O. J. and Rubin, P.** ⁵⁷Fe labeling in bone, 161
- Thorell, J. I., Larson, S. M., Cuatrecasas, P. and Wagner, H. N.** ¹²⁵I-insulin binding by cell membrane receptors and antibodies, 538*
- Thrall, J. H., Geslien, G. E., Ghaed, N., Pinsky, S. M. and Johnson, M. C.** Hyperemic effects in bone imaging, 538*
- Thrall, J. H.** see Geslien, G. E.
- Tilbury, R. S.** see Russ, G. A.
- Tilden, R.** see DeLand, F. H.
- Timins, E. L.** see DiChiro, G.
- Tinglestad, J. B., Howell, T. R. and Sharpe, A. R.** Omphalocele and diaphragmatic hernia and hepatopericardium diagnosis, 42
- Tipton, M. D. and Dowdley, J. E.** Imaging large objects with a Fresnel zone plate, 538*
- Tirnakli, V. and Blockeel, R.** Hepatic flow studies, 317
- Tofe, A. J. and Francis, M. D.** ^{99m}Tc-EHDP bone agent, 69
- Toma, N.** see Holan, T. S.
- Tomitani, T.** see Nohara, N.
- Tomura, K.** see Higashi, T.
- Tonami, N., Aburano, T. and Hisada, K.** Comparison of alpha-1-fetoprotein radioimmunoassay and liver scanning, 538*
- Tonami, N.** see Chaudhuri, Tapan, K.
see Hisada, K.
- Tonkin, A. K. and DeLand, F. H.** ^{99m}Tc-dihydrothiocetic acid for liver studies, 539*
- Tori, G., Marabini, A., Franchi, R. and Giorgetti, P. G.** ^{99m}Tc perfusion studies in kidney occupying lesions, 539*
- Torizuka, K.** see Hamamoto, K.
see Ishii, Y.
see Itoh, H.

- see Mori, T.
Tormey, D. C.
 see Frankel, R. S.
 see Richman, S. D.
Tothill, P. see Boddy, K.
Touloukian, R. J.
 see Forman, B. H.
 see Spencer, R. P.
Touya, J. J., Anselmi, O. E., Figueiroa, W. G., Riley, R. F. and Bennett, L. R. Comparison of ¹¹¹In-transferrin and iron metabolism, 539*
Touya, J. J., Byfield, J., Mena, I. and Bennett, L. R. ¹¹¹In-transferrin bone marrow imaging, 539*
Touya, J. J. see Verma, R. C.
Tow, D. E. see Garcia, D. A.
Trackler, R. T. and Mikulicich, A. G. Kinking of the internal carotid artery, 634
Tran, N. and LeBel, E. Estimating alcohol concentration, 284
Tran, N. and LeBel, E. Oxidation of ¹⁴C-DOPA in blood, 539*
Tran, N., LeBel, E. and Ntundulu, T. Radiobioassay of ¹⁴C-DOPA oxidation, 540*
Treves, S., Ahnberg, D. S., Laguarda, R. and Strieder, D. J. Regional lung function in children, 582
Treves, S., Ahnberg, D., LeFarge, G., Askenasi, J. and Maltz, D. L. Detection and quantitation of left to right shunts, 540*
Treves, S. see Dewanjee, M. K.
Trindade, H. see Davis, M. A.
Trow, R. S. see Kirch, D. L.
Tsapogas, M. J. see Peabody, R. A.
Tsuji, B. see Metz, C. E.
Tubis, M.
 see Krishnamurthy, G. T.
 see Pritchard, J. H.
Tully, T. E., Goldberg, M. E. and Loken, M. K. Intraperitoneal ^{99m}Tc-sulfur colloid distribution, 1068
Tully, T. E., Goldberg, M. E. and Loken, M. K. ^{99m}Tc-sulfur colloid assessment of ³²P-chromic phosphate distribution, 190
Tully, T. E., Shafer, R. B., Reinke, D. B. and Pliego, M. P. Carotid cavernous fistula, 797
Tully, T. E. see Shafer, R. B.
Turner, D. A. see Rayudu, G. V. S.
Turner, J. W., Syed, I. B. and Hanc, R. P. Lung uptake of ^{99m}Tc-sulfur colloid during liver imaging, 460
Turnšek, T. see Erjavec, M.
Tyson, J. W., Wilkinson, R. H., Witherspoon, L. R. and Goodrich, J. K. False-positive ¹³¹I total body scans, 1052
Tyson, J. W., Witherspoon, L. R., Wilkinson, R. H. and Goodrich, J. K. Accuracy of arteriovenous malformation detection, 953
Tyson, J. W. see Witherspoon, L. R.
Uchida, T., Yasunaga, K., Kariyone, S. and Wakisaka, G. ⁵¹Cr- and ^{99m}Tc-platelet survival, 801
Ueda, H. Liver circulation studies, 540*
Urban, R. see Milstein, D. M.
Ushio, T. see Kinoshita, F.
Uszler, J. M., Bennett, L. R., MacDonald, N. S. and Mena, I. ¹²³I-iodantipyrine brain imaging, 540*
Uszler, J. M. see MacDonald, N. S.
Valk, P. E. and McRae, J. Gel chromatography of ^{99m}Tc radiopharmaceuticals, 319
Vanags, K.
 see Kovaleski, B.
 see Schreyer, M.
Van Antwerp, J. D. see Emerson, D. A.
Van Heertum, R. L. see Teplick, S. K.
VanHove, E. D. and Heck, L. L. Cardiac ejection fractions, 541*
VanHove, E. D. see Heck, L. L.
Varady, P. D. see McNeil, B. J.
Veatch, R. see Sparagana, M.
Velten, R. J. see Sodd, V. J.
Verba, J. W., Schelbert, H. R., Brock, G. W., Alazraki, N. P. and Ashburn, W. L. Computer program for cardiac ejection fraction, 541*
Verba, J. W. see Alazraki, N. P.
Verhasselt, M. see Robertson, J. S.
Vérin, P. see Blanquet, P.
Verma, R. C. and Bennett, L. R. Choroid plexus on ^{99m}TcO₄⁻ brain scans, 541*
Verma, R. C., Touya, J. J. and Bennett, L. R. ¹¹¹In-bleomycin tumor scanning, 541*
Vescio, P.
 see Scharoff, J. R.
 see Thomas, F. D.
Victery, W.
 see Pollak, E.
 see Webber, M. M.
Voegelin, M. R. see Masi, R.
Vogel, J. M., Lockwood, D., Schneider, V. and Hulley, S. Bone mineral content measured by photon absorption, 541*
Vogel, J. M. see DeGrazia, J. A.
Vyas, M. see Wiener, S. N.
Wagner, H. N.
 see Amrein, P. C.
 see Camargo, E. E.
 see Chen, M.
 see Friedman, B. H.
 see Hill, J. H.
 see Larson, S. M.
 see Rhodes, B. A.
 see Siegel, M. E.
 see Thorell, J. I.
Wagner, J. see Webber, M. M.
Wahner, H. W. see Robertson, J. S.
Wakakuwa, S. T. see MacDonald, N. S.
Wakisaka, G. see Uchida, T.
Wallach, S. see Cohn, S. F.
Wallack, M. S. see Siemsen, J. K.
Wallner, R. J., Croll, M. N. and Brady, L. W. ⁶⁷Ga localization in acute cerebral infarction, 308
Wallner, S. F. see Brown, D. W.
Walsh, C. F. see Krishnamurthy, G. T.
Walters, T. E., Keyes, J. W. and Simon, W. High resolution transverse section tomography, 542*
Wang, Y. Comparison of regional renogram and renal arteriogram, 542*
Watson, D. D. see Serafini, A. N.
Watts, R. S., Sopher, R. L. and Peña, H. G. Iron hydroxide particle retention by primate lungs, 616
Waxman, A. D. Hepatic flow studies, 317
Waxman, A. D., Lee, G., Wolfstein, R. S. and Siemsen, J. K. ⁶⁷Ga evaluation of cerebral lesions, 542*
Waxman, A. D., Lee, G. C., Wolfstein, R. S. and Siemsen, J. K. Multi-radionuclide post-craniotomy studies, 542*
Waxman, A. D. and Siemsen, J. K. ⁶⁷Ga gallbladder scanning, 543*
Waxman, A. D. and Siemsen, J. K. Relative cost weights for nuclear medicine procedures, 543*
Waxman, A. D.
 see Lee, G. C.
 see Siemsen, J. K.
 see Wolfstein, R. S.
 see Woolfenden, J. M.
Webber, M. M., Aguilar, F. and Cragin, M. D. Ultrasonic diagnosis of pancreatic pseudocysts, 543*
Webber M. M. see Pollak, E.
Weber, P. M. and dos Remedios, L. V. ^{99m}Tc-DMSA for renal cortical imaging, 543*
Weber, P. M.
 see Bliss, R. D.
 see Enlander, D.
Wegst, A. V. see Robinson, R. G.
Weinberger, G. see Sy, W. M.
Weinraub, J. M. False-positive liver image, 143
Weinstein, M. B. and Miale, A. Total body screening for liver cancer, 544*
Weinstein, M. B. see Greenlaw, R. H.
Weiss, P. H. and Strong, J. D. Placenta abruption scanning, 900
Welch, M. J. see Harwig, J. F.
Wellman, H. U. see Browne, A. D.
Wells, H. P. see Martin, N. D.
Wells, N. see Harbert, J. C.
Wentz, D. see Grebe, S. F.
Wenzel, W. W. and Heasty, R. G. ^{99m}Tc-polyphosphate uptake in cerebral infarction, 207
Wetzel, R. A. Delayed bone scanning, 1227
White, R. see Siegel, M. E.
Whitney, W. P. see Hare, D. L.
Wieland, D. M. see Ice, R. D.
Wieland, H. C., Grames, G. M., Jansen, C. and Davidson, T. Fractional labeling of microspheres, 808
Wieland, H. C. see Grames, C. M.
Wiener, S. N., Borkat, F. R. and Floyd, R. M. Functional imaging, 65

SUBJECT INDEX

- Wiener, S. N. and Vyas, M.** Bile leakage imaging, 1044
- Wiener, S. N.** see Secker-Walker, R. H.
- Wiklund, P-E.** see Nordlander, S.
- Wilcox, M. E.** see Mincey, E. K.
- Wilkinson, R. H.**
see DeLand, F. H.
see Tyson, J. W.
- Willerson, J. T.** see Parkey, R. W.
- Williams, H.** see Erickson, J. J.
- Williams, H. P.** see Steigman, J.
- Williams, J. F.** see Goren, R. J.
- Wilson, G. A. and Keyes, J. W.**
Liver-spleen uptake ratio in liver scanning, 593
- Wilson, J. E.** see Ramanathan, M.
- Wilson, R. L.** see Lee, G. C.
- Winchell, H. S.**
see Lamb, J. F.
see Lin, T. H.
see Pierson, R. N.
- Winkel, K. Z. and Newiger, T.** Endolymphatic radiotherapy, 544*
- Winkel, K. Z., Schmidt, L. and Meves, M.** Measurement of salivary and gastric emptying, 544*
- Winston, M. A.** Pseudotumors in acute hepatitis, 1039
- Winston, M. A., Cuth, P., Endow, J. S. and Blahd, W. H.** Pancreatic concentration of ⁷⁵Se-selenomethionine, 662
- Winston, M. A. and Pritchard, J. H.** Diagnosing synovial cyst dissection, 912
- Winston, M. A.** see Pritchard, J. H.
- Winter, J.** see Stein, M. A.
- Winternitz, W. W.** see Preston, D. F.
- Witcofski, R. L., Pizzarello, D. J., Smith, E. M., Everhart, H. and Gnau, T. R.** Effect of radiation on liver cells, 241
- Witherspoon, L. R., Mahaley, M. S., Leonard, J. R., Tyson, J. W., Harris, C. C. and Goodrich, J. K.** Dynamic brain studies for recurrent neoplasm, 544*
- Witherspoon, L. R., Tyson, J. W.** and Goodrich, J. K. Peripheral postop activity and cerebral dynamics, 709
- Witherspoon, L. R.**
see Harris, C. C.
see Tyson, J. W.
- Wolf, A. P.**
see Atkins, H. L.
see Lambrecht, R. M.
see MacGregor, R. R.
- Wolf, W.** see Berman, J. A.
- Wolfstein, R. S., Tanasescu, D., Sakimura, I. T., Waxman, A. D. and Siemsen, J. K.** Brain imaging with ^{99m}Tc-DTPA, 1135
- Wolfstein, R. S.**
see Woolfenden, J. M.
see Waxman, A. D.
- Wong, D. W. and Mishkin, F. S.** Electrolytic preparation of ^{99m}Tc-fibrinogen, 544*
- Wong, P. Y., Cradduck, T. D. and Wood, D. E.** Semiautomatic in vitro thyroid function tests, 1074
- Wong, P. Y.** see Coates, G.
- Wood, D. E.**
see Coates, G.
see Wong, P. Y.
- Wood, R. A.** see MacDonald, N. S.
- Woolfenden, J. M., Waxman, A. D., DiSaia, P. J. and Siemsen, J. K.** ¹¹¹In-bleomycin scanning of carcinoma of the cervix, 545*
- Woolfenden, J. M., Waxman, A. D., Wolfstein, R. S. and Siemsen, J. K.** Scanning liver metastases from thyroid carcinoma, 545*
- Workman, J. B.** see Addlestone, R.
- Wu, H-H.** see Yeh, S-H.
- Yamamoto, I.** see Hamamoto, K.
- Yamazaki, R.** see Sasaki, Y.
- Yang, C-S., Grieco, R. V. and Bartone, N. F.** "Clear plate" technique for scan orientation, 380
- Yang, C-S., Grieco, R. V. and Bartone, N. F.** ^{99m}Tc-MAA cardiovascular dynamic perfusion study, 545*
- Yano, Y., Chu, P. and Anger, H. O.**
¹⁶⁷Tm production and distribution in mice, 545*
- Yano, Y.** see Budinger, T. F.
- Yao, J. S. T.** see Henkin, R. E.
- Yasunaga, K.** see Uchida, T.
- Yeh, E-L.** Estraosseous tumor uptake of ⁸⁵Sr and ⁶⁷Ga, 361
- Yeh, S. D. J., Grando, R. E., Young, C. W. and Benua, R. S.**
¹¹¹In-bleomycin metabolism and tumor scanning, 546*
- Yeh, S-H., Shih, W-J. and Liang, J-C.** Perfusion of hepatic metastases, 314
- Yeh, S-H., Shih, W-J., Liao, S-Q. and Chen, W-L.** Liver perfusion studies in hepatoma, 546*
- Yeh, S-H., Wu, H-H. and Chien, M-T.** ^{99m}Tc-MAA lung imaging, 546*
- Yoshikawa, B. M.** see Scheibe, P. O.
- Young, B. W.** see Handmaker, H.
- Young, C. W.** see Yeh, S. D. J.
- Youngs, G. R.** see Agnew, J. E.
- Yu, T.** see Counsell, R. E.
- Zand, L. C.** see Serafini, A. N.
- Zanzi, I.** see Cohn, S. F.
- Zaret, B. L.** see Martin, N. D.
- Zarnow, H.** see Ryo, U. Y.
- Zarocostas, G.** see Beihn, R. M.
- Zelis, R.** see Berman, D. S.
- Zielinski, F. W.** see DeNardo, S. J.
- Zimmer, A. M., Isitman, A. T., Schmitt, G. H. and Holmes, R. A.** Enzymatic mechanism for di-phosphonate binding, 546*
- Zimmer, A. M.** see Holmes, R. A.
- Zimmerman, D.** see Adams, R.
- Zimmerman, R. E.** see Kinoshita, M.
- Zimmerman, S.** see Genna, S.
- Zurbriggen, M. T.** see Bobinet, D. D.
- Zwas, T. S.** see Czerniak, P.
- Zweiman, F. G., O'Keefe, A., Idoine, J., Camin, L. L. and Holman, B. L.** ^{99m}Tc-chelates and ⁶⁷Ga uptake in myocardial infarct, 546*
- Zwieman, F. G.** see Holman, B. L.

1974 SUBJECT INDEX

Asterisk indicates abstract

Abdomen

- see also specific organ*
- abscess, ⁶⁷Ga scan, 372, 491*
- lesion evaluation, 481*, 536, 904
- pancreatic pseudocyst, ultrasound, 543*
- ³²P-chromic phosphate distribution, 190, 1067, 1068
- ^{99m}Tc-albumin aortography, 502*

Abscess

- abdominal, ⁶⁷Ga scan, 372, 491*
amebic, liver imaging, ⁶⁷Ga, 561; ^{113m}In-colloid, 1021;
^{99m}Tc-sulfur colloid, 508*
chest, ⁶⁷Ga scanning, 497*
imaging, ⁵¹Cr-leukocytes, in animals, 375

liver, ¹⁹⁸Au uptake, 305

liver, bile leakage, ¹³¹I-rose bengal, ^{99m}Tc-sulfur colloid, 1044

liver transplant, 479*

splenic, ^{99m}Tc-sulfur colloid imaging, 499*

subphrenic, ⁶⁷Ga, ^{99m}Tc-sulfur colloid scan, 371

^{99m}Tc-polyprophosphate uptake, 492*, 892, 1054

Absorption *see Gastrointestinal tract*

Academic Council

survey, Nuclear Medicine divisions, 22

Actinides

labeled bleomycin, tumor uptake, in mice, 526*

- Adrenal glands**
¹⁴C-isoxazole uptake, in rats, 187
¹⁸F-fluorodopamine, preparation, distribution, in mice, 513*
³H-, ¹⁸S-dopamine analogs, preparation, distribution, in rats, 503*
¹³¹I-iodocholesterol, imaging, 246, 513*, 531*
¹³¹I-iodocholesterol scanning, 332, 513*, 526*
¹³¹I-iodocholesterol, stability, 38
neuroblastoma, ^{99m}Tc-polyphosphate image, 904
- Adverse reaction procedure**, 213
- Aerosol**
dry, ^{99m}Tc-Sn(OH)₃-lactose, preparation, distribution, in dogs, 537
imaging, early chronic lung disease, 537*
obstructive airways disease evaluation, 492*
^{99m}Tc-sulfur colloid, respiratory tract deposition, 504*
- Alanine**
¹⁵N-, Preparation, distribution, in animals, 535*
- Albumin**
see Iodine-131, albumin; Technetium-99m, albumin
- Alcohol**
ethanol, tissue, concentration, 284
- Americium-241**
source, fluorescent excitation analysis, 525*
source, photon absorption, 487*
- Anatomy**
radionuclide, 485*
- Anger camera** *see Camera, scintillation*
- Antibiotics** *see Iodine-130; Iodine-131; Technetium-99m; Technetium-99m tetracycline; Tin-119m*
- Antibody**
see also Immunology; Radioimmunoassay
¹³¹I- and ^{99m}Tc-HSA clearance, sensitized dogs, 938
¹³¹I-CEA, tumor uptake, in animals, 323
¹¹¹In-gamma globulin preparation, 526*
titer, leukocyte metabolism of ¹⁴C-glucose, 1145
- Antimony-124**
in ^{99m}TcO₄⁻ eluate, 266
- Antitrypsin**
deficiency, lung studies, 474*
- Argon-37**
excretion, total body Ca by neutron activation analysis, 511*
- Arm** *see Extremities*
- Artifact**
Book Review; *Tomographic Imaging in Nuclear Medicine*, 144
brain image, 485*
dynamic kidney, imaging, 134
liver imaging, 496*, 1201
motion correction, 36
rim sign, ^{99m}TcO₄⁻ brain perfusion studies, 1035
^{99m}Tc gamma ray absorption, 379, 1201
- Autofluoroscope**
regional cerebral perfusion, ¹³³Xe, 504*
- Autoradiography**
-chromatography, peptidase activity of proteins, 557
⁵⁹Fe bone labeling, in animals, 161
³H-actinomycin D in kidney cells, 532
lymph node distribution of ^{99m}Tc-protoporphyrin, in dogs, 997
- Background**
correction, cardiac ejection fraction, 491*
splenic blood pool, 823
subtraction, myocardial imaging, 536*
subtraction, thyroid scanning, 810
- Bacteria**
intestinal, ¹⁴CO₂ breath test, 530*
myco-, ¹⁴C-substrate metabolism, 481*
sterility test, ¹⁴C-substrate metabolism, 1142
streptococci, salmonella, ¹⁴C-glucose metabolism, 510*
- Basal ganglia**
imaging, ⁶⁷Cu, in animals, 534*
- Bile** *see Gallbladder*
- Bismuth-206**
subcellular tumor uptake, 501*
- Bleomycin** *see also Cobalt-57; Copper-64; Indium-111 bleomycin; Technetium-99m; Uranium-237*
lanthanide and actinide labeled, tumor uptake, in mice, 526*
- Blocking dose**
perchlorate, ^{99m}TcO₄⁻ studies, 221, 884
perchlorate, ^{99m}Tc-phosphorous bone agents, 1229
- Blood**
¹⁴C-DOPA oxidation, in vitro, 539*
clearance, bone agents, 832, 848, 1153
clearance, labeled bleomycin, 338, 484*
clearance, ^{99m}Tc- and ¹³¹I-HSA, sensitized dogs, 938
kinetics of In- and Fe-transferrin, 856
disease, RE function, 495*, 532*
erythrocytes *see Red Blood Cells*
⁵⁹Fe whole body scanning, 483*, 667
hemoglobin, ^{99m}Tc binding, 487*, 703
- International Committee for Standardization in Hematology**, 376
- leukemia, lymphocytic, spleen scans, 496*
leukocytes, ¹⁴C-glucose metabolism, 352, 1145
leukocytes, ⁵¹Cr-, abscess imaging, in animals, 375
leukocytes, ⁶⁷Ga labeling, in rabbits, 98
lymphocytes, ¹⁴C-glucose metabolism, 510*
lymphocytes, ⁵¹Cr labeling, 750
lymphocytes, ^{99m}Tc-, preparation, distribution, in mice, 656
plasma oxalic acid, enzyme analysis, 486*
platelets, ^{99m}Tc-, ⁵¹Cr-, preparation, biologic fate, 801
thrombi, ¹²³I-fibrinogen imaging, in dogs, 487*
thrombi, ¹²³I-fibrinogen preparation, 195; uptake, 482*, 524*
thrombi, ¹²³I-fibrinogen, preparation, distribution, in dogs, 974; imaging, in dogs, 500*
thrombi, ^{99m}Tc-fibrinogen scanning, 1163
thrombi, ^{99m}Tc-microspheres, imaging, 171, 915
thrombi, ^{99m}Tc-, ¹²³I-urokinase, preparation, distribution, in dogs, 534*
volume, brain, transverse section scanning, ^{99m}Tc-RBC, 509*
- Blood clot** *see Blood*
- Blow flow** *see specific organ; Vascular system*
- Blood vessels** *see Vascular system*
- Bone**
blood supply effects on uptake, 182, 476*, 485*, 493*, 494*, 538*, 543*
Ca, partial body, neutron activation analysis, 929
cold lesions, 495*, 1120
¹⁶⁶Er-citrate, preparation, distribution, in animals, 1008
⁵⁹Fe labeling, in rabbits, 161
femoral head circulation, ¹⁸F, 182; ^{99m}Tc-diphosphonate, 543*
geriatric studies, 503*
heterotopic formation, 530*
high uptake areas, 1228
imaging, collimator choice, 837
imaging, comparison of bone agents, 837, 848, 1101, 1110
imaging, soft-tissue inflammation effect, in rats, 476*
kinetics, comparison of bone agents, 477*, 509*, 832, 848
Legg-Perthes disease, 485*
meningioma of the sphenoid wing, 1205
metastatic breast carcinoma, 491*
metastatic thyroid carcinoma, imaging, 51; ³²P therapy, 1037
mineral content by photon absorption, 335, 487*, 541*
multi-organ, multi-agent imaging, 485*
osteoarthropathy, 312
osteogenic sarcoma, metastatic, 53

- osteoid osteoma, 494*
- osteomyelitis, cellulitis differentiation, 494*
- osteomylelitis scanning, 533*
- osteoporosis, total body Ca, neutron activation analysis, 428, 483*
- Paget's disease, 880
- radiation dosimetry, ¹⁸F and ^{99m}Tc agents, 496*
- rib lesion positioning, 1227
- scan, comparison of ¹⁸F and ^{99m}Tc-phosphorous agents, 1153
- scan, hyperparathyroidism, 536*, 1089
- scan, renal asymmetry, 500*
- scan, shielding artifacts, ^{99m}Tc, 379
- skull scanning, 1185
- ^{99m}Tc-diphosphonate, preparation, distribution, in animals, 69, 127
- ^{99m}Tc-diphosphonate, uptake mechanism, 493*, 546*
- ^{99m}TcO⁻ distribution, effect of Sn(II), in rats, 151
- ^{99m}Tc-polyphosphate, delayed imaging, 47, 1227, 1228
- ^{99m}Tc-polyphosphate and -pyrophosphate, relationship, 652
- ^{99m}Tc-polyphosphate, tooth abscess uptake, in dogs, 492*, 892
- ^{99m}Tc-pyrophosphate kit, 124, 480*
- ^{99m}Tc-pyrophosphate, preparation, distribution, 278; toxicity, in rats, 252
- ^{99m}Tc-pyrophosphate uptake compared to ¹⁸Ca metabolism, 498*
- tomography, multiplane, 516*
- tumor, ⁶⁷Ga-citrate scanning, 480*
- tumor, ¹¹¹In-bleomycin kinetics, in mice, 273
- tumor uptake mechanism, ⁶⁷Ga-, ¹¹¹In-, ¹⁰³Yb-citrates, in rats, 502*
- tumor uptake, ¹⁵N-glutamic acid, in dogs, 515*
- uptake parameters, bone agents, in rats, 493*
- Bone marrow**
- disease, RE system imaging, 1158
- extension, 343
- ⁵⁹Fe labeling in bone, in rabbits, 161
- ⁵⁹Fe whole-body scanning, 483*, 667
- image, femoral blood supply, 543*
- imaging, ¹¹¹In-transferrin, 539*
- ¹¹¹In-bleomycin distribution, 541*
- ¹¹¹In-chloride scans, 494*, 495*, 647
- infarct in sickle cell disease, 1003
- metabolism of In- and Fe-transferrin, in animals, 856
- scanning compared to biopsy, 479*
- scanning, hematologic disease, 532*
- scanning, hematologic disease, 532*
- scanning, osteomyelitis, in rabbits, 490*
- ^{99m}Tc-sulfur colloid uptake in liver scan, 493*
- Brain**
- acoustic neurinoma, ^{99m}TcO⁻ scan, 525*
- basal ganglia imaging, ⁶⁷Cu, in rabbits, 534*
- bullet track image, 140
- ¹³C-ethanol distribution, in animals, 512*
- ¹³C-formate and -formaldehyde metabolism, in vitro, in rats, 284
- choroid plexus uptake of ^{99m}TcO⁻, 541*, 884
- corpus callosum lipoma scan, ^{99m}TcO⁻, 714
- cystic astrocytoma imaging, 494*
- delayed images, calvarial lesions, ^{99m}TcO⁻, 681
- delayed imaging, ^{99m}Tc-DTPA, 1135
- dynamic, static studies, relationship, 32
- EEG effect, ^{99m}TcO⁻ imaging, 369
- false-positive images, ⁷⁵Se-selenite, in animals, 622
- geriatric studies, 503*
- hematoma, epidural, 713; subdural, 693; intraventricular bleeding, 639
- ¹⁹⁷Hg-chloromerodrin compared to ^{99m}TcO⁻ for scanning, 520*
- ¹³¹I-iodoantipyrine imaging, in animals, 540*
- image, meningioma of the sphenoid wing, 1205
- imaging artifact, 485*
- imaging compared to microangiography in stroke, in animals, 488*
- imaging, Paget's disease, ^{99m}TcO⁻, 880
- infantile cerebral paralysis scan, 517*
- infantile hemiplegia scans, 300
- infarct, ^{99m}Tc-polyphosphate image, 207
- infarct, ⁶⁷Ga uptake, 308
- lesion differentiation, 523*; ⁶⁷Ga-citrate, ^{99m}TcO⁻, 542*
- "luxury perfusion syndrome" post CVA, 907
- metastatic disease, ^{99m}TcO⁻ scan, 620
- ⁵⁴Mn entry, in rats, 516*
- multicrystal camera imaging, ^{99m}TcO⁻, ⁶⁷Ga, ¹¹¹In-Bleomycin, ^{113m}In-DTPA, 537*
- multiple sclerosis, ^{99m}TcO⁻ scan, 131
- multiple view reconstruction techniques, ^{99m}TcO⁻ imaging, 480*
- ¹⁸O-O₂, -CO₂, -CO, equilibrium images, 505*
- radiation dose, ¹⁰³Yb-DTPA cisternography, 643
- scan, off midline falx and superior sagittal sinus, ^{99m}TcO⁻, 1047
- scan, relative cost weights, 543*
- ^{99m}Tc-diphosphonate scanning, 490*
- ^{99m}TcO⁻ scan, perchlorate blocking, 221
- tomography, axial, 515*, 519*
- tomography, scintillation camera, 439
- toxoplasmosis, ^{99m}TcO⁻ image, 641
- tumor imaging, postcraniotomy, ^{99m}TcO⁻, ^{99m}Tc-polyphosphate, ⁶⁷Ga, 542*
- tumor, ¹¹¹In-bleomycin scanning, 546*
- tumor uptake of 16 agents, in mice, 508*
- tumor uptake, ^{99m}Tc-polyphosphate, 1054
- ventricle visualization in ^{99m}TcO⁻ scan, 202
- 3D imaging, attenuation correction, 497*
- Brain, blood flow**
- aneurysm, ^{99m}TcO⁻, 358, 1113, 1217
- arteriovenous malformation detection, ^{99m}TcO⁻, 953
- automatic computer analysis, 489*
- carotid cavernous fistula, 797, 1105
- cerebral death diagnosis, 517*, 912, 914
- cerebral paralysis, infantile, ^{99m}TcO⁻, ¹¹¹In-transferrin, 517*
- computer analysis, off-line, 520*
- cystic astrocytomas, 494*
- kinked internal carotid artery, 634
- jugular vein reflex effect, 363
- lesion differentiation, 523*
- local blood volume, transverse section scanning, ^{99m}Tc-RBC, 509*
- "luxury-perfusion syndrome" post-CVA, 907
- multicrystal camera studies, 537*
- postsurgical activity, 709
- recurrent neoplasm, ^{99m}TcO⁻, 544*
- regional, ¹³³Xe, autofluoroscope, 504*
- relation to static imaging, ^{99m}TcO⁻, 32
- rim sign, ^{99m}TcO⁻, 1035
- vascular mean transit time, ¹³CO-hemoglobin, 814
- Breast**
- carcinoma, imaging bone metastases, 491*
- carcinoma, ^{99m}Tc-diphosphonate scan, 491*
- carcinoma, uptake of eight radiopharmaceuticals, in rats, 489*
- imaging, ^{99m}TcO⁻, ⁶⁷Ga, 527*
- imaging, ^{99m}Tc-polyphosphate, -diphosphonate, 1149
- shielding of ^{99m}Tc in liver scan, 1201
- tumor, ⁶⁷Ga-citrate scanning, 481*
- tumor uptake of diphosphonate, 918
- tumor uptake of ^{99m}Tc-polyphosphate, 1054
- Brookhaven Linac Isotope Producer**
- ¹³¹I purity, 1226
- ⁹⁷Ru and ⁶⁷Cu production, 511*
- Calcium**
- balance, geriatrics, 503*
- content, diphosphonate localizing soft tissue, 918
- partial body, neutron activation analysis, 929

- soft tumor calcification, ^{99m}Tc -polyphosphate uptake, 1057
 total body, neutron activation analysis, 428, 483*, 511*
- Calcium-47**
 absorption measurement, 588
 bone kinetics, 498*
- Calcium-48**
 partial body Ca, neutron activation analysis, 929
- Calcium-49**
 partial body Ca, neutron activation analysis, 929
 total body Ca, neutron activation analysis, 428, 483*
- Calculator, desk top**, 511*
- Camera, image intensifier**
 interfaced to digital computer, 506*
- Camera, multiwire proportional**
 ^{18}Er for bone and tumor, preparation, distribution, in animals, 1008
 ^{18}Er imaging, 526*
- Cameras, positron**
 angular correction measurements, 495*
 equilibrium head images, $^{15}\text{O}-\text{O}_2-\text{CO}$, $-\text{CO}_2$, 505*
 extravascular lung water, ^{15}O , ^{15}N , in dogs, 474*
- Cameras, scintillation**
 analog image processing, 844
 artifact, brain image, 485*
 collimator choice, ^{123}I , 328, 1226
 compared to portable probe, 912, 914
 compared to scanner, ^{99m}Tc -polyphosphate bone studies, 837
 -computer, heart studies, 474* 497*, 504*, 506*, 531*, 540*, 541*
 -computer, kidney perfusion, 506*, 532*, 775
 -computer, kidney washout, ^{133}Xe , 504*
 -computer, renogram, 65
 -computer, V/Q frequency distribution, ^{133}Xe , 519*
 count-rate, dynamic imaging, 500*
 data recorder, 1130
 deadline, 412, 468, 475*, 507*, 534*, 722
 ECG gated cardiac perfusion, 477*, 497*, 505*, 1182
 eye imaging, 478*
 lacrimal drainage, $^{99m}\text{TcO}_4^-$, 482*
 liver regeneration imaging, in rat, 10
 long distance image transmission, 896
 motion artifact correction hardware, 36
 multicrystal, brain imaging, 537*
 multiple view reconstruction techniques, 480*
 pseudorandom filters and correlation analysis, 507*, 508*
 resolution, comparison of ^{123}Xe and ^{133}Xe , 502*
 resolving time, 475*
 tomography, 439, 542*
 3-D image reconstruction, 497*, 520*
- Camera, semiconductor**
 germanium detector, 517*, 1196
- Carbon-11**
 ^{11}CO , left ventricular volume, 477*
 -ethanol, distribution, in animals, 512*
- Carbon-13**
 -galactose, metabolism test, 432*
- Carbon-14**
 -acetate, mycobacteria metabolism, 481*
 $-\text{CO}_2$, breath test of fat synthesis, in rats, 118
 -diphenylhydantoin, islet cell uptake, in toadfish, 476*, 685
 -DOPA, oxidation in vitro, 539*, 540*
 -dopamine, distribution, in rats, 503*
 -formaldehyde and -formate, in vitro metabolism, 284
 -galactose, metabolism test, 532*
 -glucose, CSF kinetics, 916, 917
 -glucose, leukocyte metabolism, 352, 510*; antibody titer, 1145
 -glucose, metabolism by bacteria, antisera inhibition, 510*
 -glycerol, mycobacteria metabolism, 481*
- glycine-cholate, bacterial deconjugation of bile salts, 530*
- isoxazole, estradiol effect on distribution, in rats, 187
- methylene blue, cervical cancer screening test, 733
- optimization of component ratios of ^{99m}Tc -EHDP, 69
- oxalic acid, enzyme analysis, 486*
- pyruvate, -acetate, metabolism, in rats, 118
- streptozotocin, distribution, in animals, 572
- substrate, metabolism, sterility test, 1142
- testosterone, -5- α -dihydrotestosterone, uptake in prostate, in dogs, 94
- tripalmitin, breath test, pancreas, 1125
- u-d-xylose absorption, 486*
- Carbon-15**
 $-\text{O}$ -hemoglobin, cerebral vascular mean transit time, 814
- Carcinoembryonic antigen**
 ^{131}I -antibody tumor uptake, in animals, 323
 titer, liver metastases, 514*
- Cardiac** *see Heart*
- Cardiopulmonary** *see Heart, blood flow; Lung*
- CEA titer** *see Carcinoembryonic antigen*
- Cerebral** *see Brain*
- Cerebral spinal fluid** *see Cisternography*
- Cerium-141**
 effect of scatter medium on imaging, 943
 -microspheres, ocular blood flow, in dogs, 488*
- Cervix**
 cancer, ^{11}C - and ^3H -dyes, screening test, 733
 scanning, ^{111}In -bleomycin, 545*
- Cesium**
 -RBC volume, fluorescent excitation analysis, in rabbits, 525*
- Cesium-129**
 myocardial imaging, 480*
 myocardial infarct scan, with ^{113m}In , 523*
 myocardial uptake, in rats, 1092
 uptake in damaged muscle, in rats, 527*
- Cesium-131**
 coronary blood flow and cardiac output, 490*
 in TCO_4^- eluate, 266
 myocardial infarct evaluation, 523*; in dogs, 524*
- Cesium-134**
 distribution, in animals, 526*
- Cesium-134m**
 distribution, in animals, 526*
- Cesium-137**
 radiation therapy dose calculation, 502*
- Chelates** *see Gallium-67; Indium-111; Indium-113m; Lead-203; Technetium-99m, DTPA; Ytterbium-169*
- Chemotherapy**
 Dianabol in osteoporosis, total body Ca by NAA, 483*
 effect on bone marrow RE patterns, 343
 ^{196}Pt -dichlorodiammine-platinum (II) distribution, 349
 tuberculosis of liver, 135
- Cholesterol** *see Iodine-131*
- Choroid plexus**
 $^{99m}\text{TcO}_4^-$ uptake, 541*, 884
- Chromatography**
 -autoradiography, peptidase activity of proteins in radioimmunoassay, 557
 ^{99m}Tc radiopharmaceuticals, 318, 319, 488*, 722
- Chromium-51**
 dose calibration, 501*
 $-\text{DTPA}$, cisternography, radiation dosimetry, 479*
 -leukocytes, abscess detection, in animals, 375
 leukocyte labeling compared to ^{67}Ga , in rabbits, 98
 lymphocyte binding, 750
 -platelets, survival sequestration, 801
 $-\text{RBC}$, spleen imaging, 498*
 $-\text{RBC}$, quantitative splenic sequestration, 514*
 $-\text{RBC}$ volume, compared to fluorescent excitation analysis, in rabbits, 525*
- Chromosomes**
 sex, abnormal, total body K and lean body mass, 448

Cisternography

- agents, radiation dose, cost, quality control, 496*
- diagnostic criteria, 486*
- DTPA preparations, radiation dosimetry, 479*
- geriatric, 503*
- ¹³¹I-HSA, radiation dose, 786
- ¹³¹I-HSA, ¹⁰³Yb-DTPA, 916, 917
- mathematical model, ¹¹¹In-DTPA, 521*
- shunt function, arrested hydrocephalus, ^{99m}TcO₄⁻, 529*
- subcutaneous extravasation of CSF, 200
- surgical shunt evaluation, 465
- transverse section scanning, ¹¹¹In-DTPA, 529*
- ¹⁰³Yb-DTPA, radiation dose, 375, 643, 783, 917

Clinical evaluation

- abdominal lesion diagnosis, radioisotopes, x-ray, ultrasound, 110 cases, 536*
- anatomy, radionuclide, 21,000 cases, 485*
- bone imaging, ^{99m}Tc-pyrophosphate, 134 cases, 498*
- brain, axial tomography, 500 cases, 515*, 519*
- brain, blood flow, regional, ¹³³Xe, autofluoroscope, 67 cases, 504*
- brain imaging, dynamic and static ^{99m}TcO₄⁻ studies, 200 cases, 32
- brain imaging, delayed, calvarial lesions, ^{99m}TcO₄⁻, 69 cases, 681
- brain imaging, ⁶⁷Ga-citrate and ^{99m}TcO₄⁻, 148 cases, 542*
- brain imaging, ^{99m}Tc-DTPA, 129 cases, 1135
- brain scan, comparison of ¹⁹⁷Hg-chlormerodrin and ^{99m}TcO₄⁻, 67 cases, 520*
- bone tomography, multiplane, ^{99m}Tc-polyphosphate, -EHDP, 200 cases, 516*
- breast carcinoma scanning, ^{99m}Tc-diphosphonate scan, 50 cases, 491*
- Ca, partial body, neutron activation analysis, 71 cases, 929
- cardiac shunt estimation, pulsatile flow model, 125 cases, 504*
- cardiac shunt quantitation, 105 cases, 540*
- cardiovascular and lung perfusion, ^{99m}Tc-MAA, 264 cases, 545*
- CEA titer in liver metastases, 225 cases, 514*
- dose calibration, 33 participants, 501*
- effective thyroxine ratio without alcohol extraction, 100 cases, 1032
- esophagus imaging, ^{99m}TcO₄⁻, 774 cases, 510*
- eye imaging, 300 cases, 478*
- ⁶⁷Ga scanning in chest disease, 459 cases, 497*
- ⁶⁷Ga-citrate imaging in pyelonephritis, 73 cases, 503*
- ⁶⁷Ga-citrate lung imaging, 162 cases, 227
- ⁶⁷Ga-citrate scanning in Hodgkin's disease, 151 cases, 399
- ⁶⁷Ga-citrate scanning in malignant melanoma, 167 cases, 404
- ⁶⁷Ga-citrate scanning in primary lung cancer, 172 cases, 408
- ⁶⁷Ga-citrate tumor scanning, 403 cases, 480*
- ⁶⁷Ga, ¹¹¹In whole body scans in liver cancer, 350 scans, 544*
- gastric and salivary emptying, ^{99m}TcO₄⁻, 544*
- geriatric nuclear medicine, 1200 cases, 503*
- heart, direct coronary injections, 800 cases, 2
- heart, dual isotope scanning, ¹²³Cs, ¹³¹Cs, ^{113m}In, 600 cases, 523*
- heart, radioangiography compared to echocardiography, 91 cases, 505*
- heart scans, ⁴³K, 85 cases, 495*
- ¹¹¹In-bleomycin imaging in lymphoma, 55 cases, 512*
- ¹¹¹In-bleomycin tumor imaging, 208 cases, 512*; 200 cases, 541*
- ¹¹¹In-transferrin bone marrow imaging, 100 cases, 539*
- intrathoracic mass lesion evaluation, ⁹⁷HgCl₂ and ^{99m}Tc-MAA, 81 cases, 490*
- kidney angiography, ^{99m}Tc, 310 cases, 539*
- kidney, kinetic model ¹³¹I-Hippuran, 49 cases, 102, 1066
- kidney transplant, ^{99m}TcO₄⁻, ¹³¹I-Hippuran, 200 cases, 489*

Liver angiography, 1000 cases, 535*

- liver, first transit ^{99m}Tc-sulfur colloid deposit, 154 cases, 493*
- liver, imaging and angiography, ^{99m}Tc-sulfur colloid, 64 cases, 533*
- liver, imaging compared to ultrasound, 73 cases, 511*
- liver lesion differentiation, ^{113m}In-colloid blood flow, 170 cases, 1021
- liver perfusion in hepatoma, ^{113m}In, 141 cases, 546*
- liver scan, hepatocellular disease, ^{99m}Tc-sulfur colloid, 108 cases, 493*
- liver scanning in primary cancer, 202 cases, 296
- liver size on scans, 100 cases, 237
- liver transplant, 80 cases, 479*
- liver imaging, ^{99m}Tc-MAA, 650 cases, 510*
- lung perfusion, transposition of the great arteries, ^{99m}Tc-microspheres, 41 cases, 484*
- lymph node radiotherapy, ³²P, ¹³¹I-lipiodol, 202 cases, 544*
- pancreas imaging, GI tract subtraction, 350 cases, 220
- parathyroid thermography, 106 cases, 530*
- radioimmunoassay, alpha-1-fetoprotein, 344 cases, 539*
- RE imaging in bone marrow disease, ^{99m}Tc-sulfur colloid, 58 cases, 1158
- RE scans in hematologic disease, 65 cases, 532*
- skull scanning, ^{99m}Tc-diphosphonate, 181 cases, 1185
- ^{99m}Tc-albumin microsphere venography, 53 cases, 171, 915
- ^{99m}Tc-bleomycin, thyroid cancer imaging, 56 cases, 518*
- ^{99m}Tc-pyrophosphate kit, 253 cases, 480*
- ^{99m}Tc-MAA kit, 50 cases, 192
- thyroid carcinoma, ¹³¹I therapy, 333 cases, 477*
- thyroid carcinoma, whole body ¹³¹I imaging, 58 cases, 477*
- thyroid function following cancer therapy, 58 cases, 531*
- thyroid, hyper-, ¹³¹I turnover, 100 cases, 476*
- thyroid, ¹²³I therapy, 100 cases, 257
- thyroid nodule, ¹²³I imaging, oblique view, 55 cases, 782
- thyroid nodule, nonfunctioning, ultrasound, 62 cases, 523*
- thyroid scan in lymphocytic thyroiditis, 51 cases, 522*
- thyroid uptake, ^{99m}TcO₄⁻, 304 cases, 525*; 70 cases, 1117
- thyroidectomy, subtotal, serum TSH, T₄, T₃, PBI, 53 cases, 515*
- thyroiditis, subacute, diagnosis, 62 cases, 81
- Vitamin B₁₂ radioassay, 140 cases, 688
- ¹³³Xe ventilation, 52 cases, 1179

Cobalt-57

- B₁₂, consecutive day Schilling test, 949
- B₁₂, radioassay, 688
- bleomycin, breast carcinoma uptake, in rats, 489*
- bleomycin, tumor detection, 386; in mice, 1167
- marker, anatomic, 1226
- germanium gamma camera performance, 1196

Cobalt-60

- B₁₂, consecutive day Schilling test, 949
- in ^{99m}TcO₄⁻ eluate, 266
- radiotherapy, effect on ⁶⁷Ga lung scan, 227

Collimator

- see also Filter; Fresnel zone plate
- choice for ¹²³I, camera, 328, 1226
- choice, ^{99m}Tc-microsphere venography, 171, 915
- choice, ^{99m}Tc-polyphosphate bone imaging, 837
- choice, ventilation/perfusion, ^{99m}Tc, ¹³³Xe, 964
- "constant resolution," splenic sequestration, ⁵¹Cr, 514*
- depth independent response, positron emission, 523*
- diverging, for ¹²³Xe, 502*
- focused, geometric transfer function, 1078
- high-efficiency camera, 500*
- ¹²³I thyroid scans, 261
- MTF, effect of scatter medium, 943
- multihole converging, 291, 516*
- multiple pinhole, tomography, 1063
- multiprobe, ¹³³Xe lung perfusion, in dogs, 959

- nonfocused, 679
 parallel-hole, design, 724
 pinhole and converging, comparison, 59
 pinhole, eye imaging, 478*
- pinhole, germanium gamma camera, 1196
 pinhole, lacrimal drainage, 482*
 pinhole, rat liver regeneration imaging, 10
 pseudorandom filters, 507*, 508*
⁸²Rb-⁸²Kr regional myocardial perfusion, 509*
 scanner, performance index, 757
 whole body ⁶⁷Fe scanning, 483*, 667
- Colloid**
see also specific radionuclide
 particle size, 726, 727, 728, 923
- Compton** *see Scatter*
- Computer**
see also Data processing
 analog, 2D image processing, 844
 axial tomography, brain, 515*, 519*
 background subtraction, ⁶⁷Ga thyroid scanning, 810
 brain perfusion analysis, 489*, 520*
 cardiac perfusion studies, 477*, 478*, 505*, 536*, 540*, 541*; pulsatile flow model, 504*, 506*, 527*
 central, analog camera signal transmission, 896
 data storage and retrieval, 497*, 535*
 display system, transaxial tomograph, 513*
 fluorescence scanning, thyroidal I pool, 522*
 gated imaging, small tumor phantoms, 537*
 interfaced to image intensifier camera, 506*
 interpretation, liver flow studies, 481*
 kidney function, quantitative, in dogs, 538*
 kidney perfusion, 532*, 775
 kidney, renogram processing, 65
 kidney transplant, compartmental analysis, 528*
 kidney, ¹³³Xe washout, 504*
 thyroid disease diagnosis, 521*
 transmission imaging, regional lung volume, 605
 tomography, scintillation camera, 542*
- Copper-64**
 basal ganglia imaging, in rabbits, 534*
 -bleomycin, breast carcinoma uptake, in rats, 489*
 radiation dosimetry, 1011
- Copper-67**
 -bleomycin, preparation, distribution, in animals, 484*, 498*
 production, BLIP, 511*
 radiation dosimetry, 1011
- Cost**
 benefit analysis, renovascular disease, 516*
 semiautomatic T_s and T_t, 1075
- Counting**
 gas proportional and liquid scintillation, ³H in biologic material, 115
- Count rate**
 effect on scintillation camera deadtime, 412
 for dynamic imaging, 500*
- Cows** *see Generator*
- Crystal**
 image formation, NaI, CsI, 519*
- Crystal violet**
³H-, 733
- CSF**
see also Cisternography
 cerebral ventricle visualization on ^{99m}TcO₄- brain scan, 202
- Curium-244**
 bone mineral measurement by photon absorption, 335
- Cyclotron**
 compact, ¹¹¹In production, 513*
⁴⁵Ti and ²⁰³Pb production, 475*
^{99m}Tc production, impurities, 484*
¹⁶⁷Tm production, 545*
¹³³Xe production, 502*
- Cyst** *see specific organ*
- Data processing**
see also Computer
 analog, omnidirectional scanning, 844
 attenuation correction for 3D imaging, 497*
 background correction, myocardial imaging, 536*
 ECG gated right heart dilution, 505*
 iterative 3D reconstruction, 520*
 multiple view reconstruction techniques, 480*
 off-line computer analysis, cerebral blood flow, 520*
 orthogonal tangent correction for section scanning, 377, 378, 379
 pulsatile flow heart model, 504*, 506*, 527*
 spatial filtering, 493*, 521*
 stationary linear, effect on noise and resolution, 164
 tomographic image reconstruction, Fourier transforms, 981
- Data storage and retrieval** *see Computer; Record keeping*
- Data recording system**
 tape, scintillation camera, 1130
- Deadtime**
 scanner, 728, 729
 scintillation camera, 412, 468, 475*, 507*, 534*, 722
- Detector** *see also Collimator; Fresnel zone plate*
 Cd-Te semiconductor, 492*, 892
 depth independent response, positron emissions, 523*
 germanium, camera system, 517*, 1196
 image formation in scintillating crystals, NaI, CsI, 519*
 semiconductor, 1167
- Diode**
 Si, computer interface, image intensifier camera, 506*
- Digoxin**
 effect on myocardial clearance of seven agents, 1092
 radioimmunoassay, 465
- Diphosphonate** *see Technetium-99m, diphosphonate*
- Display**
 functional imaging, 65
 iterative 3D reconstruction, 520*
 M-B cardiac scan, 536*
 minification, 219
 multiple pinhole tomographic imaging, 1063
 transaxial tomograph, 513*
- DNA**
 stimulation by T_s, in kidney, in vitro, 532*
- Dopamine**
 analogs, ³H-, ³⁵S-, preparation, distribution, in rats, 505*
¹¹C-, distribution, in rats, 503*
¹⁸F-, preparation, distribution, in mice, 513*
- Dose calibration**, 501*, 1138
- Dosimetry** *see Radiation dosimetry*
- DTPA** *see Gallium-67; Indium-111; Indium-113m; Technetium-99m, DTPA; Ytterbium-169*
- Dyes**
¹¹C- and ³H-, cervical cancer screening test, 733
- Dysprosium-157**
 tumor uptake, in animals, 501*
- Ear**
 acoustic neurinoma, brain scan, 525*
 middle, ¹³³Xe clearance, 528*
- EDTA** *see Indium-111; Lead-203; Ytterbium-169*
 effect on parathyroid hormone concentration, 763
- Education**
 nuclear medicine divisions in U.S. medical schools, 22
- Electrolysis**
^{99m}Tc labeling, chemistry, 75
- EMI scanner** *see Transverse section*
- Energy** *see Nuclear parameters*
- Enzyme**
 analysis, oxalic acid, ¹⁴C-, 486*
 inhibitor, ¹⁴C-isoxazole tumor uptake, in rats, 187
 mechanism of ^{99m}Tc-diphosphonate bone uptake, 546*
 oxidation of ¹⁴C-DOPA, in vitro, 540*
 peptidase, carrier proteins used in radioimmunoassay, 557
 synthesis of ¹⁵N-asparagine, 1223

SUBJECT INDEX

- synthesis, ^{18}N -glutamic acid and -alanine, 1192
synthesis of ^{18}N -glutamine, -glutamic acid, -asparagine, 492*
- trypsin level in false-positive pancreas scans, 90
- Eosin, ^3H , 733**
- Erbium-165**
-citrate, preparation, distribution, bone and tumor, in animals, 1008
tumor uptake, in mice, 536*
- Erbium-169**
in ^{166}Er preparation, 1008
- Erbium-171**
in ^{166}Er preparation, 1008
tumor uptake, in animals, 501*
- Erythrocytes** *see Red Blood Cells*
- Esophagus**
imaging, $^{99m}\text{TcO}_4^-$, 510*
- Estradiol**
 ^3H , uptake by prostate, in dogs, 94
- Extremities**
deep vein thrombosis, ^{125}I -fibrinogen, 482*, 524*
joint imaging, ^{99m}Tc -polyphosphate, 417; in hemophilia, $^{99m}\text{TcO}_4^-$, ^{99m}Tc -albumin, 514*
joint tumor uptake of ^{18}N -glutamic acid, in dogs, 515*
knee imaging, ^{131}I -HSA, 7, 911, 912; $^{99m}\text{TcO}_4^-$, 7, 489*
leg ulcer, vascular perfusion scanning, ^{99m}Tc -microspheres, 533*
perfusion, ^{48}K , 518*
 ^{99m}Tc -albumin microsphere venography, 171, 915
vascular disease, comparison of perfusion and arteriography scans, 533*
- Eye**
blood flow, pressure effect, ^{113}Ce - and ^{85}Sr -microspheres, in dogs, 488*
imaging, ^{131}I -diiodofluorescein, -chloroquine and $^{99m}\text{TcO}_4^-$, 478*
lacrimal drainage, $^{99m}\text{TcO}_4^-$, 482*
lacrimal gland uptake of ^{67}Ga , 630
- Fat**
embolism syndrome, lung imaging, 517*
 ^{14}C -tripalmitin breath test, 1125
 ^{131}I -lipiodol, lymph node radiotherapy, 544*
- Fetus**
placental abruption, $^{99m}\text{TcO}_4^-$ imaging, 900
placental transport of ^{113m}In - and ^{59}Fe -transferrin, 856
- Fibrinogen** *see Indium-111; Iodine-123; Iodine-125; Iodine-131; Technetium-99m*
- Field of view**
collimator comparison, 59
on-axis Fresnel zone plate, 538*
- Filter** *see also Fresnel zone plate*
polycarbonate, colloid particle size, 923
pseudorandom, 507*, 508*
spatial, dual window, 493*
spatial, optimization and limitation, 521*
- Fluorescent excitation analysis**
book review; *Tomographic Imaging in Nuclear Medicine*, 144
RBC volume, in rabbits, 525*
thyroid iodine pool, 522*
- Fluorine-18**
bone scan, osteomyelitis, 533*
bone studies, "cold lesions," 495*, 1120
bone uptake in parameters, in rats, 493*
circulation in the femoral head, 182
compared to ^{99m}Tc -phosphorous compounds for bone, 47, 832, 837, 1153, 1227, 1228
-fluorodopamine, preparation, distribution, in mice, 513*
radiation dosimetry, 496*
renal asymmetry in bone scans, 500*
- Focal plane**
geometric transfer function, focused collimator, 1078
- Fourier**,
multiple view reconstruction techniques, 480*
- transforms, LSF, 1078
transforms, tomographic image reconstruction, 981
- Fresnel zone plate**
imaging, 214, 216
on axis, large field imaging, 538*
- Fuchs, ^3H , 733**
- FWHM**
comparison of pinhole and converging collimators, 59
- Gadolinium**
tumor uptake, in animals, 501*
- Gallbladder**
bile leakage, ^{131}I -rose bengal, 1044
cyst diagnosis, ^{131}I -rose bengal, 310
differential diagnosis of jaundice, 487*
 ^{67}Ga -citrate scanning, 543*
 ^{123}I -rose bengal, preparation, distribution, in animals, 484*
 ^{131}I -rose bengal studies, splenic blood pool, 823
image in acromegaly, ^{131}I -rose bengal, 720
imaging, ^{99m}Tc -dihydrothiocetic acid, 539*
imaging, ^{99m}Tc -Sn-mercapto-iso-butyric acid, in dogs, 613
 ^{99m}Tc -protamine complex, preparation, distribution, in animals, 535*
 ^{99m}Tc -pyrodoxylideneglutamate imaging, 476*
 ^{99m}Tc -tetracyclines, preparation, distribution, in animals, 176
- Gallium-67**
abdominal abscess scan, 491*
abdominal lesion diagnosis, 536*
breast imaging, 527*
-chloride, brain tumor uptake, in mice, 508*
-DTPA, cisternography, radiation dosimetry, 479*
-Fe-DTPA, brain tumor uptake, in mice, 508*
-lactate, brain tumor uptake, in mice, 508*
-leukocyte labeling, in rabbits, 98
liver cancer, whole body scans, 544*
liver, focal lesion evaluation, with ultrasound, 525*
liver transplant evaluation, 479*
liver tumor imaging, compared to ultrasound, 511*
myocardial infarct uptake, in dogs, 546*
-(OH)_n Fe(OH)₃ colloid, lymph node imaging, in animals, 487*
-phytate, lymph node imaging, in animals, 487*
scans in chest disease, 497*
subcellular tumor uptake, 501*
- Gallium-67, citrate**
brain imaging, 308, 542*
breast carcinoma uptake, in rats, 489*
cleansing bowel activity, 470
extraosseous tumor scanning, 361
gallbladder scanning, 543
kidney image, pyelonephritis, 503*; tumor, 491*
kidney uptake in congestive heart failure, 564
lacrimal gland uptake, 630
liver imaging, amebic abscess, 561
liver scan, hepatitis, 356
liver uptake in regeneration, in rat, 818
lung scanning, 227, 408
metastatic adenocarcinoma, negative uptake, 458
scanning in Hodgkin's disease, 399
scanning in malignant melanoma, 404
scanning in primary lung disease, 408
subphrenic abscess scan, 371
thyroid nodule scanning, 424, 810
tumor detection, compared to ^{113m}In - and ^{99m}Co -Bleomycin, 386
tumor scanning, clinical evaluation, 480*, 497*
tumor uptake compared to actinide and lanthanide labeled bleomycin and citrate, in mice, 526*
tumor uptake, compared to ^{99m}Co -Bleomycin, in mice, 1167
tumor uptake, compared to rare earth radionuclides, in animals, 501*
tumor uptake, in animals, 323, 489*
tumor uptake mechanism, in rats, 502*

- Gamma ray**
see also Nuclear parameters
 transitions, iodine isotopes, 328
- Gas proportional counting**
 ^3H in biologic materials, 115
- Gastrointestinal tract**
 absorption, ^{14}C -d-xylose, 486*; calcium, 588; $^{99m}\text{TcO}_4^-$, 314; vitamin B_{12} , 949
 bacterial deconjugation of bile salts, $^{14}\text{CO}_2$ breath test, 530*
 bowel cleansing of ^{99}Ga -citrate, 470
 colon cancer, ^{87m}Sr uptake, 824, 825
 ^{133}Cs , ^{134m}Cs distribution, in animals, 526*
 emptying time, $^{99m}\text{TcO}_4^-$, 544*; $^{99m}\text{Tc-DTPA}$, 391, 483*, 497*, 918
 ^{131}I in saliva, false-positive thyroid metastases scan, 1052
 imaging, $^{99m}\text{TcO}_4^-$, 365, 374
 scanning, ^{99}Ga -citrate, 481*; ^{113}In -bleomycin, 546*
 subtraction from pancreas image, 220, 221
 $^{99m}\text{TcO}_4^-$ distribution, effect of Sn(II), in rats, 151
- Gating**
 heart studies, 477*, 478*, 480*, 497*, 505*, 527*, 1182
 small tumor phantom imaging, 537*
- Generator**
 ^{98}Mo - ^{99m}Tc , radiochemical purity, 266, 466, 486*, 889
 ^{89}Rb - ^{81m}Kr , constant infusion, 514*
 ^{89}Rb - ^{81m}Kr , continuous, 868, 874
- Glomerular Filtration Rate** *see Kidney*
- Gold-198**
 liver abscess uptake, 305
 liver size on scans, 237
 liver subtraction from pancreas scan, 90
 particle size, 923
 primary liver cancer scanning, 296
 radiation damage to liver cells, in rats, 241
 RE function in hematologic disease, 495*
 spleen scans in lymphoma, lymphocytic leukemia, 496*
- Granulocyte** *see Blood*
- Half-time, biologic**
 Fe(OH)_3 macroaggregates, in mice, 17
 ^{131}I -fibrinogen, in dogs, 974
 ^{199m}Pt -cis-dichlorodiammine platinum II, 349
 $^{99m}\text{Tc-Sn-MAA}$, 192, 199
 ^{140}Yb -DTPA for cisternography, 786
- Heart**
 angiography *see Heart, blood flow*
 animal model for myocardial damage, 527*
 ^{13}C -ethanol distribution, in animals, 512*
 congenital disease, lung perfusion, $^{99m}\text{Tc-MAA}$, 492*
 ^{133}Cs , ^{134m}Cs distribution, in animals, 526*
 failure, kidney uptake of ^{99m}Tc -sulfur colloid, 564
 ^{131}I -hexadecanoic acid uptake, in dogs, 528*
 $^{113m}\text{In-Sn-MAA}$ preparation, 821
 ^{42}K scan accuracy, 495*
 ^{81m}Kr catheter imaging, in dogs, 874
 M-B scan, 536*
 mitral valve disease, lung function, 536*
 multi-organ, multi-agent imaging, 485*
 myocardial contusion imaging, ^{99m}Tc -polyphosphate, in dogs, 494*, 1174
 myocardial imaging, non-coronary patterns, ^{42}K , 524*
 myocardial infarct, dual isotope scanning, ^{133}Cs , ^{131}Cs , ^{113m}In , 523*
 myocardial infarct imaging, ^{99m}Tc -pyrophosphate, 521*, 536*; in dogs, 475*, 479*
 myocardial infarct imaging, ^{99m}Tc -tetracycline, 503*
 myocardial infarct uptake, diphosphonate, 918
 myocardial infarct uptake, in animals, ^{133}Cs and ^{99m}Tc -tetracycline, 524*; ^{67}Ga and ^{99m}Tc -chelates, 546*; ^{131}I -bretium, 991; ^{99m}Tc -glucoheptonate, 529*
 myocardial uptake, ^{42}K and ^{131}I -hexadecanoic acid, in dogs, 524*
 myocardial uptake of seven agents, drug effects, in rats, 1092
- ^{13}N -asparagine, preparation, myocardial uptake, in dogs, 1223
- ^{85}Rb , production, 522*
 scanning, ^{15}N -glutamine, -glutamic acid, -asparagine, in dogs, 492*
- ^{99m}Tc -tetracycline, distribution, in animals, 528*
- Heart, blood flow**
 aortic aneurysm detection, $^{99m}\text{Tc-RBC}$, 1014
 cardiac output, ^{113m}In , single probe, 478*
 cardiac output, $^{99m}\text{Tc-HSA}$, camera computer, 541*
 cardiac output, ^{99m}Tc -albumin and dyes, camera, 474*
 coronary, and cardiac output, ^{133}Cs infusion, 490*
 direct coronary injection of labeled microspheres, 2
 echocardiography compared to radionuclide angiography, 505*
 ejection fraction, 491*, 531*, 541*
 fractional organ distribution of $^{13}\text{N-NH}_3\text{Cl}$, in dogs, 518*
 gated, 477*, 478*, 480*, 497*, 505*, 527*, 1182
 ^{81m}Kr constant infusion, in dogs, 514*
 left ventricle, ^{85}Sr -microspheres compared to ^{85}Rb , in dogs, 969
 left ventricular aneurysm evaluation, 527*
 left ventricular volume, 477*
 model, pulsatile, 504*, 506*, 527*
 myocardial ischemia, stress-induced, $^{113m}\text{In-MAA}$, $^{99m}\text{Tc-MAA}$, 499*; in dogs, 499*
 ^{85}Rb perfusion imaging, 480*, 500*, 509*, 514*
 right, dilution curve, 505*
 shunt estimates, pulsatile flow model, ^{113m}In , 504*
 shunt quantitation, ^{99m}Tc , 540*
 systole and diastole imaging, 478*, 480*
 tricuspid insufficiency, ^{99m}Tc -sulfur colloid, 205, 518*
 ventricular function, ECG gating, 497*
 with lung perfusion study, $^{99m}\text{Tc-MAA}$, 545*
- Hemoglobin**
 ^{13}C , cerebral vascular mean transit time, 814
 ^{99m}Tc binding, 487*, 703
- Hepatic** *see Liver*
- Hepatitis**
 antigen, radioimmunoassay sensitivity, 516*
 liver imaging, 356, 1039
- Hippuran** *see Iodine-131, Hippuran*
- Human serum albumin** *see Iodine-131, albumin; Technetium-99m, albumin*
- Hydrogen-3**
 actinomycin D, T₃ stimulation of DNA, kidney cells, in vitro, 532*
 5α -dihydrotestosterone, -estradiol, -pregnenolone, prostate uptake, in dogs, 94
 β -dopamine analogs, preparation, distribution, in rats, 503*
 -dyes, cervical cancer screening test, 733
 gas proportional counting in biological materials, 115
 β -leucine, kidney cells uptake, T₃ stimulation, 532*
 β -streptozotocin, distribution, in animals, 572
- Imaging** *see Camera; specific organs*
- Immunology**
see also Radioimmunoassay
 ^{131}I - and $^{99m}\text{Tc-HSA}$ clearance, sensitized dogs, 938
 ^{106}Pd -protoporphyrin rejection suppression, skin homografts, in dogs, 997
- Indium-111**
 angular correction measurement, positron camera, 495*
 -bifunctional EDTA-proteins, -peptides, preparation, distribution, in animals, 495*
 bone marrow scans, compared to biopsies, 479*
 β -chloride, bone lesion evaluation, 1120
 β -chloride, bone marrow scanning, 495*; in myelofibrosis, 647
 β -chloride, tumor uptake, in animals, 273, 323, 489, 508*
 β -citrate, bone marrow scans, 494*
 β -citrate, tumor uptake mechanism, in rats, 502*
 compact cyclotron production, 513*
 β -DTPA, cisternography, 917; mathematical model, 521*
 β -DTPA, cisternography, transverse section scanning, 529*

SUBJECT INDEX

- DTPA, cost, quality control, 496*
- DTPA, radiation dosimetry, 479*, 496*
- gamma globulin, preparation, 526*
- liver cancer scanning, 544*
- subcellular tumor uptake, 501*
- transferrin, bone marrow imaging, 539*
- transferrin metabolism, compared to 99m Fe-transferrin, 539*
- transferrin, metabolism, in animals, 856
- Indium-111, bleomycin**
 - brain imaging, multicrystal camera, 537*
 - distribution, tumor scanning, 546*
 - imaging in lymphoma, 512*
 - kinetics, tumor bearing mice, 273
 - scanning, carcinoma of the cervix, 545*, 546*
 - tumor imaging, 512*, 541*; compared to 99m Ga-citrate, 386
 - tumor uptake, in animals, 323, 508*, 546*
- Indium-113m**
 - cardiac output, single probe, 478*
 - cardiac shunt estimation, 504*
 - colloid, bone marrow scans compared to biopsy, 479*
 - colloid, kidney uptake, 367
 - colloid, liver blood flow, lesion differentiation, 1021
 - DTPA, brain imaging, multicrystal camera, 537*
 - DTPA, brain tumor uptake, in mice, 508*
 - DTPA, cisternography, radiation dosimetry, 479*
 - DTPA, dual clearance with 99m Tc-DTPA, in animals, 442
 - double window spatial filtering, 493*
 - Fe(OH)₃, macroaggregates, biologic fate, in mice, 17
 - imaging 1-2 mm tumor phantoms, 537*
 - liver metastases perfusion, 314
 - liver perfusion in hepatoma, 546*
 - lung perfusion in sequestration, 636
 - MAA, myocardial ischemia imaging, 499*; in dogs, 499*
 - microspheres, peripheral arteriography, 533*
 - myocardial infarct, dual isotope scan, with 130 Cs or 131 Cs, 523*
 - nonfocused collimator evaluation, 679
 - "puffing response" of monkeys, 528*
 - radiation damage to liver cells, in rats, 241
 - Sn-MAA, preparation, 821
 - transferrin, brain scan, 517*
 - transferrin, metabolism, in animals, 856
 - transferrin, metastatic adenocarcinoma uptake, 458
- Indium-114m**
 - Fe(OH)₃, macroaggregate clearance, in mice, 488*
 - transferrin, metabolism, in animals, 856
- Injection**
 - direct coronary, 2
- Insulin**
 - effect on myocardial uptake of seven agents, in rats, 1092
 - 125 I, binding by cell membrane and antibodies, 538*
- Iodine**
 - pool, thyroid, fluorescence scanning, 522*
- Iodine-123**
 - capsules, thyroid uptake, 770
 - collimator choice, 328, 1226
 - compared to 131 I for thyroid studies, 261
 - fibrinogen, thrombi imaging, in dogs, 487*
 - gamma-ray transitions, 328
 - idoantipyrine, brain imaging, in animals, 541*
 - phenylalanine and -tryptophan, melt method preparation, distribution, in animals, 863
 - rose bengal, preparation, distribution, in animals, 484*
 - thyroid nodule imaging, 782
- Iodine-124**
 - gamma-ray transitions, 328
- Iodine-125**
 - angiotension I, radioimmunoassay, peptidase activity of carrier proteins, 557
 - bretylium analogs, preparation, distribution, in animals, 991
 - digitoxigenin, breast carcinoma uptake, in rats, 489*
 - digoxin radioimmunoassay kit, 465
- diphenylhydantoin for pancreas studies, 476*
- estradiol, breast carcinoma uptake, in rats, 489*
- fibrinogen, preparation, 195; thrombus uptake, 482*, 524*
- hexadecanoic acid, myocardial perfusion, in dogs, 524*
- insulin, binding by cell membranes and antibodies, 538*
- MTF of focused collimator, 516*
- multi-organ, multi-agent imaging, 485*
- prolactin, breast carcinoma uptake, in rats, 489*
- source, transmission scanning, 541*
- thyroid phantom, multiple pinhole tomography, 1063
- thyroid therapy, 257
- thyroxine, preparation, serum T₄, 1075
- TSH, comparison of preparations, 529*
- urokinase, preparation, distribution, in dogs, 534*
- Iodine-126**
 - gamma-ray transitions, 328
- Iodine-130**
 - gamma-ray transitions, 328
- tetracyclines, preparation, distribution, in rats, 483*
- Iodine-131**
 - benzoic and -benzene-sulphonic acid derivatives for kidney, 486*
 - CEA antibody, tumor uptake, in animals, 323
 - chloroquine, eye imaging, 478*
 - cholesterol, adrenal imaging, 246, 513*, 531*; scanning, 332, 513*, 526*
 - cholesterol, metastatic adrenal carcinoma scan, 332
 - cholesterol, stability, 38
 - compared to 123 I for thyroid studies, 261
 - content, Ohio river, 534*
 - diiodofluorescein, eye imaging, 478*
 - dose calibration, 1138
 - fibrinogen, preparation, distribution, in dogs, 974
 - fibrinogen, thrombus imaging, in dogs, 500*; scanning, 1163
 - gamma-ray transitions, 328
 - hexadecanoic acid, preparation, heart imaging, in dogs, 528*
 - hexadecanoic acid, uptake, in damaged muscle, in rats, 527*
 - in 99m Tc eluate, 889
 - lipiodol, radiotherapy, lymph nodes, 544*
 - lymphoma therapy, 475*
 - multi-organ, multi-agent imaging, 485*
 - oleic acid, myocardial uptake, in rats, 1092
 - oleic acid, uptake in damaged muscle, in rats, 527*
 - parathyroid hormone, EDTA response, radioimmunoassay, 763
 - scatter medium effect on imaging, 943
 - thyroid carcinoma metastases scanning, 51, 477*, 545*, 1037, 1052
 - thyroid scan, TSH stimulation test, 1209
 - thyroid therapy, carcinoma, 477*; large dose, 674; radiation dose to patient's family, 499*, 887
 - thyroid uptake, compared to 99m TcO₄⁻, 525*
 - thyroid uptake, effect of capsule, 770; normal, 213; subacute thyroiditis, 81
 - thyroxine, -T₄, preparation, 270
 - toluidine blue, preparation, distribution, insulinoma scan, 1212
 - turnover in hyperparathyroidism, 476*
 - T₄, kidney kinetics, 482*
 - uptake in damaged muscle, in rats, 527*
- Iodine-131, albumin**
 - brain tumor uptake, in mice, 508*
 - cisternography, cost quality control, 496*
 - cisternography, radiation dosimetry, 479*, 496*, 786
 - clearance, sensitized dogs, 938
 - CSF kinetics, 916, 917
 - MAA, direct coronary injection, 2
 - MAA, lung retention, 1230
 - synovial rupture imaging, 7, 911, 912

- Iodine-131, hippuran**
 kidney, dynamic imaging artifact, 134
 kidney, functional imaging, 65
 kidney studies in nephrosis, 500*
 kidney transplant evaluation, 489*, 528*
 kinetic model, renal perfusion/excretion determination, 102, 1066
 kinetics, normal and anephric subjects, 512*
 renal mass lesion differentiation, 485*
 unilateral kidney disease studies, in dogs, 531*
- Iodine-131, rose bengal**
 bile leakage, 1044
 compared to ^{99m}Tc-Sn-mercaptopropanoic acid for biliary studies, in dogs, 613
 gallbladder image in acromegaly, 720
 liver, choledochal cyst, 310
 liver transplant evaluation, 479*
 primary liver cancer scanning, 296
 splenic blood pool, 823
- Iodine-132**
 contamination of ^{99m}Tc eluate, 466, 889
- Iodine-133**
 contamination of ^{99m}Tc eluate, 889
- Iron**
 deficiency, Mn entry into brain, in rats, 516*
- Iron-55**
 metabolism in RBC, 156
- Iron-59**
 bone labeling, in rabbits, 161
 -Fe(OH)₃ macroaggregates, biologic fate, in mice, 17, 488*
 -hydroxide, particle retention in lungs, in animals, 616
 kinetics in myelofibrosis, 647
 metabolism, whole body counting, 156
 -transferrin, metabolism compared to ¹¹¹In-transferrin, 539*
 -transferrin, metabolism, in animals, 856
 whole-body scanning, 483*, 667
- Joints**
see also Extremities
 femoral blood supply, ^{99m}Tc-sulfur colloid, -diphosphonate, 543*
 heterotrophic bone formation, ^{99m}Tc-diphosphonate scan, 530*
 imaging in hemophilia, ^{99m}TcO₄-, ^{99m}Tc-albumin, 514*
 synovial rupture, ¹¹¹I-HSA imaging, 7, 911, 912; ultrasound, 912
 tumor uptake of ¹⁵N-glutamic acid, in dogs, 515*
- Kidney**
 asymmetry in bone scans, ¹⁸F, ^{99m}Tc-pyrophosphate, 500*
¹¹C-ethanol distribution, in animals, 512*
 cell, in vitro, T_s and leucine uptake, 532*
 cells, in vitro, T_s stimulation of DNA, 532*
 clearance, dual ^{113m}In- and ^{99m}Tc-DTPA, in animals, 442
 clearance, ^{99m}Tc-diphosphonate, 477*
¹³²Cs, ^{134m}Cs distribution, in animals, 526*
 disease, RE imaging, 1158
 failure, bone scan in secondary hyperparathyroidism, 536*
 failure, partial body Ca, 929
⁶⁷Ga citrate imaging, 491*, 503*
 image on bone scan, 837, 848
¹³¹I- and ^{113m}Hg-benzoic acid derivatives, 486*
¹³¹I-T_s kinetics, 482*
^{113m}In-bleomycin distribution, 541*
^{113m}In-bleomycin, -Cl, kinetics, in mice, 273
 mass abdomen evaluation in children, 481*
 mass lesion differentiation, ¹¹¹I-Hippuran, ^{99m}Tc-DTPA, in children, 485*
 nephrosis, ¹¹¹I-Hippuran image, 500*
 observer image interpretation, 507*
 quantitative function, computer, in dogs, 538*
^{99m}Tc kit imaging agents, distribution, in animals, 475*
- ^{99m}Tc-DMSA, distribution, 34; in animals, 512*
^{99m}Tc-DMSA imaging, 499*, 543*, 743
^{99m}TcO₄- distribution, effect of Sn(II), in rats, 151
^{99m}Tc-penicillamine imaging, 506*
^{99m}Tc-Sn-dextrose complex scanning, 474*
^{99m}Tc-tetracycline imaging, 528*
^{99m}Tc-tetracycline, preparation, distribution, in animals, 176
 transplant evaluation, 489*, 493*, 528*
 tuberous sclerosis, ¹⁰⁹Hg-chlormerodrin, ^{99m}TcO₄- imaging, 478*, 699
 uptake of ^{113m}In-colloid and ^{99m}Tc-sulfur colloid, 367
 uptake of ^{186m}Pt-cis-dichloro-bis-cyclopentylammine-Pt (II), in rats, 478*
- Kidney, blood flow**
 arteriography compared to the regional renogram, 542*
 camera compared to flow meter, ^{99m}Tc-sulfur colloid, in dogs, 506*
 ERPF, ¹¹¹I-hippuran, 102, 1066
 fractional distribution of ¹⁵N-NH₄Cl, in dogs, 518*
 lesion differentiation, ^{99m}Tc, 539*
 quantitation, computer assisted, in dogs, 538*
⁸⁵Rb, ^{81m}Kr, 500*
 relative, ^{99m}Tc-HSA, camera-computer, 532*
 sensitivity, ^{99m}TcO₄-, in dogs, 507*
 transplant evaluation, ^{99m}TcO₄-, 489*; ^{99m}Tc-sulfur colloid, 493*
 tuberous sclerosis, ^{99m}TcO₄-, 478*
 unilateral disease studies, in dogs, 530*
¹³³Xe, computer-camera system, 504*, 775
- Kidney, renogram**
 artifact, ¹¹¹I-hippuran, 134
 computer-assisted, in dogs, 538*
 cost/benefit analysis, 516*
 geriatric studies, 503*
 kinetic model, RP/ED, ¹¹¹I-hippuran, 102, 1066
 kinetic model, three compartment, ¹¹¹I-hippuran, 512*
 in nephrosis, ¹¹¹I-hippuran, 500*
 regional, compared to arteriogram, 542*
 regional rate constants method, 65
 transplant evaluation, ¹¹¹I-hippuran, 489*, 528*
- Kit**
¹²⁵I-digoxin radioimmunoassay, cross reaction, 564
¹¹¹In-gamma globulin, preparation, 526*
 Sn-DTPA, dual clearance evaluation, 442
^{99m}Tc-albumin microspheres, preparation, 509*
^{99m}Tc-complexes for kidney imaging, 475*
^{99m}Tc-pyrophosphate, 480*
^{99m}Tc-RBC, 498*, 534*
^{99m}Tc-Sn-MAA, 192, 198, 464
 Vitamin B₁₂ radioassay, 688
- Krypton-81m**
see also Rubidium-81
 constant infusion generator, heart imaging, in dogs, 514*
 continuous generator, 868, 874
 lung ventilation, 874
- Lanthanum-140**
 -bleomycin and -citrate, tumor uptake, in mice, 526*
- LD₅₀** *see Toxicity*
- Lead-203**
 bone studies, radiation dose, 910
 -EDTA for cisternography, 496*
 myocardial uptake, in rats, 1092
 production, tumor uptake, in animals, 475*
 -RBC, preparation, distribution, in dogs, 498*
- Leg** *see Extremities*
- Lesion**
see also Abscess; Tumor
 Angiomyolipoma, 478*
 detection, 1–2 mm, computerized gated imaging, 537*
 differentiation, delayed brain imaging, ^{99m}TcO₄-, 681
 differentiation, ^{113m}In-colloid liver blood flow, 1021
 vascularity, whole-body imaging, 507*
- Leukocytes** *see Blood*

- Line spread function**
camera collimators, ^{123}I , 328, 1226
collimator, whole-body ^{60}Fe scanning, 483*, 667
effect of a scatter medium, 943
focused collimator, ^{123}I , 1078
scanner performance index, 757
- Liquid scintillation counting**
 ^3H in biologic materials, 115
- Liver**
abdominal lesion evaluation, 481*, 536*
abscess, amebic, ^{67}Ga imaging, 561; ^{99m}Tc -sulfur colloid imaging, 508*
abscess, ^{196}Au uptake, 305
anatomic marker, 1226
axial view, ^{99m}Tc -sulfur and -Sn-colloid, 505*
 ^{11}C -ethanol distribution, in animals, 512*
 ^{14}C , ^{18}C -galactose metabolism test, 532*
cancer, ^{67}Ga , ^{111}In , whole body scans, 544*
cancer, primary, 202 scans, 296
cavernous hemangioma, in newborn, 902
cells, oxidation of ^{14}C -DOPA, in vitro, 540*
choledochal cyst, ^{131}I -rose bengal scan, 310
cirrhosis, bacterial deconjugation of bile salts, $^{14}\text{CO}_2$ breath test, 530*
clearance, ^{131}I and ^{99m}Tc -HSA, sensitized dogs, 938
 ^{134}Cs , ^{134m}Cs distribution, in animals, 526*
diaphragmatic herniation diagnosis, ^{99m}Tc -sulfur colloid, 42
false-positive images, ^{99m}Tc -sulfur colloid, 142, 717
flow, lesion vascularity, ^{113m}In colloid, 1021
focal lesions, 508*, 525*, 725, 1039
geriatric studies, 503*
hematologic disease, ^{99m}Tc -sulfur colloid scans, 532;
 ^{99m}Tc -sulfur colloid, ^{196}Au uptake, 495*
hepatitis lesion, 1039; ^{99m}Tc -sulfur colloid, ^{67}Ga scans, 356
hepatocellular disease, ^{99m}Tc -sulfur colloid scan, 493*
hot spot, superior vena caval obstruction, ^{99m}Tc -sulfur colloid, 1041
 ^{131}I -rose bengal, preparation, distribution, in animals, 484*
image, bile leakage, ^{99m}Tc -sulfur colloid, ^{131}I -rose bengal, 1044
image interpretation, 519*
image, ^{99m}Tc -sulfur colloid in acromegaly, 720; in bone marrow disease, 1158
image, ^{99m}Tc -sulfur colloid kidney uptake, 564; lung uptake, 460, 1028, 1228
imaging compared to function tests, 533*; ultrasound, 511*
imaging with colloids, 496*
 ^{111}In -bleomycin distribution, 541*, 546*
 ^{111}In -chloride scanning in myelofibrosis, 647
metabolism of ^{14}C -formate and -formaldehyde, in vitro, in rats, 284
metastases, CEA titer, 514*
motion correction hardware, phantom studies, 36
multi-organ, multi-agent, 485*
pancreas image separation, 707, 935
radiation damage to cells, in rats, 241
regeneration, in rats, ^{67}Ga -citrate uptake, 818; ^{99m}Tc -sulfur colloid, ^{75}Se -selenomethionine imaging, 10
scan, compared to alpha-1-fetoprotein radioimmunoassay, 538*
scan, liver-spleen uptake ratio, ^{99m}Tc -sulfur colloid, 593
scan, paroxysmal nocturnal Hemoglobinuria, 535*
scan, tuberculosis chemotherapy, 135
 ^{75}Se -selenomethionine uptake suppression, in dogs, 1171
size on scans, 237
splenic blood pool background, ^{131}I -rose bengal, 823
subtraction, subphrenic abscess scan, 371
 ^{99m}Tc -dihydrothiocetic acid imaging, 539*
 $^{99m}\text{TcO}_4^-$ distribution, Sn(II) effect, in rats, 151
 ^{99m}Tc -protamine complex, preparation, distribution, in animals, 535*
- ^{99m}Tc -Sn-mercaptopropanoic acid distribution, in dogs, 613
 ^{99m}Tc -tetracycline complex, uptake, in rats, 987
thyroid carcinoma metastases, ^{131}I scan, 545*
transplant evaluation, 479*
uptake of ^{133}Xe during ventilation studies, 1179
- Liver, blood flow**
differential diagnosis of jaundice, 487*
first transit, ^{99m}Tc -sulfur colloid, 493*
fractional distribution of $^{15}\text{N}-\text{NH}_4^+$, in dogs, 518*
halo, ascites, $^{99m}\text{TcO}_4^-$, 396
hepatoma, ^{113m}In , 546*
lesion differentiation, ^{113m}In -colloid, 1021
metastases, perfusion, $^{99m}\text{TcO}_4^-$, ^{113m}In , 314
neoplastic tumors, 535*
observer and computer interpretation, ^{99m}Tc -sulfur colloid, 481*
parasitic tumor, ^{99m}Tc -sulfur colloid, 137
 ^{85}Rb - ^{81m}Kr , 500*
superior vena caval obstruction, 1041
 $^{99m}\text{TcO}_4^-$, ^{99m}Tc -sulfur colloid, 317
 ^{99m}Tc -sulfur colloid, compared to function tests, 533*
 ^{99m}Tc -sulfur colloid, -Sn-colloid, 540*
- LSF see Line Spread Function**
- Lung**
aerosol, dry ^{99m}Tc -Cn(OH)₂-lactose, preparation, distribution, in dogs, 537*
aerosol imaging, delayed, 524*
aerosol imaging, early chronic disease, 537*
aerosol, respiratory tract deposition, ^{99m}Tc -sulfur colloid, 504*
alveolar retention of ^{99m}Tc -Sn-phytate, 503*
capillary blockade, ^{99m}Tc -Fe hydroxide macroaggregates, in mice, 436
cardiac shunt quantitation, ^{99m}Tc , 540*
differential vital capacity, ^{133}Xe , 625
disease due to oxygen toxicity, in infants, 492*
disease, tricuspid valve involvement, 518*
extravascular water, in dogs, 474*
retention of radioactivity, 1229, 1230; ^{59}Fe -hydroxide, in animals, 17, 488*, 616
 ^{67}Ga -citrate scanning, 227, 497*
geriatric studies, 503*
imaging, fat embolism syndrome, 517*
multi-organ, multi-agent imaging, 485*
perfusion, congenital heart disease, ^{99m}Tc -MAA, 492*
perfusion, multiprobe, ^{133}Xe , in dogs, 959
perfusion, transposition of the great arteries, ^{99m}Tc -microspheres, 484*
perfusion, with cardiovascular dynamic perfusion, ^{99m}Tc -MAA, 545*
phantom, 1-2 mm tumor imaging, ^{113m}In -transferrin, 537*
"puffing response" of monkeys, ^{113m}In , 528*
 ^{85}Rb - ^{81m}Kr imaging, 500*
regional function, ^{133}Xe , in children, 582
regional ventilation and perfusion in alpha-1-antitrypsin deficiency, 474*
sequestration diagnosis, ^{133}Xe gas, ^{113m}In , 636*
 ^{99m}Tc -MAA imaging, intrathoracic lesions, 490*
 ^{99m}Tc -MAA kit evaluation, 192, 198, 464
 ^{99m}Tc -MAA preparation, imaging, 510*
 ^{99m}Tc -microsphere kit, 509*
 ^{99m}Tc -polyphosphate imaging, 53, 1057
 ^{99m}Tc -protamine, preparation, distribution, in animals, 534*
 ^{99m}Tc -sulfur colloid uptake, 460, 726, 727, 728, 1220; IP endotoxin effect, in rats, 1028
 ^{99m}Tc -Sn-macroaggregates, preparation, imaging, in animals, 546*
toxicity of Sn-MAA, in dogs, 567
tumor, ^{67}Ga -citrate scanning, 481*
tumor, ^{111}In -bleomycin kinetics, in mice, 273
ventilation, ^{81m}Kr , 874

- ventilation, regional ^{133}Xe , in dogs, 598
 ventilation, perfusion, mitral valve disease, $^{99m}\text{Tc-MAA}$, ^{133}Xe , 536*
- ventilation, perfusion, ^{99m}Tc -microspheres, ^{133}Xe , 455, 964
 ventilation, perfusion, ^{133}Xe , frequency distribution, 519*;
 x-ray occult cancer, 520*
- ventilation, ^{133}Xe , liver uptake, 1179
 volume, regional, transmission imaging, 605
 ^{133}Xe gas delivery system, 288
- Lymphocyte** see *Blood*
- Lymph node**
 imaging, ^{99m}Tc -, ^{67}Ga -phytate, ^{67}Ga -Fe hydroxide, in animals, 487*
 intrathoracic mass evaluation, 490*
 ^{32}P and ^{131}I lymphoma therapy, 475*
 ^{32}P and ^{131}I -lipiodol therapy, 544*
 ^{103}Ru production, 511*
 skin homograft rejection suppression, ^{100}Pd -protoporphyrin, in dogs, 997
 spleen scans in lymphoma, ^{198}Au , ^{99m}Tc , 496*
 tumor, ^{67}Ga -citrate scanning, 481*
- Manganese-54**
 brain entry, Fe deficiency and age effects, 516*
- Mercury-197**
 Cl_2 , intrathoracic mass lesion evaluation, 490*
 $-\text{Cl}_2$, tumor uptake, in mice, 489*
 -chlormerodrin, brain scan, compared to $^{99m}\text{TcO}_4^-$, 520*
 -chlormerodrin, brain tumor uptake, in mice, 508*
 -chlormerodrin, kidney imaging, tuberous sclerosis, 478*, 699
 delayed radioaerosol lung imaging, 524*
 dose calibration, 1138
- Mercury-203**
 -mersalyl, compared to -benzoic and -benzene-sulphonic acid derivatives for kidney, 486*
- Methylene blue**, ^{14}C , 733
- Microspheres** see *Cerium-141*; *Srontium-85*; *Technetium-99m, microspheres*
 induced kidney disease, in dogs, 530*, 538*
- Model**
 cellular necrosis, 577
 compartmental, radiation dose calculation, 1025
 dog, cardiopulmonary toxicity of Sn-MAA, 567
 kinetic, hippurate distribution and clearance, 102, 1066
- Modulation transfer function**
 collimator, ^{99m}Tc whole body scanning, 483*, 667
 effect of scatter medium, 943
 multihole focused collimator, ^{99m}Tc , 291
 multihole focused collimator, geometric factor, 516*
 scanner performance index, 757
 scattered radiation effect, 316
- Molybdenum-99**
 contamination of ^{99m}Tc eluate, 266, 466, 484*, 889
- Muscle**
 damaged, myocardial animal model, 527*
 $^{99m}\text{TcO}_4^-$ distribution, effect of Sn(II), in rats, 151
- Myocardium** see *Heart*
- Neohydrin** see *Mercury-197*
- Neodymium**
 tumor uptake in animals, 501*
- Neptunium-239**
 -bleomycin and -citrate, tumor uptake, in mice, 526*
- Neutron activation analysis**
 Ca , partial body, 929
 Ca , total body, ^{40}Ar excretion, 511*
 Ca , total body, in osteoporosis, 428, 483*
- Nickel-63**
 -protoporphyrin, distribution, in dogs, 997
- Niobium-92**
 contamination of ^{99m}Tc eluate, 466
- Nitrogen-13**
 -alanine for pancreas, preparation, distribution, in animals, 535*
 -ammonium, tumor scanning, in dogs, 483*
- asparagine, enzymatic synthesis, myocardial uptake, in dogs, 492*, 1223
 -glutamic acid, -alanine, enzymatic synthesis, 1192
 -glutamic acid, bone and joint tumor uptake, in dogs, 515*
 -glutamine, -glutamic acid, enzymatic synthesis, heart scan, in dogs, 492*
 -glutamine, tumor scanning, in dogs, 483*
 $-\text{N}_2$, perfusion/ventilation, in dogs, 474*
 $-\text{NH}_2\text{Cl}$, organ blood flow by fractional distribution, in dogs, 518*
- Noise**
 effect of image processing, 164
 -to-signal ratio, Fresnel zone plate imaging, 214, 215
- Nuclear Medicine Pioneer Citation, Hal Oscar Anger**, 471
- Nuclear parameters**
 ^{24}Cm and ^{146}Pm , 335
 ^{64}Cu and ^{67}Cu , 1011
 ^{166}Er , 526*, 1008
 ^{123}I , 328, 335, 484*, 1163
 iodine isotopes, 328
 ^{83m}Kr , 868, 874
 ^{203}Pb , 910
 ^{85}Rb , 522*, 868
 ^{99m}Tc , 964
 ^{123}Xe , 502*
 ^{133}Xe , 964
- Observer performance**
 display minification, 219
 kidney images, 507*
 liver flow studies, 481*
 liver image, 519*
 myocardial infarction size, in dogs, 475*
 thyroid scan, 522*
- Orthogonal tangent correction**
 section scanning, 377, 378, 379
- Ovaries**
 ^{14}C -isoxazole uptake, effect of estradiol, in rats, 187
 radiation dosimetry, bone agents, 496*
 tumor, ^{67}Ga -citrate scanning, 481*
- Oxygen**
 toxicity, infants, lung disease, 492*
- Oxygen-15**
 $-\text{CO}$, $-\text{CO}_2$, $-\text{O}_2$, equilibrium images, head, 505*
 H_2^{18}O , C^{18}O , extravascular lung water in dogs, 474*
 $-\text{O}_2$, equilibrium imaging, in dogs, 529*
- Palladium-109**
 -protoporphyrin, reject suppression, skin homografts, in dogs, 997
- Pancreas**
 abdominal lesion diagnosis, ^{75}Se -selenomethionine, 536*
 ^{14}C - and ^{3}H -streptozotocin, distribution, in animals, 572
 ^{14}C -diphenyldihydantoin uptake in islet cells, 476*, 685
 ^{14}C -tripalmitin breath test, 1125
 false-positive ^{75}Se -selenomethionine scan, 90
 ^{123}I -phenylalanine and -tryptophan, preparation, distribution, in animals, 863
 ^{131}I -toluidine blue insulinoma scan, 1212
 imaging, GI tract visualization, 220, 221
 imaging, suppression of liver uptake of ^{75}Se -selenomethionine, in dogs, 1171
 imaging views, 707, 935
 ^{15}N -alanine, preparation, distribution, in dogs, 535*
 pseudocyst, ultrasound, 543*
 scan, false-positive rate, 662
 stimulation of ^{75}Se -selenomethionine uptake, 662
- Parathyroid**
 adenoma, ^{99m}Tc -polyphosphate bone scans, 1089
 hormone, EDTA response, radioimmunoassay, 763
 secondary hyperparathyroidism, bone scan, 536*
 thermography, 530*
- Patient position**
 anatomic marker, 1226
 axial view of liver, 505*

- liver-pancreas image separation, 707, 935
oblique views, ^{123}I thyroid imaging, 782
rib lesion imaging, 1227
- Pediatrics**
adrenal carcinoma scan, ^{131}I -cholesterol, 332
adrenal neuroblastoma, $^{99\text{m}}\text{Tc}$ -polyphosphate uptake, 904
brain imaging, cystic astrocytoma, 494*; toxoplasmosis, 641
brain scan, cerebral paralysis, 517*; hemiplegia, 300; ventricle visualization, 202
cellulitis, osteomyelitis differentiation, $^{99\text{m}}\text{Tc}$ -methylene diphosphonate, 494*
choledochal cyst diagnosis, ^{131}I -rose bengal, 310
kidney mass lesion differentiation, ^{131}I -hippuran, $^{99\text{m}}\text{Tc}$ -DTPA, 485*
kidney studies in nephrosis, ^{131}I -hippuran, 500*
left upper abdomen evaluation, 481*
liver, cavernous hemangioma image, in newborn, 902
liver, diaphragmatic herniation, $^{99\text{m}}\text{Tc}$ -sulfur colloid image, 42
lung disease due to oxygen toxicity, 492*
lung imaging, congenital heart disease, $^{99\text{m}}\text{Tc}$ -MAA, 492*
lung perfusion, transposition of the great arteries, $^{99\text{m}}\text{Tc}$ -HSA microspheres, 484*
lung, regional function ^{133}Xe , 582
osteoid osteoma imaging, $^{99\text{m}}\text{Tc}$ -methylene diphosphonate, 494*
radiation dosimetry of ^{64}Cu and ^{67}Cu , 1011
secondary osteoarthropathy imaging, $^{99\text{m}}\text{Tc}$ -polyphosphate, 312
spleen, delayed rupture, $^{99\text{m}}\text{Tc}$ -sulfur colloid image, 632
spleen uptake, $^{99\text{m}}\text{Tc}$ -sulfur colloid, 294, 446
splenomegaly in sarcoidosis, $^{99\text{m}}\text{Tc}$ -sulfur colloid, 45
tricuspid valve insufficiency due to lung disease, 518*
- Personnel**
nuclear medicine divisions in U.S. medical schools, 22
relative cost weights for nuclear medicine procedures, 543*
- Phantom**
1-2 mm tumor computerized gated imaging, 537*
- Phosphorous**
content in diphosphonate localizing soft tissue, 918
- Phosphorous-32**
-chromic phosphate, distribution in therapy, 190, 1067, 1068
-microspheres, tongue cancer therapy, 481*
therapy, lymph nodes, 544*
therapy, lymphoma, 475*
therapy, thyroid carcinoma metastatic to bone, 1037
- Photopeak**
see also Nuclear parameters
fraction, effect on scintillation camera deadtime, 412
- Placenta**
abruption, $^{99\text{m}}\text{TcO}_4^-$ image, 900
- Plasma volume**
International Committee for Standardization in Hematology, 376
- Platelets** *see Blood*
- Platinum-195**
-dichlorodiammine-platinum-(II), preparation, distribution, 349
- Platinum-195m**
-cis-dichloro-bis-cyclopentylammine-Pt(II), distribution, in rats, 478*
- Polyphosphate** *see Technetium-99m, polyphosphate*
- Potassium**
total body, abnormal sex chromosomes, 448
- Potassium-43**
extremity perfusion, 518*
myocardial imaging, noncoronary patterns, 524*
myocardial perfusion, 480*; compared to ^{123}I -hexadecanoic acid, in rats, 524*
myocardial scan accuracy, 495*
- myocardial uptake, in rats, 1092
uptake in damaged muscle, in rats, 527*
- Pregnenolone**
 ^3H -, uptake by prostate, in dogs, 94
- Probe**
collimator evaluation, 679
multi-, ^{133}Xe lung perfusion, in dogs, 959
portable, cerebral death diagnosis, 912, 914
- Prometheum-145**
source, photon absorption, 335
- Prostate**
carcinoma, metastatic to bone, $^{99\text{m}}\text{Tc}$ -pyrophosphate image, 517*
scanning, ^{62}Zn , ^{66}Zn , 739
uptake of ^3H - and ^{14}C -steroids, in dogs, 94
- Pyronin-B**
 ^3H -, cervical cancer screening, 733
- Pyrophosphate** *see Technetium-99m, pyrophosphate*
- Quality control**
cisternography agents, 496*
dose calibration, 1138
enzymatic synthesis of ^{18}N -glutamic acid and -alanine, 1192
free $^{99\text{m}}\text{TcO}_4^-$ in bone agents, 1229
free $^{99\text{m}}\text{Tc}$ in $^{99\text{m}}\text{Tc}$ -albumin, 1061
 ^{123}I and ^{131}I capsules, thyroid uptake, 770
 ^{131}I -hippuran "artifact," 134
 ^{131}I -19-iodocholesterol stability, 38
radioactivity assay, 501*
 ^{85}Rb , 500*
saline paper analysis of $^{99\text{m}}\text{Tc}$ -albumin, 1018
scanner performance index, 757
sterility testing, ^{14}C -substrate, 1142
 $^{99\text{m}}\text{Tc}$ -thiocyanate complexes, spectrophotometry, 505*
 $^{99\text{m}}\text{Tc}$, radiochemical purity, 266, 466, 889
 $^{99\text{m}}\text{Tc}$ -DTPA, $^{113\text{m}}\text{In}$ -DTPA, dual clearance, in animals, 442
 $^{99\text{m}}\text{Tc}$ -sulfur colloid and ^{198}Au particle size, 923
 $^{99\text{m}}\text{Tc}$ -tetracycline stability, 176, 987
- Radiation damage**
bone marrow, whole body ^{59}Fe scanning, 483*, 667
 ^{131}I thyroid therapy, large doses, 674
to cholesterol, 38
x-ray, $^{113\text{m}}\text{In}$, ^{198}Au , liver cells, in rats, 241
- Radiation dosimetry**
bone agents, 496*
cisternography agents, 210, 375, 479*, 496*, 643, 786
compartmental model calculations, 1025
 ^{64}Cu , ^{67}Cu , 1011
 ^{166}Er -citrate for bone and tumor, 1008
iodine isotopes, 261, 328
 ^{131}I thyroid therapy, 674; to patient's family, 499*, 887
 ^{208}Pb for bone, 910
 ^{85}Rb - $^{81\text{m}}\text{Kr}$ myocardial studies, 480*, 500*, 509*
 $^{99\text{m}}\text{Tc}$ -DMSA kidney imaging, 512*
 $^{99\text{m}}\text{Tc}$ -MAA, 192
 $^{99\text{m}}\text{Tc}$, radionuclide impurities, 484*
x-ray, $^{113\text{m}}\text{In}$, ^{198}Au , damage to liver cells, in rats, 241
 ^{166}Yb -citrate for tumor, 210
 ^{62}Zn , ^{66}Zn , $^{99\text{m}}\text{Zn}$ for prostate, 739
- Radiation safety**
 ^{60}Co , effect on ^{67}Ga lung tumor scan, 227
 ^{137}Cs , dose calculation, 502*
effect on bone marrow RE patterns, 343, 483*, 667, 856
effect on thyroid, 531*
effect on tumor blood flow, 463
- Radioimmunoassay**
alpha-1-fetoprotein, 538*
angiotensin I, peptidase activity of carrier proteins, 557
hepatitis antigen, sensitivity, 516*
high solid phase, 481*
 ^{123}I -digoxin, 465
 ^{123}I -insulin binding by cell membrane and antibodies, 538*
parathyroid hormone, EDTA response, 763

- plasma renin, 220
serum T_s, 482*
- Record keeping**
computer system, 218, 497*, 535*
- Red blood cell**
binding of In and Fe from labeled transferrin, 856
⁵⁹Fe-, metabolism, 156
Howell-Jolly bodies, splenic ^{99m}Tc-sulfur colloid uptake, 294
metabolism of ¹⁴C-formate and -formaldehyde, in vitro, 284
²⁰⁸Pb-, preparation, survival, spleen studies, in dogs, 498*
^{99m}Tc binding to hemoglobin, 703
^{99m}Tc-, cardiac angiography, 1014
^{99m}Tc labeling kit, 498*, 534*, 1187
^{99m}Tc-, local brain blood volume, 509*
^{99m}-, preparation, distribution, in mice, 656
volume, fluorescent excitation analysis, in rabbits, 525*
volume, International Committee for Standardization in Hematology, 376
- Renin**
radioimmunoassay, 220
- Resolution**
collimator, comparison of pinhole and converging, 59
collimator, geometric transfer functions, 1078
collimator, multi-hole converging, ^{99m}Tc, 291
computer-scintillation camera tomography, 542*
CsI crystal, 519*
effect of image processing, 164
effect of scatter medium, 943
geometric, 724
germanium gamma-ray camera, 1196
multiple pinhole tomography, 1063
on-axis Fresnel zone plate, 538*
scanner performance index, 757
scattered radiation correction, 316
spatial filtering, 493*, 521*
spatial, tomography image, 981
- Rhenium-186**
in MEK extracted ^{99m}Tc, 266
- Rose bengal**
see also Iodine-123; Iodine-131, rose bengal
differential diagnosis of jaundice, 487*
- Rubidium-81**
cyclotron production, 522*, 868
^{85m}Kr generator, constant infusion heart imaging, in dogs, 514*
^{85m}Kr generator, continuous, 868, 874
myocardial perfusion imaging, 480*, 500*, 509*, 514*
radiation dose, 500*
- Rubidium-83**
contaminant in ⁸⁵Rb, 500*
- Rubidium-84**
contaminant in ⁸⁵Rb, 500*
- Rubidium-86**
left ventricular blood flow, in dogs, 969
myocardial uptake, in rats, 1092
- Ruthenium-97**
production, BLIP, 511*
- Salivary glands**
emptying ^{99m}TcO₄-, 544*
saline load test, ^{99m}Tc-DTPA, 497*
- Samarium**
tumor uptake, in animals, 501*
- Samarium-153**
-bleomycin and -citrate, tumor uptake, in mice, 526*
- Scandium-49**
partial body Ca, neutron activation analysis, 929
- Scanner, rectilinear**
bone scans, ¹⁸F and ^{99m}Tc-polyphosphate, 837
"clear plate" anatomical orientation, 380
deadtime, 728, 729
performance index, 757
scalar attachment for ^{99m}TcO₄ thyroid uptake, 1117
- Scanning** *see specific organ*
Scanning, transverse section *see Transverse section*
- Scatter**
Compton, correction, 316
Ge gamma-ray camera performance, 1196
medium, effect on imaging, 943
rim sign in brain perfusion studies, ^{99m}TcO₄-, 1035
^{99m}Tc-, pre-¹³³Xe lung studies, 964
- Schilling test**
consecutive day, 949
relative cost weights, 543*
- Selenium-75**
-selenite, false-positive images, in animals, 622
- Selenium-75, selenomethionine**
false-negative liver scans, 234
false-positive pancreas scans, 90
liver regeneration imaging, in rats, 10
liver uptake suppression, in dogs, 1171
pancreas imaging, GI tract subtraction, 220, 221
pancreas imaging views, 707, 935
pancreas studies, abdominal lesion diagnosis, 536*
pancreas uptake stimulation, 662
- Sensitivity**
collimator, multi-hole converging, ^{99m}Tc, 291
collimators, pinhole and converging, 59
CsI crystal, 519*
depth-independent, positron emission, 523*
on-axis Fresnel zone plate, 538*
scanner performance index, 757
- Sinus**
imaging, ¹³³Xe gas, 477*, 528*
superior sagittal, off-midline position, ^{99m}TcO₄ brain scan, 1047
- Skin**
homograft, ¹⁰⁰Pd-protoporphyrin rejection suppression, in dogs, 997
^{99m}TcO₄ distribution, effect of Sn(II), in rats, 151
tumor, ¹¹¹In-Bleomycin kinetics, in mice, 273
- Skull**
lesions, delayed brain imaging, ^{99m}TcO₄, 681
- Sodium-24**
CSF kinetics, 916, 917
- Spectrophotometry**
Tc-thiocyanate complexes, 505*
- Spleen**
abdominal lesion diagnosis, 481*, 536*
abscess, ^{99m}Tc-sulfur colloid imaging, 499*
blood pool on ¹³¹I-rose bengal studies, 823
dilated vein, false-positive liver image, 142
function in hematologic diseases, 495*, 496*, 532*
imaging in bone marrow disease, ^{99m}Tc-sulfur colloid, 1158
imaging, platelet survival, ⁵¹Cr, 801
¹¹¹In-chloride scanning in myelofibrosis, 647
infarct "healing", 303
²⁰⁸Pb-RBC studies, in dogs, 498*
²⁰⁸Pb uptake, in animals, 910
position, axial liver view, 505*
rupture, delayed, 632
sequestration, quantitative, ⁵¹Cr, 514*
splenomegaly in childhood sarcoidosis, 45
^{99m}Tc-protamine complex, preparation, distribution, in animals, 535*
^{99m}Tc-RBC kit, 498*, 1187
^{99m}Tc-sulfur colloid, spleen-liver uptake ratio, 593
^{99m}Tc-sulfur colloid uptake, 135, 294, 446, 493*, 1203
- Steroids**
³H- and ¹⁴C-, uptake by prostate, in dogs, 94
- Stomach**
see also Gastrointestinal tract
metastatic tumor, ^{99m}Tc-polyphosphate, uptake, 1057
- Strontium-85**
bone imaging, compared to ^{99m}Tc-pyrophosphate, 480*
bone uptake parameters, in rats, 493*

SUBJECT INDEX

- extraosseous tumor scanning, 361
-microspheres, ocular blood flow, in dogs, 488*
-microspheres, quantitative renal perfusion, in dogs, 530*, 538*
-microspheres, ventricular perfusion, compared to ^{86}Rb , in dogs, 969
- Strontium-87**
colon cancer uptake, 824, 825
- Strontium-87m**
-citrate, uptake by metastatic carcinoma, 458
- Sulfur-35**
-dopamine analogs, preparation, distribution, in rats, 503*
- Synovium** *see Joints*
- Technetium**
reduction by Sn (II), O₂ effect, 521*
thiocyanate complexes, spectrophotometry, 505*
- Technetium-99m**
-bleomycin, preparation, tumor imaging, 338
-bleomycin, thyroid cancer imaging, 518*
brain scanning, subdural hematoma, 693
cardiac shunt quantitation, 540*
collimator comparison, 59
colloid, abdominal lesion diagnosis, 536*
-complexes, kidney studies, in animals, 475*, 530*
-compounds, abdomen evaluation, in children, 481*
content, Ohio River, 534*
-dihydrothioctic acid, liver, gallbladder imaging, 539*
-DMSA, kidney imaging, 34, 475*, 499*, 543*, 743; in dogs, 530*
-DMSA, preparation, distribution, 512*
dose calibration, 522*, 1138
-Fe-ascorbic acid, brain tumor uptake, in mice, 508*
-Fe-hydroxide macroaggregates, capillary blockade, in mice, 436
-fibrinogen, electrolytic preparation, 544*
free, in $^{99\text{m}}\text{Tc}$ -compounds, 1061, 1229
-glucoheptonate for kidney imaging, 475*
-glucoheptonate, myocardial infarct uptake, in animals, 529*, 546*
-HEDSPA, preparation, for bone, 127
-hematoporphyrin, preparation, distribution, in animals, 480*
hemoglobin binding, 487*, 703
kidney angiography, 539*
-lactobionate for kidney imaging, 475*
-lymphocytes, preparation, distribution, in mice, 656
-mannitol, for kidney imaging, 475*
-monofluorophosphate, bone imaging, compared to $^{99\text{m}}\text{Tc}$ -EHDP, 1110
multihole converging collimator, 291
-penicillamine, kidney studies, 506*
-phytate, alveolar retention, 503*
-phytate, lymph node imaging, in animals, 487*
-platelets, preparation, biologic fate, 801
-protamine complex, preparation, distribution, in animals, 535*
-pyridoxylideneglutamate for biliary tract, 476*
radiochemical purity, 266, 466, 484*, 889
-radiopharmaceuticals, chromatography, 318, 319, 488*, 722
-RBC, brain blood volume, transverse section scanning, 509*
-RBC, cardiac perfusion, 1014
-RBC, kit, 534*, 1187
-RBC, preparation, distribution, in mice, 656
-sarcoma cells, preparation, distribution, in mice, 656
-Sn-colloid, liver perfusion, 540*
-Sn-dextrose complex for kidney scanning, 474*
-Sn-gluconate, gel chromatography, 318, 319
-Sn-macroaggregates, lung imaging, in animals, 546*
-Sn-mercapto-iso-butyric acid, biliary system imaging, in dogs, 613
-Sn(OH)₃ lactose, dry aerosol, preparation, distribution, in dogs, 537*
- Sn reduced, uptake in damaged muscle, in rats, 527*
- Sn (II) reduction, effect of O₂, 521*
- source, deadtime determination, camera, 507*
- source, Ge gamma camera performance, 1196
- source, transmission imaging, 605
- spatial filtering, dual window, 493*
- spleen scans in lymphoma, lymphocytic leukemia, 496*
- tumor perfusion, 463
- urokinase, preparation, distribution, in dogs, 534*
- whole body imaging for vascular lesions, 507*
- Technetium-99m, albumin**
aortography, 502*
cardiac ejection fraction, 531*, 541*
cardiac output, 474*, 541*
cardiac perfusion, ECG gated, 505*, 1182
clearance, sensitized dogs, 938
column chromatography, 488*
electrolytic preparation, 75
free $^{99\text{m}}\text{Tc}$ test, 1061
joint imaging in hemophilia, 514*
-MAA, cardiovascular and lung perfusion imaging, 545*
-MAA, direct coronary injection, 2
-MAA, kit, 192, 198, 464
MAA, lung imaging, intrathoracic lesions, 490*
-MAA, lung perfusion, congenital heart disease, 492*, 536*
-MAA, preparation, lung imaging, 510*
-MAA, stress induced myocardial ischemia, 499*; in dogs, 499*
relative renal blood flow, 532*
saline paper analysis, 1018
- Technetium-99m, diphosphonate**
bone image soft tissue inflammation effect, in rats, 476*
bone imaging, compared to $^{99\text{m}}\text{Tc}$ -monofluorophosphate, 1110; $^{99\text{m}}\text{Tc}$ -polyphosphate, 1101
bone, multiplane tomography, 516*
bone scan, breast prosthesis shielding, 379
bone scan, heterotrophic bone formation, 530*; osteomyelitis, 533*
bone uptake mechanism, 546*
bone uptake parameters, in rats, 493*
brain scanning, 490*
breast imaging, 491*, 1149
column chromatography, 488*
distribution, 279
extraosseous neurofibroma uptake, 1207
femoral blood supply, with $^{99\text{m}}\text{Tc}$ -sulfur colloid, 543*
kinetics, 477*, 509*; compared to other bone agents, 848, 1153
lung retention, 503*
-methylene-, cellulitis, osteomyelitis differentiation, 494*
multi-organ, multi-agent imaging, 485*
myocardial infarct uptake, in dogs, 546*
optimization of ratio of components, 69
radiation dosimetry, 496*
skull scanning, 1185
tumor uptake compared to ^{15}N glutamic acid, in dogs, 515*
- Techetium-99m, DTPA**
brain image, 639; delayed, 1135
brain tumor uptake, in mice, 508*
chromatography, 488*, 722
cisternography, radiation dosimetry, 479*
dual clearance with $^{113\text{m}}\text{In}$ -DTPA, in animals, 442
electrolytic preparation, 75
gastric emptying time, 391, 483*, 497*, 918
kidney localization, 503*
kidney mass lesion differentiation, 485*
- Technetium-99m, microspheres**
angiography, peripheral vascular disease, 533*
direct coronary injection, 2
labeling, 808; kit, 509*
lung perfusion, 455, 484*, 964
venography, in legs, 171, 915

- Technetium-99m, pertechnetate**
 brain, choroid plexus uptake, 541*, 884
 brain, dynamic and static studies, relationship, 32
 brain imaging, 369, 542*, 641, 681, 709, 1205
 brain imaging, compared to axial tomography, 515*, 519*; microangiography in stroke, in animals, 488*
 brain imaging, multicrystal camera, 537*
 brain perfusion, 358, 363, 517*, 531*, 544*, 634, 797, 907, 953, 1035, 1050, 1084, 1105, 1113, 1217
 brain scan, 131, 525*, 620, 712, 714, 1047
 brain scan, compared to ¹¹³Hg-chlormerodrin, 520*; ^{99m}Tc-diphosphonate, 490*
 brain tumor uptake, in mice, 508*
 breast carcinoma uptake, in rats, 489*
 breast imaging, 527*
 cerebral death diagnosis, 912, 914
 CSF shunt function, arrested hydrocephalus, 529*
 distribution, effect of Sn(II), in rats, 151
 esophagus imaging, 510*
 eye imaging, 478*
 free, in bone agents, 1229
 gastric and salivary emptying, 544*
 GI tract absorption, 314, 316
 GI tract imaging, 220, 221, 365, 374
 joint imaging, 7, 489*, 514*
 kidney perfusion, 478*, 489*, 699; in dogs, 507*
 lacrimal drainage, 482*
 lung perfusion, 142, 314, 317, 396, 902
 multi-organ, multi-agent imaging, 485*
 myocardial uptake, in rats, 1092
 perchlorate blocking dose, 221, 884
 placenta abruption imaging, 900
 radiochemical purity, 266, 466, 484*, 889
 soft tissue inflammation and bone imaging, in rats, 476*
 synovial rupture, 7, 911, 912
 testicular torsion imaging, 501*, 518*
 thyroid scan, 1209
 thyroid uptake, 525*, 1117
 uptake in cellular necrosis model, 577
 uptake in damaged muscle, in rats, 527*
 ventricle visualization, on brain scan, 202
- Technetium-99m, polyphosphate**
 abscess uptake, 1054
 bone imaging, 47, 52, 312, 485*, 491*, 538*, 837, 1037, 1089, 1120, 1205, 1227; delayed, 47
 bone, multiplane tomography, 516*
 bone scan, 495*, 536*
 bone uptake parameters, in rats, 493*
 brain image, 207, 542*, 1054
 breast imaging, 1149, 1054
 CdTe probe, tooth abscess, in dogs, 492*, 892
 chromatography, 488*
 compared to other bone agents, 832, 837, 1153
 extraosseous tumor uptake, 53, 458, 904, 1054, 1057
 hydrolysis, compared to ^{99m}Tc-pyrophosphate, 652
 joint imaging, 417
 kinetics, 509*, 538*, 832, 848
 myocardial imaging, in dogs, 494*, 1174
 radiation dosimetry, 496*
 uptake by penis, 837
- Technetium-99m, pyrophosphate**
 bone imaging, 498*, 503*, 517*, 880
 breast carcinoma uptake, in rats, 489*
 chromatography, 488*, 722
 compared to other bone agents, 1153; to ⁴⁵Ca, 517*
 hydrolysis, compared to ^{99m}Tc-polyphosphate, 652
 kinetics, 498*, 509*, 517*, 1153
 kit, 124, 480*
 myocardial imaging, 521*, 536*; in dogs, 479*
 preparation, distribution, 279
 radiation dosimetry, 496*
 renal asymmetry on bone scans, 500*
 toxicity, in rats, 252
- Technetium-99m, sulfur colloid**
 aerosol, lung imaging, 504*, 524*
 angiocardiogram, tricuspid insufficiency, 205
 bone marrow imaging, 343
 bone marrow scanning, 479*, 490*, 1003
 femoral blood supply, with ^{99m}Tc-diphosphonate, 543*
 kidney perfusion, 493*; in dogs, 506*
 kidney uptake, 367, 564
 liver, first transit deposit, 493*
 liver imaging, 42, 142, 505*, 508*, 533*, 546*, 707, 720, 902, 1041, 1201
 liver perfusion, 137, 317, 481*, 533
 liver regeneration image, in rats, 10
 liver scan, 135, 234, 296, 310, 356, 479*, 493*, 717
 liver size on scans, 237
 liver-spleen scan, 367, 564, 647
 lung uptake, 460, 726, 727, 728, 1220; IP endotoxin effect in rats, 1028
³²P-chromic phosphate distribution aid, 190, 1067, 1068
 particle size, 923
 RE function in hematologic disease, 495*, 532*, 1158
 shielding artifact, 1201
 spleen imaging, 45, 294, 303, 499*, 632, 1203
 spleen, percent uptake, 446
 subphrenic abscess scan, subtraction technique, with ⁶⁷Ga, 371
- Technetium-99m, tetracycline**
 chromatography, 488*
 complex, preparation, distribution, in rats, 987
 myocardial infarct evaluation, in dogs, 524*, 546*
 myocardial infarct imaging, 503*
 preparation, distribution, in animals, 176, 528*
 uptake in cellular necrosis model, 577
 uptake in damaged muscle, in rats, 527*, 528*
- Terminology**
 "radiopharmaceutical scientist," 723
 tissue isotope distribution, 725
- Testes**
^{99m}TcO₄⁻ imaging in testicular torsion, 501*, 518*
⁶⁵Zn metabolism in infertility, 520*
- Testosterone**
¹⁴C-, uptake by prostate, in dogs, 94
- Tetracycline** see *Iodine-130; Iodine-131; Technetium-99m, tetracycline; Tin-119m*
- Therapy**
see also Chemotherapy; Radiation therapy
¹³¹I, thyroid, 257
¹³¹I and ³²P for lymphoma, 475*
¹³¹I-lipiodol and ³²P, lymph nodes, 544*
¹³¹I, thyroid, 477*, 674
³²P-chromic phosphate, distribution, 190, 1067, 1068
³²P-microspheres, tongue cancer, 481*
³²P, thyroid carcinoma metastatic to bone, 1037
¹⁰⁰Pd-protoporphyrin rejection suppression, skin homografts, in dogs, 997
- Thermography**
 carotid artery obstruction, 531*
 parathyroid, 530*
- Thiocyanate**
 Tc complexes, spectrophotometry, 505*
- Thionin**
³H-, 733
- Thrombus** see *Blood*
- Thulium-167**
 cyclotron production, 545*
 tumor uptake, in animals, 501*, 545*
 tumor uptake, subcellular, 501*
- Thulium-170**
 tumor uptake, in animals, 501*
- Thyroid**
 carcinoma, metastatic, ¹³¹I scan, 50, 477*, 545*, 1052
 carcinoma, metastatic to bone, ³²P therapy, 1037
 computerized diagnosis, 521*
 effective thyroxine ratio test, 1032

- function, following radiation therapy and surgery, 531*
 function tests, in vitro, post subtotal thyroidectomy, 515*
⁷⁷Ga-citrate scanning, 424, 481*, 810
 I pool, fluorescence scanning, 522*
¹²³I therapy, 257
¹²³I-TSH preparation, 529*
¹³¹I therapy, large doses, 674
¹³¹I therapy, radiation dose to patient's family, 499*, 887
¹³¹I turnover in hyperthyroidism, 476*
 nodule, autonomous, TSH stimulation test, 1209
 nodule, non-functioning, ultrasound, 523*; ⁷⁷Ga scan, 424
 nodule, oblique view, ¹²³I, 782
 phantom, ¹²³I collimator choice, 328
 phantom, multiple pinhole tomography, ¹²³I, 1063
 phantom, pseudorandom aperture imaging, 508*
 scan, evaluation of parathyroid thermography, 530
 scan, lymphocytic thyroiditis, 522*
 scan, comparison of ¹²³I and ¹³¹I, 261
 subacute thyroiditis diagnosis, 81
^{99m}Tc-bleomycin imaging, 518*
 T_s and hormone metabolism, 502*
 T_s radioimmunoassay, 482*, 515*, 531*
 uptake, ¹²³I compared to ¹³¹I, 261, 770
 uptake, ¹³¹I, capsule effect, 770
 uptake, normal values, 213
 uptake, ^{99m}TcO₄⁻ compared to ¹³¹I, 525*; instrumentation, 1117
 T_s and T_a, low cost, 1075
Thyroid stimulating hormone
¹²³I-, preparation, 529*
 serum, posthead and neck cancer therapy, 531*
 serum, postsubtotal thyroidectomy, 515*
 stimulation test, autonomous thyroid nodule, 1209
Thyroxine
 ETR test, 1032
 free, postsubtotal thyroidectomy, 515*
¹³¹I-, preparation, 270
 serum, posthead and neck cancer therapy, 531*
 serum, semiautomatic method, 1075
 serum, subacute thyroiditis, 81
 T_s and thyroid hormone metabolism, 502*
Tin
 stannous, effect on ^{99m}TcO₄⁻ distribution, in rats, 151
 stannous, reduction of ^{99m}Tc, O₂ effect, 521*
Tin-113
 optimization of component ratios of ^{99m}Tc-EHDP, 69
Tin-119m
 -tetracyclines, preparation, distribution, in animals, 176
Titanium-45
 production, tumor uptake, in animals, 475*
Toluidine blue
³H, 733
¹³¹I-, preparation, distribution, insulinoma scan, 1212
Tomography
see also Transverse section
 axial, brain scans, 515*, 519*
 Book Review; *Tomographic Imaging in Nuclear Medicine*, 144
 computer-scintillation camera, 540*
 iterative 3D reconstruction, 520*
 multiplane, bone, ^{99m}Tc-polyphosphate, -EHDP, 516*
 multiple pinhole, 1063
 unmodified scintillation camera, 439
Tongue
³²P-microsphere therapy, 481*
Total body *see Whole body*
Toxicity
 adverse reaction procedure, 213
 antineoplastic platinum compounds, 478*
 capillary blockade with ^{99m}Tc-Fe hydroxide macroaggregates, in mice, 436
 dimercaptosuccinic acid, 34, 512*
⁵⁹Fe-hydroxide particles, in animals, 17, 616
 oxygen, infants' lungs, 492*
 Sn(II), in rats, 151
 Sn-macroaggregated albumin, in dogs, 567
 -Sn-pyrophosphate, in rats, 252
^{99m}Tc-pyrophosphate, 279
^{99m}Tc-tetracyclines, in animals, 176
Transferrin *see Indium-111; Indium-113m; Indium-114m; Iron-59*
Transit time *see specific organ*
Transmission
 imaging, liver, 496*
 imaging, regional lung volume, 605
 imaging, ¹³³Xe source, 453
 scanning, ACTA scanner, 511*
 scanning, axial tomography, brain, 515*, 519*
 scanning, bone mineral, ¹²³I, 541*
 scanning, EMI scanner, 513*
 scanning, image reconstruction, 981
Transplant *see Kidney; Liver*
Transverse section scanning
 ACTA scanner, 511*
 Book Review; *Tomographic Imaging in Nuclear Medicine*, 144
 cisternography, ¹¹¹In-DTPA, 529*
 display system, 513*
 image reconstruction, Fourier transforms, 981
 local brain blood volume, ^{99m}Tc-RBC, 509*
 orthogonal tangent correction, 377, 378, 379
 reconstruction techniques, 480*
Trauma
 abdominal, 481*, 632, 1044
 bullet track in brain, 140
 subcutaneous extravasation of CSF, 200
Tritium *see Hydrogen-3*
Tumor
 adrenal, ¹³¹I-cholesterol imaging, 246, 332, 531*
 bifunctional EDTA compounds, preparation, distribution, in animals, 495*
 bone, ^{99m}Tc-polyphosphate imaging, 47, 53, 491*, 538*, 1120, 1205, 1227, 1228
 bone, ^{99m}Tc-pyrophosphate imaging, 517*
 bone, osteoid osteoma, ^{99m}Tc-methylene diphosphonate, 494*
 bone, skull imaging, ^{99m}Tc-diphosphonate, 1185
 brain, axial tomography, 519*
 brain, cystic astrocytomas, 494*
 brain, dynamic ^{99m}TcO₄⁻ studies, 525*, 544*, 1050
 brain, lesion differentiation, 523*, 681
 brain, postcraniotomy imaging, ⁷⁷Ga, ^{99m}TcO₄⁻, ^{99m}Tc-polyphosphate, 542*
 brain, ^{99m}Tc-DTPA imaging, 1135
 brain, ^{99m}TcO₄⁻ imaging, 620, 714, 1205
 brain, uptake, in mice, 16 agents, 508*; ¹¹¹In-chloride and -bleomycin, 508*
 breast carcinoma, ¹⁴C-isoxazole distribution, in rats, 187
 breast carcinoma, uptake of eight radiopharmaceuticals, in rats, 489*
 breast, ⁷⁷Ga, ^{99m}TcO₄⁻ imaging, 527*; ^{99m}Tc-diphosphonate uptake, 491*, 1149; ^{99m}Tc-polyphosphate uptake, 1054, 1149
 carcinoma, kidney, parasitic to liver, 137
 carcinoma, uptake of ¹¹¹In-Cl₄, ⁷⁷Ga-citrate and ¹⁹⁷HgCl₂, in mice, 489*
 CEA titer, 514*
 cervical carcinoma, ¹¹¹In-bleomycin scan, 545*
 cervical carcinoma, radioactive dye screening test, 733
⁵⁷Co-bleomycin and ⁷⁷Ga-citrate uptake, in mice, 1167
⁵⁷Co-bleomycin scanning, 386
⁷⁷Cu-bleomycin, preparation, distribution, in animals, 484*, 498*
¹⁶⁶Er uptake, in animals, 536*, 1008
 extraosseous, ⁸⁵Sr and ⁷⁷Ga uptake, 361; ⁸⁷Sr, 458, 824, 825; ^{99m}Tc-diphosphonate, 491*, 1149, 1207; ^{99m}Tc-polyphosphate, 458, 904, 918, 1054, 1057, 1149

- "Ga-citrate scanning, 227, 361, 386, 399, 404, 408, 424, 458, 480*, 491*, 497*, 525*, 527*, 542*
- "Ga-citrate uptake, in animals, 323, 489*, 502*, 1167
- gastrointestinal tract, ^{99m}TcO₄⁻ image, 365
- geriatric studies, 503*
- head and neck cancer, 531*
- Hodgkin's disease, "Ga scanning, 399
- ¹³¹I-CEA antibody, ¹¹¹In-bleomycin, ^{113m}InCl₃, "Ca-citrate uptake, in animals, 323
- ¹³¹I-tetracyclines, preparation, distribution, in rats, 483*
- ¹³¹In-bleomycin imaging, 386, 512*, 541*, 545*, 547*
- ¹³¹In-bleomycin uptake, in animals, 273, 323, 508*
- insulinoma, ¹³¹I-toluidine blue scan, 1212
- kidney, "Ga-citrate scan, 491*
- liver, imaging, 234, 296, 483*, 511*, 1008; focal uptake, 525*, 725
- liver, perfusion studies, 535*; ^{99m}TcO₄⁻, ^{113m}In, 314*; ^{113m}In-colloid, 1021
- lung cancer, "Ga-citrate scan, 227, 408, 497*
- lung cancer, ¹³³Xe ventilation/perfusion, 520*
- lymph node, ³²P, ¹³¹I-lipiodol therapy, 544*
- lymphoma, "Ga-citrate scan, 404, 497*
- lymphoma, ¹³¹In-bleomycin imaging, 512*
- malignant melanoma, spleen uptake of ^{99m}Tc-sulfur colloid, 1203
- meningioma of the sphenoid wing, 1205
- ¹⁵N-ammonium and -glutamine scanning, in dogs, 483*
- ¹⁵N-glutamic acid uptake, in dogs, 515*
- parathyroid adenoma, bone scans, 1089
- phantom, 1-2 mm, computerized gated imaging, 537*
- ^{198m}Pt-cis-dichloro-bis-cyclopentylammine-Pt(II), distribution, in rats, 478*
- ⁷⁵Se-selenite imaging, in animals, 622
- subcellular uptake of "Ga, ¹¹¹In, ²⁰⁰Bi and ¹³⁷Tm, 501*
- ^{99m}Tc-bleomycin, preparation, imaging, 338, 518*
- ^{99m}Tc-hematoporphyrin preparation, distribution, in animals, 480*
- ^{99m}Tc-sarcoma cells, distribution, in mice, 656
- ^{99m}Tc-tetracycline complex, uptake, in rats, 987
- thyroid cancer, ¹³¹I therapy, 477*, 674
- thyroid cancer, metastatic, ¹³¹I scans, 51, 477*, 545*, 1037
- thyroid cancer metastatic to bone, ³²P therapy, 1037
- thyroid cancer, ^{99m}Tc-bleomycin imaging, 518*
- thyroid, nonfunctioning nodule, 424, 522*, 523*
- ⁴⁵Ti and ²⁰⁸Pb uptake, in animals, 475*
- ¹³⁷Tm production, distribution, in mice, 545*
- tongue cancer, ³²P-microsphere therapy, 481*
- uptake of lanthanide and actinide-bleomycin and -citrate, in mice, 526*
- uptake of rare earth radionuclides, 501*
- Yashida sarcoma, uptake mechanism of "Ga, ¹⁶⁶Yb, ¹¹¹In-citrates, in rats, 502*
- ¹⁶⁶Yb-citrate imaging, 210
- ultrasound, 511*, 523*, 525*
- vascularity, 314, 463, 538*, 1021
- T**
- ¹³¹I, kidney kinetics, 482*
- ¹³¹I, preparation, 270
- postsubtotal thyroidectomy, 515*
- semiautomatic, 1075
- serum, polyethylene glycol method, 482*
- stimulation of DNA, kidney cells, in vitro, 532*
- stimulation of T₃ and leucine uptake, in vitro kidney cells, 532*
- thyroid function following head and neck cancer therapy, 531*
- thyroid hormone metabolism, 502*
- T₄** see *Thyroxine*
- Ultrasound**
- abdominal mass lesion diagnosis, 536*
- aortic aneurysm, 1014
- liver lesion, 511*, 525*
- pancreatic pseudocyst, 543*
- synovial rupture of knee, 912
- thyroid, non-functioning nodules, 523*
- thrombi, legs, 171, 915
- Uranium-237**
- bleomycin and -citrate, tumor uptake, in mice, 526*
- Urecholine**
- regimen for pancreas imaging, 662
- Urine**
- see also Bladder*
- enzyme analysis, oxalic acid, ¹³C, 486*
- Vascular system**
- see also Blood; specific organ*
- aortic aneurysm imaging, ^{99m}Tc-RBC, 1014
- carotid artery obstruction, ^{99m}TcO₄⁻, thermography, 531*
- circulation in the femoral head, ¹⁸F, 183
- equilibrium images, ¹⁸O-O₂, -CO, -CO₂, head, 505*
- image of ^{81m}Kr catheter, in dogs, 874
- internal carotid artery kink, brain image, 634
- peripheral, isotope perfusion studies compared to arteriography, 533*
- splenic vein, false-positive liver image, 142
- ^{99m}Tc-albumin aortography, 502*
- ^{99m}Tc-microsphere venography, legs, 171, 915
- Vitamin B₁₂**
- radioassay, 688
- Schilling test, consecutive day, 949
- Schilling test, cost weights, 543*
- Whole body**
- Ca, neutron activation analysis, 428, 483*, 511*
- ⁷⁵Co-bleomycin, "Ga-citrate scanning, 386
- counter, high level, 610
- counting, iron metabolism, 156
- ⁵⁷Fe scan, 483*, 667
- "Ga-citrate scan, 361, 399, 404, 408, 1054
- ¹³¹I scan, thyroid cancer metastases, 477*, 1052
- ¹³¹I-fibrinogen scan, 1163
- ¹¹¹In-chloride scan, in myelofibrosis, 647
- imaging, lesion vascularity, 507*
- imaging, steady-state ¹⁸O, in dogs, 529*
- K, abnormal sex chromosomes, 448
- ⁸⁵Sr, "Ga scan, extraosseous tumor, 361
- ⁸⁵Sr scan, 458
- scan, bone marrow infarct in sickle cell disease, 1003
- scanning, transverse axial tomograph, 511*
- ^{99m}Tc-diphosphonate image, 1101
- ^{99m}Tc-DMSA scan, 743
- ^{99m}Tc-polyphosphate scan, 53, 459, 1054, 1101
- ^{99m}Tc-pyrophosphate scan, 124, 279
- Xenon-125**
- production, nuclear parametres, 502*
- Xenon-133**
- compared to radioaerosol, 504*, 524*
- differential vital capacity, 625
- dose calibrator accuracy, 522*
- gas delivery system, 288
- kidney perfusion, 775
- kidney washout, 504*
- liver uptake in lung ventilation studies, 1179
- lung perfusion, multiprobe, in dogs, 959
- lung ventilation, 455, 536*, 636; in dogs, 598
- lung ventilation/perfusion, 519*, 520*, 582, 964
- regional cerebral blood flow, 504*
- sinus and middle ear ventilation, 528*
- sinus imaging, 477*
- transmission source, 453
- X-ray**
- compared to bone imaging, 880
- compared to ¹³³Xe lung studies, 520*
- photodensitometry, partial body Ca, 929
- radiation damage to liver cells, in rats, 241
- source, tomography, 511*, 513*, 515*, 519*, 981
- Ytterbium-169**
- bleomycin and -citrate, tumor uptake, in mice, 526*

SUBJECT INDEX

- citrate, tumor imaging, 210
- citrate, tumor uptake mechanism, in rats, 502*
- DTPA, brain tumor uptake, in mice, 508*
- DTPA, cisternography, cost, quality control, 496*
- DTPA, cisternography, kinetics, 786, 916, 917
- DTPA, cisternography, radiation dose, 375, 479*, 496*, 643, 786, 917
- tumor uptake, in animals, 501*
- Zinc-62**
prostate scanning, 739
- Zinc-65**
metabolism in male infertility, 520*
prostate uptake, 739
- Zinc-69**
myocardial uptake, in rats, 1092
- Zinc-69m**
prostate uptake, 739

INDEX TO ADVERTISERS

Abbott Laboratories	
North Chicago, Ill.	4A, 5A
Ackerman-Schmehl Ind., Inc.	
Cerritos, Calif.	75A
Amersham/Searle Corp.	
Arlington Heights, Ill.	56A, 57A
Atomic Energy of Canada	
Ottawa, Canada	16A
Baird-Automic	
Bedford, Mass.	69A
Biolab S.A.	
Brussels, Belgium	17A
Brattle Instrument Corp.	
Cambridge, Mass.	1267
Capintec, Inc.	
Mt. Vernon, N.Y.	1269
CIS Radiopharmaceuticals	
Bedford, Mass.	52A
Cleon Corp.	
Natick, Mass.	18A, 19A
Clinical Assays, Inc.	
Cambridge, Mass.	28A, 68A
Curtis Laboratories	
Los Angeles, Calif.	67A
Diagnostic Isotopes, Inc.	
Upper Saddle River, N.J.	13A
Digital Equipment Corp.	
Maynard, Mass.	47A
Dunn Instruments	
San Francisco, Calif.	37A
Elscint, Inc.	
Palisades Park, N.J.	10A
General Electric Medical Systems	
Milwaukee, Wis.	58A, 59A
Hewlett-Packard	
Colorado Springs, Colo.	78A
Hoechst Radiopharmaceuticals	
Frankfurt, Germany	3A
Isolab, Inc.	
Akron, Ohio	40A
Mallinckrodt/Nuclear	
St. Louis, Mo.	30A, 31A, 32A, 42A, 43A, 48A, 49A
Matrix Instruments	
New York, N.Y.	61A
Medi-Physics, Inc.	
Emeryville, Calif.	IFC, 1A, 63A, 79A, 80A, 81A, 82A
Micromedic Systems, Inc.	
Philadelphia, Pa.	20A, 21A
New England Nuclear	
Boston, Mass.	8A, 22A, 23A, 26A, 74A, 87A, 93A
Nuclear Enterprises	
Edinburgh, Scotland	53A
Ohio-Nuclear, Inc.	
Solon, Ohio	14A, 15A, 62A, 76A, 77A
Omnimedical Services, Inc.	
Paramount, Calif.	64A, 92A
Packard Instruments Co.	
Downers Grove, Ill.	27A, 29A
Picker Corp.	
Mentor, Ohio	50A, 51A, 83A, 84A, 85A, 86A
Princeton Electronic Products	
North Brunswick, N.J.	12A
Procter & Gamble	
Cincinnati, Ohio	70A, 71A, 72A
Radiochemical Centre	
Amersham, England	60A, 88A
Radx Corp.	
Houston, Texas	54A, 55A
Raytheon Co.	
Burlington, Mass.	6A
Roche Diagnostics	
Nutley, N.J.	34A, 35A, 36A
Searle Analytical, Inc.	
Des Plaines, Ill.	65A
Searle Radiographics, Inc.	
Des Plaines, Ill.	33A, 87A, 89A, 90A, 91A, 94A, BC
SNM Placement	
New York, N.Y.	66A, 68A, 69A
E. R. Squibb & Sons, Inc.	
Princeton, N.J.	38A, 39A, 44A, 45A, 46A
Technical Associates	
Canoga Park, Calif.	73A
Teledyne Isotopes	
Westwood, N.J.	41A
Toshiba International Corp.	
Wheeling, Ill.	24A
Wien Labs., Inc.	
Succasunna, N.J.	25A